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ABSTRACT 
Exercise intolerance is well documented in patients with chronic obstructive pulmonary disease 
(COPD). Historically, this exercise intolerance has been attributed to the central factors of lung 
damage and subsequent heart failure. However, recent evidence suggests that (i) patients with 
cardiac and renal failure suffer from skeletal muscle (SM) abnormalities that impair exercise 
tolerance and (ii) patients with chronic obstructive pulmonary disease (COPD) may have metabolic 
and functional abnormalities of SM. However, no studies have conducted a detailed investigation 
of SM structure and function and their relation to exercise tolerance in patients with COPD. 
In the first study of this dissertation, exercise tolerance and SM function was examined in 13 
patients with moderate COPD (FEV1/FVC = 37 ±9%) and compared to age matched controls. 
Patients and subjects underwent i) tests of lung function ii) anthropometry iii) six minute walk test 
(SMWT) iv) graded cycle ergometry to exhaustion for determination of peak V02, peak workload 
(WL) and peak ventilation (VE) and v) isokinetic tests of SM strength and endurance. 
Patients achieved a significantly lower Peak V02 (17 ±3 vs 25 ±5 mi02/kg/min; p<0.01), WL (72 
±37 vs 211 ±69 W; p<0.01) and VE (41 ±13 vs 87 ±221/min; p<0.01) during the cycle test and 
distance walked during the SMWT (494 ±150 vs 718 ±75 m; p<0.01) compared to controls. 
Similarly, concentric quadriceps strength was reduced in patients compared to controls before (169 
±90 vs 257 ±99 Nm; p<0.01 ), but not after correction for lean thigh volume (LTV) (62 ±28 vs 69 
±28 Nm/1; NS; COPD vs C). Eccentric quadriceps strength was lower in patients before (135 ±43 
vs 198 ±51 Nm; p<0.05) and after correction for LTV (0.9 ±1.2 vs 2.6 ±0.7 Nm/1; p<0.05). 
Quadriceps total power (92 ±45 vs 161 ±54 W; p<0.01) and work done (211 0 ±998 vs 3936 ±1386 
Nm; p<0.01) during the isokinetic endurance test were lower in patients compared to controls 
before and after correction for LTV. In addition, correlations were found between variables of 
skeletal muscle function and measures of exercise capacity in patients with COPD. These data 
support the hypothesis that SMfunction may play a role in exercise Hmitation in patients with 
COPD. 
In the second study of this dissertation, 11 patients and 11 control subjects underwent a SM biopsy 
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for analysis of histology and ultrastructure. All patients with COPD demonstrated pathological 
abnormalities including Type II fibre atrophy, variation in fibre size, fibre splitting, moth-eaten fibres, 
subsarcolemmal aggregations and abnormalities of nuclei including; nuclear knots, nuclear bags, 
nuclear chains, internal and pyknotic nuclei. A blinded impartially scored method for grading SM 
pathology showed significant pathology in patients compared to age matched counterparts (9 ±3 
vs 3 ±6; COPD vs C; p<0.01 ). A relationship was shown between SM structure and; parameters of 
exercise capacity, SM function and distance walked during the SMWT (r= -0.63; p=0.05). These 
data suggest that SM structure may play a role in the exercise intolerance experienced by patients 
with COPD. 
In the third study of this dissertation, predictors of exercise capacity in patients with COPD were 
evaluated. FEV1/FVC was related to peak V02 during the incremental cycle test (r=0.72; p<0.01) 
and distance walked during the SMWT (r=0.81; p<0.01 ). The biopsy pathology score correlated 
with peak V02 (r=-0.63; p=0.05), peak WL (r=-0.67; p<0.05) and distance walked during the SMWT 
(r=-0.65; p<0.05). Duration of disease correlated with peak WL (r=-0.60; p<0.05) and distance 
walked during the SMWT (r=-0.65; p<0.05). Various measures of SM function correlated with peak 
WL and distance walked during the SMWT. These data suggest that measures of lung function 
and measures of SM structure and function are useful predictors of exercise capacity in patients 
with COPD. However, patients with COPD who undergo exercise training improve their exercise 
capacity with no alterations in lung function. This implies that factors other than improved lung 
function are responsible for the improved exercise capacity in patients with COPD and renders the 
FEV1/FVC a less accurate predictor of exercise capacity in trained patients. 
Therefore the last study in this dissertation was a case study that examined changes in SM 
structure and function in relation to exercise tolerance in a single patient with COPD after exercise 
training. The patient showed improved exercise tolerance and improved SM structure and function 
after training with no corresponding change in lung function. This preliminary finding suggests that 
improvements in SM structure ·and function- may be responsible for improved exercise capacity in 
trained patients with COPD. 
The data in this dissertation thereforasuggestthat (i) SM structural and functional abnormalities 
exist in patients with COPD (ii) these abnormalities may play a role in the exercise intolerance 
experienced by these patients, (iii) these abnormalities may be a useful predictor of exercise 
capacity in patients with COPD and (iv) that improvements in SM structure and function may 
account, at least in part, for the improved exercise tolerance experienced by patients with COPD. 
xi 
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GLOSSARY OF AS BREVIA TIONS 
In the study of respiratory, muscle and exercise physiology frequent use is made of abbreviations. To simplify the text 
in this cissertation abbreviations are used where appropriate. Therefore, a glossary of abbreviations is provided. 
ADP = Adenosine diphosphate 
ATP = Adenosine triphosphate 
ATS = American thoracic society 
C =Celsius 
CO= Carbon monoxide 
C02 = Carbon dioxide 
CS = Citrate synthase 
FEV1 = Forced expiratory volume in the first second of maximal forced expiration 
FEV1/FVC = FEV1 as a% of the total forced expiratory volume 
FEFso = Expiratory flow at 50% of the total forced expiratory flow volume 
FRC =Functional residual capacity 
FVC = Forced vital capacity 
HAD = 3-hydroxyacyi-CoA dehyrdogenase 
He= Helium 
HK =Hexokinase 
HR = Heart rate 
J =Joules 
Kg = kilogram 
kPa = Kilopascals 
kp.m = kiloponds per metre 
K10 =Transfer coefficient 
I= litres 
LDH = Lactate dehydrogenase· 
LTV = Lean thigh volume 
ml = Millilitres 
MSVC = Maximum sustained ventilatory capacity 
MW = Maximum voluntary ventilation 
NADH = P- nicotinamide adenine dinucleotide reduced 
Nm = Newton metres 
PaC02 = Partial pressure of carbon dioxide in arterial/arterialised blood 
Pa02 = Partial pressure of oxygen in arterial/arterialised blood 
PAS= Periodic acid shift's glycogen 
PCr = Phosphocreatine 
PEFR = Peak expiratory flow rate 
PFK =Phosphofructokinase 
Pi= Inorganic phosphate 
PIFR =Peak inspiratory flow rate 
PK = Pyruvate kinase 
RER = Respiratory exchange ratio 
rpm = Revolutions per minute 
RV = Residual volume 
Sa02 = Saturation of oxygen in arterial blood 
SO = Standard deviation 
SOH = Succinate Dehydrogenase 
SMWT = Six minute walk test 
TOP= Transdiaphragmatic pressure 
11m = Micrometres 
VC = Vital capacity 
VC02 = Output of carbon dioxide during breathing 
VD = Physiological deadspace 
VE = Minute ventilation 
V02 = Oxygen uptake during breathing 
VT = Tidal volume 
VTNC =Tidal volumeNital capacity 
W =Watts 
WOB = Work of breathing 
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CHAPTER ONE 
A REVIEW OF THE LITERATURE 
2 
1. Introduction 
(a) Definition of COPD 
COPD is the medical term applied to a disease that is generally a result of emphysema, chronic 
bronchitis or a mixture of these two pathophysiological processes (West 1 992). Emphysema is a 
result of enlarged air spaces distal to the terminal bronchioles and the destruction of their walls. 
Chronic bronchitis is a result of excessive mucus production and inflammation in the bronchial tree 
with resultant narrowing of the airways (Guyton 1 976; Wiles et al., 1 984; West 1 992). It is often 
difficult to determine the extent to which patients with COPD suffer from either emphysema or 
chronic bronchitis because a combination of the two pathophysiological processes is common 
(Guyton 1 976; Anderson 1980; Wiles et al., 1 984; Belman 1 990; West 1 992; Weaver et al., 1 997). 
COPD is therefore characterized by gradual, largely irreversible chronic air11ow limitation, a chronic 
cough, overinflated lungs and impaired gas exchange. Despite ample documentation of the 
pathophysiology of COPD, (Guyton 1 976; Anderson 1 980; Wiles et al., 1 984; Belman 1 990; West 
1 992; Weaver et al., 1 997), the epidemiology of the disease is not well understood (MacNee 1 997). 
(b) Incidence of COPD 
In the USA COPD is reported to be the fourth highest cause of death, similarly in the European 
Union as the third highest cause of mortality (Siafakis 1 995; Weaver et at., 1997). In South Africa, 
the incidence of COPD is rapidly rising as demonstrated by the Guardian National Insurance 
Company statistics (1 996) showing that COPD is the third highest cause of disability in South 
Africa. Additionally, COPD is the only one of the top five causes of disability in South Africa that is 
increasing (Guardian National Insurance Company Statistics 1 996). In the Medical Research 
Council Technical Statistical report for the period 1985-1990, COPD accounted for 4% of total 
deaths in South Africa and for the first time exceeded deaths from acute respiratory incidents. In 
addition, cigarette smoking is cited as a major cause of chronic lung disease (McNee 1997; 
O'Donnel1997) and whilst the incidence of people smoking cigarettes is decreasing in the USA 
and Europe, it is rapidly increasing in most African countries, incluoing South Africa (Tobacco 
Action Group statistics 1996). 
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(c) Treatment of COPO 
COPD is regarded as a largely irreversible disease. However, treatment of patients suffering from 
COPD focuses primarily on improvements in, or maintenance of, functional capacity. This is an 
attempt to allow continued participation in activities of daily living by these patients (Weaver et al., 
1997; MacNee 1997). 
(d) Functional capacity In patients with COPD 
Functional capacity is often clinically measured by exercise tolerance, particularly in patients with 
chronic disease (Wiles et al., 1984). Patients with COPD demonstrate marked exercise 
intolerance compared to healthy individuals (Gallagher 1990; Carteret al., 1991; Belman 1992, 
Cooper et al., 1995; Clark et al., 1996) and typically present with exaggerated breathlessness, 
muscle wasting and often malnutrition (Karlsson et al., 1992). 
Much research in the last three decades has focused on the possible factors causing exercise 
limitation in patients with COPD. Because COPD is primarily a disease of the lungs, in the period 
between the 1960's and the 1980's most of the research examining exercise intolerance in patients 
with COPD focused on central factors relating directly to the lungs and heart, such as ventilation 
mechanics, impaired gaseous exchange and cardiovascular function. However during the 1990's 
the concept that peripheral factors may contribute to exercise tolerance in patients with COPD has 
emerged. 
Therefore, for the sake of simplicity this review of the literature examining possible causes of 
exercise intolerance in patients with COPD will be discussed under the following sections; 
Ventilation mechanics as a limiting factor during exercise in patients with COPD, impaired gas 
exchange as a limiting factor during exercise in patients with COPD, peripheral skeletal muscle as 
a limiting factor during exercise in patients with COPD and other non respiratory variables that may 
play a role in exercise intolerance in patients with COPD. Lastly, a-section discussing factors 
predicting exercise capacity in patients with COPD will be reviewed. 
2. Ventilation Mechanics as a Limiting Factor During Exercise in Patients with COPD 
(a) Dynamic hyperinflation 
The inflammation and mucus obstruction typically found within the respiratory bronchioles of 
patients with chronic bronchitis causes narrowing of the airways. Similarly, alveolar wall 
destruction, typically seen in patients with emphysema, results in a loss of elastic tissue in the 
alveoli leading to a loss of radial traction which causes narrowing of the respiratory airways. 
Therefore expiration becomes slower and more difficult in patients with COPD compared to normal 
healthy individuals (Gallagher 1990; West 1992). The extent of this obstruction to expiration is 
traditionally measured by the FEV1 (Guyton 1976; Wiles et al., 1984; West 1992), which is the 
amount of air expired in the first second of a maximal expiratory breath. In a healthy individual this 
would be 80% of the maximal forced vital capacity. As expiration is slower in patients with COPD, 
the FEV1 may be markedly reduced to 1 0-60% of a maximal expiratory breath (West 1992) and 
therefore less air is expired. This results in an increased residual lung volume (Anderson 1980; 
Belman 1992). This excess residual volume "inflates" the lungs and is termed "dynamic 
hyperinflation" (Gallagher 1990; Wiles et al1984; Anderson 1980). The more severe the reduction 
in FEV1, the more likely the residual volume is to approach the TLC {De Troyer et al., 1995). 
This dynamic hyperinflation facilitates expiratory airflow in patients with COPD by two 
mechanisms. Firsfiy, a positive relationship exists between lung volume and expiratory air flow 
such that the higher the lung volume, the faster the expiratory airflow due to the elastic recoil of the 
lungs, this is termed the "expiratory flow volume curve" {West 1995). Therefore, dynamic 
hyperinflation allows expiration to function along a higher portion of the expiratory flow volume 
curve, which increases the speed of expiratory airflow (Belman 1993). The second mechanism by 
which dynamic hyperinflation aids expiratory air flow is by increasing muscular force during 
expiration. In healthy individuals, the internal intercostal muscles act as expiratory muscles whilst 
the external intercostals act as inspiratory muscles (West 1995). In patients with COPD, dynamic 
hyperinflation shifts the extern-al intercostal muscles to a mechanical position that results in their 
behaving as an expiratory muscle. In studies on dogs, De Troyer et al., (1995) reported that as RV 
approaches TLC both the internal and the external intercostal muscles act as expiratory muscles, 
aiding expiration with increased muscular force. 
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However, whilst aiding expiration, dynamic hyperinflation hinders inspiration (Derenne et al., 1978). 
Firstly, hyperinflation shifts the ribs from the normal oblique position to a more horizontal position, 
making it difficult for the inspiratory intercostal muscles to lift the ribs and expand the rib cage, 
movements necessary for inspiration (Belman 1993). Secondly, in healthy individuals, the 
diaphragm functions as the major inspiratory muscle. In order to generate transdiaphragmatic 
pressure and aid inspiration the diaphragm needs to be in a curved position with an upward 
convexity (West 1992). However, in patients with COPD, during dynamic hyperinflation the 
diaphragm is moved to a shortened position with a flattened shape. In this shortened, flattened 
position, the diaphragm acts as an expiratory muscle rather than an inspiratory muscle (Tobin 
1988). Accordingly, the contribution of muscular force to inspiration is reduced. In addition, 
inspiration becomes more difficult as it occurs on a less compliant portion of the pressure volume 
curve with a resultant decrease in the elastic recoil by the lungs and increased WOB (Belman 
1992). As a result of this impaired ability to inspire, the (h cost of breathing increases. Healthy 
subjects have an (h cost of breathing of 2.5ml/min at rest, this increases to 30mllmin in patients 
with COPD. This translates to 15% vs 1-2% of total body (h consumption relative to healthy control 
subjects (Tobin 1988). 
Thus dynamic hyperinflation aids expiration but hinders inspiration in these patients. It has been 
hypothesized that this impaired inspiration may play a role in exercise intolerance in patients with 
COPD (Belman 1985; O'Donnell et al., 1988; Gallagher 1990). 
(b) Abnonnal breathing patterns in patients with COPD 
As these patients experience slow and difficult expiration, inspiration often begins before FRC is 
reached. As a result, during inspiration the respiratory muscles are forced to generate additional 
pressure to overcome the elastic recoil of the lungs that occurs during expiration (Belman 1992). 
This further increases the inspiratory WOB. In addition, patients with COPD reportedly recruit their 
respiratory muscles in an inefficient manner during ventilation, further increasing the work of 
breathing (WOB) (Derenne et al., 1978). 
An abnormal breathing pattern of increased VTNC is present at rest and is exacerbated during 
exercise in patients with COPD and may therefore contribute to exercise intolerance (Marin et al., 
1993). It would appear that those patients with the greatest impairment of resting lung mechanics 
showed the greatest abnormalities in breathing patterns at rest and during exercise (Marin et al., 
1993). 
Therefore, both dynamic hyperinflation and abnormal breathing patterns result in an increased 
WOB and an increased ventilatory demand which may limit exercise capacity in patients with 
COPD. 
(c) Measurement of ventilatory demand during exercise in patients with COPD 
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To examine the hypothesis that increased ventilatory demand may limit exercise tolerance in 
patients with COPD, researchers have made use of comparisons between an MW achieved at 
rest and the maximum VE achieved during exercise in these patients. The MW is a measure of the 
maximum ventilation in subjects when asked to breathe maximally for 12 seconds. The result of 
this test is then extrapolated to one minute to calculate a rate in 1/min. The maximum VE achieved 
during exercise is then compared to the MVV to assess whether the maximum ventilatory capacity 
was reached during exercise. Many authors have reported that VE during exercise approaches or 
exceeds an MW measured at rest in some patients with COPD (Clark et al., 1969; Spiro et al., 
1977; Mahler et al., 1988; Mathews et al., 1989). In contrast, in a more recent study, Marin et al., 
(1993) reported an average VsMVV of 76% in 29 patients with COPD. This finding implies that a 
factor other than ventilatory mechanics may limit exercise tolerance in these patients. 
(d) The relationship between changes in ventilatory mechanics and changes in exercise 
tolerance after exercise training in patients with COPD 
An important consideration when reviewing the role of ventilatory mechanics in exercise 
intolerance in patients with COPD are exercise training studies. Patients with COPD demonstrate 
an improved functional capacity after exercise training (McGavin et al., 1977; Belman 1982; 
Gallagher 1990). If ventilation mechanics were limiting exercise ability in these patients, then an 
improvement in ventilation mechanics would be expected after exercise training to explain the 
improved functional ability. However, many authors have shown improved exercise perfonnance 
in patients with COPD after training, without changes in dynamic hyperinflation, breathing patterns 
or VSMW ratio (McGavin et al., 1977; O'Donnell et al., 1993, Olopade et al., 1992; Carteret 
al., 1991 ). This finding suggests that factors other than ventilatory mechanics are responsible for 
the improved exercise tolerance reported in patients with COPD after exercise training and 
therefore that ventilatory mechanics are unlikely to have been the sole cause of exercise 
intolerance prior to training. 
(e) The role of dyspnea in exercise intolerance in patients with COPD 
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The increased muscle effort required for ventilation during exercise in patients with COPD, as 
discussed previously, results in a parallel increase in the sensation of dyspnea (EI-Manshawi et 
al., 1986; Leblanc et al., 1986; McParland et al., 1986). Some authors argue that the increased 
sensory perception of dyspnea and the anxiety and distress accompanying dyspnea, cause early 
tennination of exercise in patients with COPD (Jones 1984; Kilian et al., 1986; Woodcock et al., 
1982; Olopade et al., 1992). Woodcock et al., (1982) tested this theory by administering a mild 
central nervous system depressant (dihydrocodeine) to patients with COPD suffering from 
dyspnea. Dihyrdocodeine would decrease the stress and anxiety that accompany the sensation of 
dyspnea. Woodcock et al., (1982) reported decreased exertional dyspnea and increased 
exercise tolerance in patients after ingesting dihydrocodeine. This finding suggests that the 
anxiety and stress accompanying the sensation of dyspnea contribute to exercise intolerance in 
patients with COPD. This theory is further supported by studies demonstrating decreased 
dyspnea and subsequent increased exercise tolerance after exercise training in patients with 
COPD (McGavin et al., 1977; O'Donnel et al., 1993). This finding suggests that these patients may 
experience decreased anxiety due to familiarization with the sensation of dyspnea during exercise 
training and thereby improve their exercise capacity (O'Donnel et al., 1993). 
In contrast, Carrieri-Kohlman et al., {1996) recently demonstrated that it was not the stress and 
anxiety accompanying dyspnea that prompted early exercise tennination in 54 patients with 
COPD, but the sensation of dyspnea itself. Subjects were asked to differentiate between four 
components of dyspnea during exercise. The four components included : shortness of breath, 
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perceived work of breathing, distress associated with dyspnea and anxiety associated with 
dyspnea. The authors assumed that both work of breathing and shortness of breath were a 
reflection of the sensation of dyspnea itself. The distress and anxiety associated with the dyspnea 
were regarded as the affective components that accompany dyspnea in the patients. The 54 
patients with COPD rated work of breathing and shortness of breath significantly higher compared 
to the affective components of dyspnea during exercise. Therefore, the authors suggest that (i) 
patients with COPD are able to distinguish between the physical sensation of dyspnea and the 
affective components of dyspnea and (ii) that the physical sensation of dyspnea and not ifs 
affective components limit exercise tolerance. 
The role of dyspnea in exercise intolerance in patients with COPD is therefore unclear. 
Furthermore, the psychological components that accompany the sensation of dyspnea make it 
difficult to effectively investigate dyspnea in a well controlled trial. 
(f) The role of the respiratory muscles in exercise intolerance in patients with COPD 
(i) Respiratory muscle weakness and fatigue in patients with COPD 
Conflicting evidence is presented in the literature concerning the role that respiratory muscle 
weakness and fatigue may play in limiting exercise tolerance in patients with COPD. As explained 
previously, it is the inspiratory muscles of these patients that are overworked and therefore prone 
to fatigue (Derenne et al., 1978; Dodd et al., 1983). The inspiratory muscles in humans are the 
external intercostal muscles and the diaphragm (West 1985). The diaphragm is the most important 
inspiratory muscle in_ the body (West 1985). In a healthy individual the diaphragm is stronger and 
more resistant to fatigue than other skeletal muscles (Derenne et al., 1978). However, as 
explained in the section on dynamic hyperinflation, in patients with COPD the diaphragm is moved 
to a shortened, flattened position that is mechanically disadvantageous (Rochester 1991; Tobin 
1988). This decreased mechanical efficiency may lead to functional weakness and an increased 
susceptibility to fatigue during-exercise (Rochester 1991 ). 
Various authors argue that respiratory muscle fatigue may limit exercise in patients with COPD 
(Pardy et al., 1980; Bellemare et al., 1983; Dodd et al., 1983; Polkey et al., 1995). In contrast, 
9 
Gallagher (1986) argues that respiratory muscle fatigue does not occur during exercise in these 
patients. Table 1.1 presents a summary of the literature reviewing inspiratory muscle fatigue during 
exercise in patients with COPD. 
T bl 1 S a e 1. - ummary o s u 1es exam1nmg msp1r ory muse e lgue unng exercise mp; en WI f t d' 'at I fati d . . . ati ts 'th COPD 
Authors Sample size Diaphragm fatigue Inspiratory intercostal 
fatigue 
Pardy et al., 1980 n= 12 n=6 n=6 (same 6 as for OF) 
Bellamare et al., 1983 n= 20 n=20 NE 
Dodd et al., 1983 n=7 n=4 n=7 
Gallagher 1986 n=7 n=O n=O 
Pelkey et al., 1995 n=6 n=O n=6 
.. Abbreviations: NE, not excmmed; OF, dil:llhragn fatigue; n, scmple SIZe 
Pardy et al., (1981) demonstrated diaphragm fatigue and external intercostal muscle fatigue in six 
of 12 patients with COPD using EMG analysis during an incremental cycle test to exhaustion. 
Similarly, Bellemare et al., (1983) demonstrated diaphragm fatigue using EMG analysis in 20 
patients with COPD during maximum breathing. As mentioned previously, the diaphragm functions 
by creating transdiaphragmatic pressure (TOP) to assist inspiration. Therefore, the amount ofTDP 
generated is used to assess the effectiveness of the diaphragm during inspiration. If the TOP 
generated during exercise is close to the maximum TOP possible, then the diaphragm would be 
functioning close to its maximum ability for a prolonged period of time which is likely to result in 
fatigue (Bellemare, 1983). As a result of this fatigued diaphragm, early exercise termination is 
possible. Bellamare (1983) demonstrated a TOP close to maximum TOP during maximal 
breathing in the 20 patients with COPD and therefore concluded that diaphragm fatigue is likely to 
cause exercise intolerance in these patients. 
Dodd et al., (1983) reported that the diaphragm and the inspiratory intercostal muscles in patients 
with COPD who demonstrated exercise intolerance generated a higher proportion of peak 
inspiratory pleural pressure and peak TOP compared to those patients who were able to exercise 
longer. Dodd et al., (1983) concluded that the inspiratory muscle are required to function close to 
their maximum during exercise in patients with COPD and therefore inspiratory muscle fatigue is 
likely to limit exercise tolerance. 
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As previously mentioned, various authors have concluded that if patients with COPO produce a 
TOP close to their maximum during exercise, then the inspiratory muscles are fatigued and 
exercise is likely to be terminated early. If this were the case then a drop off in TOP at end 
exercise would be expected. However, Pelkey et al., (1995) reported that six patients with COPO 
failed to demonstrate reduced TOP at termination of exhaustive exercise. The same six patients 
did however show a decline in maximal relaxation rate in the inspiratory intercostal muscles at the 
termination of exhaustive exercise. This finding would suggest that the inspiratory intercostal 
muscles fatigue during exercise in patients with COPO. The authors therefore suggest that the 
inspiratory muscle fatigue during exercise in patients with COPO results in dyspnea, which in turn 
causes early exercise termination prior to diaphragm fatigue. The authors suggest that this is a 
protective mechanism to preserve the diaphragm in patients with COPO. 
In contrast to the studies previously discussed, Gallagher (1983) argued that neither the inspiratory 
intercostal muscles nor the diaphragm fatigue during exercise in patients with COPO and therefore 
do not play a role in their exercise intolerance. Gallagher (1983) argued that inspiratory muscle 
fatigue is known to cause rapid shallow breathing and as he failed to demonstrate rapid shallow 
breathing in seven patients with COPO immediately after maximal exercise, he concluded that 
respiratory muscle fatigue did not cause early exercise termination in these patients. 
Therefore, the role of respiratory muscle fatigue in exercise intolerance in patients with COPO is 
unclear although it does appear that functional abnormalities exist in the respiratory muscles of 
patients with COPO. 
(ii) The effect of inspiratory muscle training on exercise tolerance in patients with COPD 
Various authors have demonstrated that exercise tolerance improves in patients with COPO after 
participation in an inspiratory muscle training programme (Belman _et al :• 1980; Pardy et al., 1980; 
Wanke et al., 1994). 
Belman et at., (1980) demonstrated improvements in maximum sustained ventilatory capacity 
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(MSVC), in ten patients with COPD after inspiratory muscle training. Oxygen consumption during 
the MSVC, arm and leg ergometer submaximal exercise time and maximum distance walked in a 
12 minute walk test all improved in ten patients with COPD after six weeks of inspiratory muscle 
training. Additionally, Pardy et al., (1980) demonstrated improvements in peak V02 during cycle 
ergometry, peak endurance time during cycle ergometry and distance walked in six of 12 patients 
with COPD after an eight week inspiratory muscle training programme. Upon entry to the study, 
the extent of inspiratory muscle fatigue during exercise was measured in the patients using EMG 
analysis. The six patients who initially demonstrated inspiratory muscle fatigue showed improved 
exercise tolerance after inspiratory muscle training. In contrast, the six patients who did not initially 
demonstrate inspiratory muscle fatigue during exercise did not benefit from inspiratory muscle 
training. Similarly, Wanke et al., (1994) reported improved maximum power output and 02 uptake in 
42 patients with COPD following an eight week cycle ergometer training programme. However, in 
the 21 patients in this group who included inspiratory muscle training in addition to the cycle 
ergometer training in their rehabilitation programmes, the improvements in maximal power output 
and (h uptake were, on average, significanijy greater. 
Thus it would appear that in some patients with COPD, inspiratory muscle fatigue may play a role 
in exercise intolerance. Accordingly, training of the inspiratory muscles may therefore improve 
exercise tolerance in those patients with impaired inspiratory muscle mechanics. 
(iii) Histology of respiratory muscle in patients with COPD 
The studies discussed previously suggest that functional abnormalities exist in the respiratory 
skeletal muscle of patients with COPD. Investigation into the structure or histology of the 
respiratory skeletal muscles in patients with COPD is therefore warranted. 
Patients with COPD demonstrate an altered respiratory muscle fibre composition, respiratory 
pattern/function and neuromotor innervation compared to healthy subjects (Mizuno 1991 ). Mizuno 
(1991) noted a decreased fibre size in both Type I and Type II fibres in the thoracic respiratory 
muscles in patients with COPD. The author was uncertain as to whether the decreased fibre size 
was due to overuse as a result of increased ventilatory WOB, or disuse due to an increased 
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involvement of the extra thoracic muscles. Mizuno (1991) also reported a reduced percentage of 
slow twitch fibres (49%) in the inspiratory and expiratory intercostal muscles in some patients with 
COPD, whilst in other patients the percentage of slow twitch fibres was the same as in normal 
human respiratory muscle (62%). 
Campbell et al.,(1980) biopsied the internal intercostal muscles, the external intercostal muscles 
and the latissimus dorsi muscles of 22 patients suspected of pulmonary neoplasm and suffering 
from clinical airways obstruction (COPD). Morphological changes were observed in the respiratory 
muscles of 17 of the 22 patients. The changes included: fibre splitting, variation in fibre size, fibre 
atrophy and centralized nuclei. None of these changes were evident in the latissimus dorsi 
muscle. A greater percentage of Type II fibres was reported in the intercostal muscles compared 
to the latissimus dorsi muscle in the patients with COPD. A similar distribution of Types I and II 
fibres was found in both intercostal muscles whilst atrophy was only evident in the Type II (fast 
twitch) fibres. The expiratory intercostal muscles demonstrated greater atrophy of Type II fibres 
than the inspiratory intercostal muscles in the patients with COPD. In addition, the authors reported 
a relationship between FEV,/FVC and extent of Type II atrophy in the expiratory intercostal 
muscles (r-0.78, p<0.001 ). No hypertrophy was found in any of the biopsies. Biochemical 
analysis of the skeletal muscle biopsies revealed decreased concentrations of ATP and PCr in 
both the inspiratory and the expiratory intercostal muscles and in the lattisimus dorsi muscles. 
Thus, morphological and biochemical abnormalities were clearly evident in the respiratory muscles 
of the patients. 
In the opinion of Campbell et al., (1980), the morphological changes seen in the respiratory 
muscles of the patients were specific to the respiratory muscles and not a general effect in the 
skeletal muscle of the body. The author argued this conclusion as only one of the eight latissimus 
dorsi muscle biopsies showed morphological abnormalities in the patients with COPD. 
Additionally, Campbell et al., (1980) concluded that the morphological changes seen in the 
respiratory muscles of the patients were due to disuse rather than overuse for two reasons. Firstly, 
the expiratory intercostals had greater morphological abnormalities than the inspiratory 
intercostals, whilst, as previously discussed the inspiratory muscles in patients with COPD are 
overused to a greater extent than the expiratory muscles. Therefore, if overuse was the cause of 
the morphological abnormalities seen in the respiratory muscles of the patients with COPD, a 
greater abnormality would have been expected in the inspiratory intercostal muscles which was 
not the case. Secondly, there was an absence of fibre hypertrophy, which is likely to be found in 
muscle subjected to overuse. 
In contrast to the morphological abnormalities, the authors suggested that the biochemical 
changes measured in the respiratory muscle of the patients with COPD were a more generalized 
abnormality, as these same changes have been reported by two other authors in the quadriceps 
muscles in patients with COPD {Bergstrom et al., 1976, Gertz et al., 1977). Unfortunately, 
Bergstrom et al., {1976) and Gertz et al., {1977) did not examine the morphological status of the 
quadriceps muscles in the patients with COPD. 
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In summary, Campbell et al., (1980) reported biochemical and morphological abnormalities in the 
respiratory muscles of patients with COPD, which in their opinion were due to disuse of these 
respiratory muscles. They concluded that the morphological abnormalities were specific to the 
respiratory muscles whilst the biochemical abnormalities reported may have been a more general 
abnormality in the skeletal muscle of these patients. 
In contrast to Campbell et al., {1980) who reported a greater percentage of Type II fibres in the 
respiratory muscles of patients with COPD, Karlsson et al., {1992) reported a higher than normal 
percentage of Type I (slow twitch) fibres in the respiratory muscles of patients with COPD. 
However, these results need to be interpreted with caution as (i) only four patients underwent 
skeletal muscle biopsy and {ii) to negate a genetic effect, the relative predominance of fibre types 
in the respiratory muscles were calculated by dividing the percentage of fibre types in the 
respiratory muscles relative to the percentage fibre types in the same subject's vastus lateralis 
muscle. This would effectively negate a generalized fibre type shifting which might be the case in 
patients with COPD. In fact, when the results are scrutinized, the percentage fast twitch fibres in 
the internal and external intercostal muscles of the four patients biopsied averages 52%, which is 
within the "normal· range for fast twitch percentage in nonnal adult males (Dubowitz 1985). The 
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percentage fast twitch fibres in the vastus lateralis muscles of the patients was not presented. 
Lastiy, a recent case report demonstrated histological abnormalities in the mitochondria of the 
diaphragm muscle, yet no abnormalities in the latissimus dorsi and intercostal muscles of a patient 
with COPD (Uoreta et al., 1996a) were found. The histological abnormalities described in the 
diaphragm of the patients with COPD included large aggregates of mitochondria with 
mitochondrial paracrystalline rectangular inclusions. In contrast, the latissimus dorsi and 
intercostal muscles showed only a moderately increased number of mitochondria and no 
mitochondrial paracrystalline rectangular inclusions. This is the first known report of 
paracrystalline deposits in the respiratory muscles of a patient with COPD. As these paracrystalline 
deposits are more commonly found in the myopathy of hyperthyroidism (Lioreta et al., 1996), the 
authors concluded that selective overuse of the diaphragm may be responsible for these 
mitochondrial changes. It is interesting that mitochondrial paracrystalline deposits have been 
reported in the vastus lateralis muscle of patients with end stage renal failure (Diesel et al., 1993). 
In summary, it would appear that functional, biochemical and structural abnormalities exist in the 
respiratory muscles of patients with COPD. It is therefore possible that these abnormalities may 
contribute to exercise intolerance in these patients. 
(iv) Enzyme activity in the respiratory muscles of patients with COPD 
As mentioned, biochemical abnormalities have been reported in the respiratory muscles of patients 
with COPD. Similarly, Sanchez et al., (1988) measured activities of the glycolytic enzyme lactate 
dehydrogenase (LDH), and the oxidative enzymes; hexokinase (HK), citrate synthase (CS) and 3-
hydroxyacyi-CoA dehydrogenase (HAD) in the expiratory and inspiratory intercostal muscles, the 
serratus anterior muscle (an accessory inspiratory muscle) and the latissimus dorsi (a non-
respiratory muscle), in nine subjects with normal lung function and 11 patients with moderate 
COPD. 
The metabolic activities of HK, CS and HAD were higher in the internal and external intercostal 
muscles when compared with the latissimus dorsi muscle in the patients with COPD. Additionally, 
the metabolic activities of HK, CS and HAD in the internal and external intercostal muscles of the 
patients was significantiy higher compared to the control group. No differences were found in 
activity levels of LDH (an enzyme necessary for energy production using the non-oxidative 
pathway in skeletal muscle) in the patients compared to the control group. These metabolic 
changes are normally seen in skeletal muscle that has undergone endurance training (Jones 
1990). Therefore, the authors concluded that because of diaphragm fatigue the intercostal 
muscles were subjected to overuse and consequentiy demonstrated the metabolic effects of 
endurance training. Accordingly, this finding suggests that the intercostal muscles are unlikely to 
cause early exercise termination in patients with COPD. However, the author's suggest that the 
diaphragm does fatigue during exercise in these patients. 
In summary, the respiratory muscles of patients with COPD demonstrate functional, structural, 
biochemical and metabolic abnormalities and these abnormalities may play a role in exercise 
intolerance. Furthermore, although various hypotheses have been suggested, the mechanism of 
these abnormalities in the respiratory muscle of patients with COPD is not known. 
3./mpaired Gas Exchange as a Limiting Factor During Exercise in Patients With COPD 
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As discussed earlier, patients diagnosed with COPD may have a larger degree of either bronchial 
obstruction and inflammation (chronic bronchitis) or alveoli destruction (emphysema), depending 
on the primary component of their disease. Those patients with a large degree of alveolar 
destruction suffer greater impaired gaseous exchange than those with bronchiolar obstruction and 
inflammation. 
Patients with emphysema have an increased physiological dead space due to the destruction of 
the alveoli (West 1992). In a healthy individual, during exercise, physiological dead space 
decreases relative to the increasing tidal volume 0/D/VT) to compensate for the increased 
ventilatory demand (West 1992). However, in patients with COP[)., the-VDNT ratio increases 
during exercise due to increased physiological dead space. This results in an exacerbation of 
ventilation/perfusion mismatch (Oiopade et al., 1992). An increased ventilation/perfusion mismatch 
results in less blood being effectively oxygenated with resultant systemic hypoxaemia (low Pa02) 
(West 1992}. Whilst some patients with COPD respond to the hypoxaemia by increasing VE, 
others do not (Jones 1988}. This systemic hypoxaemia may limit exercise tolerance in two ways. 
FirsHy, in the patients who respond to the hypoxaemia by increasing VE, the resultant increased 
ventilatory demand and the mechanical factors limiting their ability to respond to this increased 
ventilatory demand (as previously discussed in the section on ventilation} may limit exercise 
capacity (Belman 1993}. Secondly, the subsequent rise in PaC02 as a result of hypoventilation 
may limit exercise tolerance (Jones 1988}. 
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However, blood gas concentrations vary between patients with COPD. Patients may be 
hypoxaemic at rest, hypoxaemic during exercise or maintain normal levels of Pa02 at all times 
(West 1992}. Some patients display transient oxygen desaturation during daily living activities 
such as walking, washing and eating even in the absence of resting hypoxaemia (Soguel Schenkel 
et al., 1996}. This variable hypoxaemic state results in conflicting literature when considering 
exercise intolerance in patients with COPD. 
If hypoxaemia was the factor limiting exercise capacity in patients with COPD, then oxygen 
supplementation should improve exercise capacity in these patients. Palange et al., (1995} 
demonstrated decreased VE and V02 at the same submaximal work load during cycling in nine 
patients with COPD whilst taking supplemental oxygen Similarly, Woodcock et al., (1981} 
demonstrated significant improvement in walking distance in only six of ten patients who used 
supplemental oxygen during a walking test. These finding suggest that only some patients with 
COPD demonstrate improved exercise tolerance when using supplemental oxygen and that 
impaired gas exchange was initially limiting exercise capacity in some patients with COPD. 
However, not all the patients demonstrated improved exercise tolerance with supplemental 
oxygen. Thus factors other than hypoxaemia may have been responsible for early exercise 
termination in other patients with COPD. 
Accordingly, other authors argue against hypoxaemia as a major limiting factor during exercise in 
patients with COPD. Chester et al., (1970}; Nicholas et al., (1977} and Patessio et al., (1992} 
demonstrated that although exercise tolerance in patients with COPD improved with exercise 
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training, no parallel improvements in either resting or exercising levels of Pain were evident. 
Therefore, it is unlikely that impaired gas exchange was responsible for the exercise intolerance in 
these patients with COPD before training. In addition, Spiro et al., (1975) reported that changes in 
blood gas tensions in a group of patients with moderate COPD were small (less than 2mmHg) and 
in the authors opinion unlikely to have contributed to exercise intolerance in these patients. Spiro 
et al., (1975) did however report a significant decrease in blood gas tensions during exercise in a 
group of patients with severe COPD. 
In summary, it seems unlikely that hypoxaemia is the major limiting factor during exercise in 
patients with COPD not in chronic respiratory failure. However, in patients suffering from severe 
emphysema, chronic respiratory failure and consequent severe hypoxaemia at rest (Pa02 < 
60mmhg), exercise may be limited by insufficient gas exchange. 
3. The Role of Skeletal Muscle in Exercise Intolerance in Patients with COPD 
Most research investigating exercise tolerance in patients with COPD has focused on central 
factors, including cardiorespiratory factors. Far less research has investigated the role of skeletal 
muscular factors in exercise intolerance in these patients. 
(a) Skeletal muscle strength and endurance in patients with COPD 
Skeletal muscle weakness may contribute to exercise intolerance in patients suffering from other 
chronic diseases. Patients suffering from renal failure (Kempeneers et al., 1990; Diesel et al., 
1990) and patients in cardiac failure (Derman et al., 1993), demonstrate a skeletal muscle 
weakness which contributes to exercise intolerance. In end stage renal dialysis patients, Diesel et 
al., (1990) reported peak isokinetic muscle strength to be a much better predictor of exercise 
capacity than variables determining blood oxygen carrying capacity. Similarly, Lipkin et al., (1988) 
found a significant correlation between isokinetic muscle power and peak oxygen consumption in 
patients with congestive heart failure. It therefore appears that skeletal.muscle function may be an 
important component of exercise intolerance in patients with chronic diseases. Additionally, a 
significant number of patients with COPD terminate exercise because of muscular fatigue (Kilian et 
al., 1992). Accordingly, in the 1990's, the hypothesis that skeletal muscle may contribute to 
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exercise intolerance in patients with COPD is being researched. 
Most of the central variables discussed previously, including ventilation mechanics and gas 
exchange, do not improve in patients with COPD after exercise training. This is despite improved 
exercise tolerance in these patients. In contrast, exercise training studies in patients with COPD 
demonstrate improvement in skeletal muscle strength and improved exercise tolerance (Simpson 
et al., 1992; Clark et al., 1996). Clark et al., (1996) reported improved whole body endurance, 
measured by treadmill walking time, in 32 patients with COPD after 12 weeks of low intensity 
skeletal muscle conditioning. Additionally, various measures of upper and lower body skeletal 
muscle isotonic endurance in the 32 patients with COPD improved significantly after training. The 
same group of patients demonstrated no improvements in maximum V02 or in peak isokinetic 
quadriceps strength after exercise training, but did show lower VQ.z and ventilatory requirements at 
the same submaximal work load during progressive cycle ergometry. The findings of this study 
suggest that isotonic skeletal muscle endurance contributes to exercise capacity in patients with 
COPD and improves with training. 
Simpson et al., (1992) reported similar results in 14 patients with COPD who underwent a 
controlled weightlifting training programme for eight weeks. They demonstrated improvements of 
isotonic and isometric skeletal muscle strength, exercise endurance and subjective responses to 
some of the demands of daily living compared to an untrained control group (n=14).1mprovements 
in isotonic strength were measured as a 1 repetition max (1 RM). Improvements of 33% in arm curl 
1RM, 44% in leg extension 1RM and 16% in leg press 1RM (p<0.01 for all) in the trained patients 
were reported. The control group showed no change in isotonic muscle strength after an eight 
week period. Similarly the mean isometric force in the quadriceps muscle of the patients with 
COPD who participated in the exercise training programme improved by 18%, whilst the control 
group showed no improvement. Exercise endurance was measured by a submaximal cycle 
ergometry test at 80% of maximal power output until self termination. The trained group of patients 
demonstrated a 73% improvement in endurance time during this submaximal exercise test (518 
seconds vs 898 seconds; p<0.01) whilst the control group showed no change in exercise 
endurance time. Peak VQ.z recorded during an incremental cycle test to exhaustion and distance 
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walked during the SMWT did not improve in either the trained patients or the control group. The 
results of this study suggest that isotonic and isometric skeletal muscle strength may contribute to 
submaximal exercise endurance in patients with COPD. 
A third study investigating skeletal muscle weakness in patients with COPD was conducted by 
Gosselink et al., (1996) who measured skeletal muscle isometric strength (peak quadriceps force 
and peak hand grip force) and exercise capacity (peak V02 achieved during an incremental cycle 
test to exhaustion and distance walked during a SMWT) in 41 patients with COPD. Peak isometric 
quadriceps strength (QF) and peak isometric hand grip strength (HF) correlated to distance walked 
during the SMWT (r-0.63 I p<0.05; r-0.61 I p<0.05; QF;HF) and to peak vo2 achieved during the 
incremental cycle test (r-0.55, p<0.05; r-0.53, p<0.05; QF;HF) in the patients with COPD. 
Additional correlations were found between peak V~ achieved during the incremental cycle test 
and TLCOsb (r-0.68;p<0.05). Significant, but lower correlations were found between TLCOsb and 
distance walked during the SMWT (r-0.38; p<0.05) and between inspiratory muscle strength {PI 
max) and distance walked during the SMWT (r-0.49; p<0.05). The findings of this study suggest 
that isometric skeletal muscle strength contributes significantly to exercise tolerance in patients 
with COPD. 
In summary, it would appear that isometric and isotonic skeletal muscle strength as well as isotonic 
skeletal muscle endurance may all contribute to exercise intolerance in patients with COPD. In 
contrast, isokinetic muscle strength may not be an important contributing factor. The results of the 
above mentioned studies can be interpreted in a different way. The measures of isotonic skeletal 
muscle endurance improved in response to isotonic muscle endurance training (Clark et al., 1996) 
whilst in a second study isotonic and isometric skeletal muscle strength improved in response to 
isotonic and isometric skeletal muscle strength training (Simpson et al., 1992). In contrast 
isokinetic skeletal muscle peak strength did not improve in response to isotonic muscle endurance 
training (Clark et al., 1996). Thus it would appear that if the muscle testing conducted in the 
studies was specific to 1) the type of muscle training conducted (strength vs endurance) and 2) the 
method of muscle training (isotonic vs isokinetic vs isometric), improvements were noted in the 
functional ability of the skeletal muscle of the patients with COPD. To our knowledge, no study has 
examined the role of isokinetic or isometric skeletal muscle endurance in determining exercise 
capacity in patients with COPD. Additionally, the mechanism causing this skeletal muscle 
weakness and fatigue is not known. Further research is therefore warranted. 
(b) Skeletal muscle and health care utilization in patients with COPD 
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Decramer et al., (1997) studied factors predicting the frequency of health care utilization in 57 
patients with COPD. Patients were divided into two groups: those admitted to hospital twice, or 
more than twice in the previous year and those that were not admitted at all. The only significant 
difference reported between the groups was isokinetic peak muscle strength (quadriceps force 
63±20 vs 82 ±26 % of predicted respectively; p< 0.05) and, to a lesser degree, respiratory muscle 
force. No differences were found between the two groups for pulmonary function tests, serum 
electrolyte concentrations, blood gas concentrations, ASA score (a scoring system used to 
categorize patients with COPD in terms of severity of disease) or distance walked during the 
SMWT. Additionally a significant inverse relationship was found between the number of days 
spent in hospital and the peak quadriceps force (r=-0.35; p<O.OS). The authors concluded that 
frequency of health care utilization was related to skeletal muscle weakness in patients with 
COPD. Thus it would seem that skeletal muscle weakness as measured by isokinetic peak 
quadriceps force may contribute, at least in part, to the health care utilization of patients with 
COPD. 
(c) Skeletal muscle metabolism in patients with COPD 
With the advent of nuclear magnetic resonance imaging it became possible to study the 
metabolism of skeletal muscle in patients with COPD. Abnormalities exist in oxidative skeletal 
muscle metabolism of patients with COPD (Jacobbsen et al., 1990; Tada et al., 1992; Wuyam et 
al., 1992;Thompson et al., 1992). These abnormalities will be discussed firstly at rest and 
secondly during exercise. 
(i) Skeletal muscle metabolism at rest in patients with COPD 
A summary of research papers analyzing skeletal muscle metabolism in patients with COPD at 
rest is presented in Table 1.2 
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Tab e 1.2 Summary o stu 1es exammmg s e e f d' k I tal muse e me o 1sm m pa en WI res tab r ti ts 'th COPD at t 
Authors Sample size Muscle ATP PCr Gly Pi pH Pi/PCr 
Bioll_sied I NMR 
Gertz et al., 1977 n=12 (ARF) Quadriceps Femoris -l- -l-
Fiaccordi et al., 1987 n=10 (ARF) Quadriceps Femoris -l- -l-
Jacobbson et al., 1990 n=10 (NRF) Quadriceps Femoris B B B 
Jacobbson et al., 1990 n=8 (CRF) Quadriceps femoris -l- -l- -l-
Tada et al., 1992 n=11 (NRF) Flexor Digitorum B B B 
Superficialis (NMR) 
Wuyam et al., 1992 n=8 (CRF) Gastrocnemius B B 
(NMR) 
.. .. Abbrevtat1ons: ATP, adenosme triphosphate; PCr, phosphocreatine; P1, morgamc phosphate; pH, mtracellular pH; P11PCr, 
inorganic phosphate:phosphocreatinine; ARF, acute respiratory failure; CRF, chronic respiratory failure; NRF, patients with COPD 
not in respiratory failure; .J... significantly decreased relative to controls; t . significantly increased relative to controls; ~ no 
significant difference between patients with COPD and controls; NMR. Nuclear magnetic resonance ~n these studies no biopsy 
was performed); Gly,Giycogen. 
Gertz et al., (1977) reported reduced ATP and PCr concentrations in 12 patients with COPD 
admitted to hospital for acute respiratory failure compared to patients admitted to hospital for 
reasons other than respiratory disease. These finding suggest impaired skeletal muscle oxidative 
metabolism in patients with COPD who are in acute respiratory failure. In 1987 Fiaccadori et al., 
biopsied the quadriceps femoris muscle of ten hypoxic-hypercapnic (acute respiratory failure) 
patients with COPD. These patients demonstrated a 30-35% reduction in ATP and PCr 
concentrations and in the ATP/ADP ratio. 
Similarly, Jacobbson et al., (1990) reported reduced ATP , PCr and glycogen concentrations in the 
quadriceps femoris muscles of eight patients with COPD in respiratory failure compared with ten 
patients with COPD not in respiratory failure. This finding suggests that the oxidative metabolism 
in the skeletal muscle of patients with COPD who are in acute respiratory failure is impaired. In 
contrast, those patients with COPD not in acute respiratory failure maintain normal skeletal muscle 
oxidative metabolism at rest. In support of this hypothesis, Tada et al., (1992) reported that resting 
concentrations of PCr and Pi in the calf muscles of 11 patients with chronic lung disease, not in 
respiratory failure, where not different from healthy controls. Howev~r, W!Jyam et al., (1992) 
reported no significant difference in pH and no difference in the Pi/PCr ratio at rest in the calf 
muscles of eight patients with COPD who were in respiratory failure, compared to nine healthy 
control subjects. 
22 
In summary, it therefore appears that at rest impaired oxidative skeletal muscle metabolism is 
present in the skeletal muscle of patients with COPD who are in acute respiratory failure. In 
contrast, the oxidative skeletal muscle metabolism at rest appears to be maintained in patients with 
COPD who are not in acute respiratory failure. It is interesting that Campbell et al., (1980) reported 
decreased A TP and PCr in the intercostal muscles of patients with COPD. 
(ii) Skeletal muscle metabolism during exercise in patients with COPD 
A summary of studies investigating skeletal muscle metabolism during exercise in patients with 
COPO is presented in Table 1.3 
T bl 13 a e . Summary o stu tes examining s e eta muse e me otsm unng exerctse tn pa ents With CO f d' k I I tab r d · tl 
Oxidative Enzymes Glycolytic Enzymes 
PO 
Authors Sample size cs HAD HK PFK LDH pH Pi/PCr 
Tada et al., 1992 n=11(NRF) ~ t 
WlJifam et al., 1992 n=8 (CRF) ~ t 
Thompson et al., 1992 n=5 {CRF) ~ t 
Maltais et al., 1997 n=9 (NRF) -1- ~ ~ ~ ~ 
.. • 0 AbbreVIations: ATPO adenOSille triphosphate; PCr, phosphocreatine; Pi 0 magaruc phosphate; pH, 1ntracellula' pH: Pi/PCr, 
inorganic phosphate:phosphocreatine ratio; ARF, acute respiratory failure; CRF. clvonic respiratory failure; NRF 0 patients with 
COPD not in respiratory failll'e; J. 0 significantly deaeased relative to controls; ! 0 significantly increased relative to controls: ~ no 
significant difference between patients with COPD and controls. 
Metabolic abnormalities in the skeletal muscles of patients with COPD during exercise were 
reported by Tada et al., (1992). Eleven patients with COPD, who were not in respiratory failure, 
produced a higher PiiPCr ratio in the third and fourth minute of four minutes of repeated isotonic 
muscular contractions of the forearm compared to control subjects. An elevated Pi/PCr ratio 
reflects a reduction in oxidative capacity of skeletal muscle (f ada et al., 1992). The authors 
measured blood flow to the area during the exercise and found no significant difference between 
the groups. A<kfrtionally, nutritional parameters assessed by means of anthropometry and serum 
chemistry were not different between groups. The results of this study therefore suggest that 
metabolic abnormalities, independent of nutritional status or blood flow to the working muscles, 
exist in the skeletal muscle of pauents with COPD. Similar results we.re reported by Wuyam et al., 
(1992) who demonstrated an elevated Pi/PCr ratio during repeated contractions of the calf 
musculature and a slower resynthesis of PCr during recovery in eight patients with COPD who 
were in chronic respiratory failure compared to eight healthy control subjects. Additionally, 
23 
Thompson et af., (1992) investigated skeletal muscle metabolism during repeated contractions of 
the calf musculature in five patients with COPD who were in respiratory failure. They reported 
faster depletion of PCr and more rapid onset of intracellular acidosis compared to control subjects. 
However, no difference in PCr depletion and intracellular acidosis was reported between groups in 
recovery. The findings from these studies suggest that the oxidative ability of peripheral skeletal 
muscle during exercise in patients with COPD is impaired. 
Further evidence of reduced skeletal muscle oxidative capacity in patients with COPD was 
provided by Maltais et at., (1996) who demonstrated significanUy lower activity of the oxidative 
enzymes CS and HAD in the vastus lateralis muscle of nine patients with COPD compared to 
controls. In contrast, no differences were reported in activity levels of the glycolytic enzymes PFK, 
HK and LDH between groups. This finding implies that the oxidative metabolism in the skeletal 
muscles of patients with COPD is impaired, whilst the non oxidative, glycolytic metabolism remains 
intact. 
Various mechanisms for impaired oxidative capacity in the skeletal muscles of patients with COPD 
have been suggested. These include: reduced arterial oxygen content, physical detraining (Tada 
et al., 1992) and hypoxaemia in patients in chronic respiratory failure (Wuyam et al., 1992; 
Thompson et al., 1993). However, at present, the mechanism causing the peripheral skeletal 
muscle abnonnalities in patients with COPD is unknown. 
In summary, therefore, a review of the available literature suggests impaired oxidative metabolism 
in the skeletal muscles of patients with COPD during exercise. In conflict to this, as discussed 
earlier, the intercostal muscles in patients with COPD demonstrate an increase in the skeletal 
muscle oxidative enzymes CS, HAD and NADH (Sanchez et al., 1988). 
Tada et al., (1992) found identical abnormalities in the forearm musculature of nine patients with 
chronic heart failure. This finding suggests that the metabolic abnormalities seen in the peripheral 
skeletal muscle of patients with COPD may be common to other chronic diseases. 
(iii) The effect of training on skeletal muscle metabolites in patients with COPD 
Maltais et al., (1996) exercise trained the 11 COPD patients who had demonstrated abnormalities 
in skeletal muscle oxidative metaboftsm during exercise. The training programme included 30 
minutes of cycle ergometry, upper body resistance exercises, walking and stretching for three 
sessions per week for a period of 12 weeks. After exercise training, the patients demonstrated a 
significant increase in the activity levels of the oxidative enzymes CS and HAD in the vastus 
lateralis muscle. However, no improvements in the glycolytic enzymes PFK, HK and LDH were 
reported. The peak VO-;. achieved during an incremental ergometer cycle test improved by 14%. 
Additionally, Ve and blood lactate accumulation were significantly reduced at a set submaximal 
work load and a significant inverse relationship was found between blood lactate accumulation 
during exercise and the activity levels of CS (r-0.83; p<0.01) and HAD (r-0.81; p<0.01 ). These 
findings imply that exercise training in patients with COPD increases the activity of CS and HAD in 
the working skeletal muscle, as would be the case in control subjects. 
In contrast, Belman et al., (1981) failed to demonstrate an increase in the activity of the oxidative 
enzymes CS, HAD and PK after six weeks of training in 15 patients with COPD despite improved 
endurance time during an incremental cycle test to exhaustion. Additionally, the patients with 
COPD failed to demonstrate a typical cardiovascular training response, as measured by heart rate 
and blood pressure during the incremental cycle test. The training programme involved two, 20 
minute sessions of ergometry four times a week. The exercise training load was initially set at one 
third of the maximum reached during the incremental cycle test to exhaustion and increased as 
rapidly as possible to a load that could be tolerated for the 20 minute period. The authors 
concluded that the patients were unable to train at an intensity high enough to generate a 
cardiovascular or oxidative skeletal muscle training effect and that some other factor must be 
responsible for the improved submaximal endurance in these patients with COPD. It is possible 
that the six week period was not long enough, or the training intensity and/or frequency not high 
enough to induce changes in skeletal muscle oxidative enzymes in these-patients. 
In summary, the literature presents evidence of abnormal skeletal muscle oxidative metabolism 
during exercise in patients with COPD, the mechanism of which is unknown. Additionally, the 
response of skeletal muscle oxidative metabolism in patients with COPD to exercise training 
remains unclear and further research is therefore required. 
(d) The effect of age on skeletal muscle metabolites 
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Due to the progressive nature of COPD, most patients are middle aged or elderly. As various 
physiological changes occur with increasing age, it is important that these changes are considered 
when the metabolic profile of skeletal muscle in patients with COPD is discussed. Taylor et al., 
(1984) found no significant differences in ATP, PCr, Pi, Pi/PCr or pH in the exercising skeletal 
muscle of subjects aged between 20-45 years compared to subjects aged between 70-80 years. In 
contrast, Moller et al., (1980) reported intramuscular concentrations of total adenine nucleotides 
and PCr to be 5% lower in the elderly (age range 52-79yrs) compared to subjects aged between 
18 to 36 years. The total ATP and ATP/ADP ratio was, however, unchanged compared to 40 year 
old individuals. These findings suggest that age alone is unlikely to cause the changes in 
phosphagen concentrations seen in the skeletal muscles of patients with COPD. 
(e) Skeletal muscle morphometry and histology in patients with COPD 
(i) Morphometry of skeletal muscle in patients with COPD 
Very few studies have examined the morphometry of the skeletal muscle in patients with COPD. 
Jacobsson et al., (1990) reported a decrease in the percentage of Type I (slow twitch) fibres in the 
quadriceps femoris muscle of eight patients with COPD in respiratory failure (17% decrease) and 
11 patients with COPD not in respiratory failure (22% decrease) relative to control subjects. 
These findings suggest morphometric abnormalities in the skeletal muscle of patients with COPD, 
independent of the degree of respiratory failure. 
Thus, very little is known about skeletal muscle morphometry in patients with COPD. Considering 
the hypothesis that skeletal muscle may play a role in the exercise intolerance experienced by 
patients with COPD, research into skeletal muscle morphometry of these-patients is indeed 
warranted. 
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(ii) Skeletal muscle histology in patients with COPD 
Abnormal skeletal muscle histology has been reported in patients with chronic heart failure 
(Derman et al., 1993) and patients with end stage renal disease (Diesel et af., 1990). Evidence that 
both skeletal muscle function and skeletal muscle oxidative metabolism in patients with COPD is 
impaired has been provided. Despite this, to the best of our knowledge no studies have provided 
a detailed histological anafysis of the skeletal muscle of patients with COPD. 
4. Non Respiratory Variables that may Play a Role in Exercise Limitation in Patients with 
COPD 
(a) Cardiovascular function In patients w;th COPD 
Patients with COPD develop increased pulmonary vascular resistance as a consequence of the 
destruction of the vascular bed by emphysema, increased alveolar pressure and increased 
haematocrit (Wilkinson 1988). Increased pulmonary vascular resistance results in decreased 
stroke volume and a subsequent rise in heart rate relative to VD£ in patients with COPD at rest and 
during exercise. Furthermore, a higher pulmonary artery pressure is generated at rest and during 
exercise in patients with COPD (Matthay et at., 1992). The increased heart rate and higher 
pulmonary artery pressure increases the afterload on the right ventricle and can lead to right 
ventricular dysfunction in patients with COPD (Wilkinson et al., 1988; Gallagher 1990; Fujii et al., 
1996). Fujii et al., (1996) demonstrated an inverse relationship between V02 max and P-Q slope 
(an indicator of the severity of pulmonary vasculature dysfunction) during exercise in 21 patients 
with COPD. Fuji et al., (1996) therefore suggested that right ventricular failure and subsequent left 
ventricular dysfunction, may play a role in exercise intolerance in patients with COPD by means of 
impaired 02 delivery to the working muscles. 
Several studies present evidence opposing this hypothesis. Chester et al., (1977) exercise trained 
21 patients with COPD for four weeks on a daily basis. The exercise training involved daily 
walking on a treadmill at an average heart rate of approximately 125b/min. After training, the 
patients with COPD showed no changes in heart rate, pulmonary vascular resistance and cardiac 
index at the same submaximal work loads during incremental exercise, yet total work performed on 
the treadmill and minute ventilation improved significantly. Similarly, Degre et al., ( 197 4) trained 11 
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patients with COPD. The programme involved 25 minutes of cycling three times a week for a six 
week period. The patients showed a ten percent improvement in peak V02 achieved during 
maximal cycle ergometry, despite no improvement in cardiac output or stroke volume. These 
findings suggest that factors other than cardiovascular limitations are responsible for the exercise 
intolerance experienced by patients with COPD. 
(b) Altered blood lactate accumulation during exercise in patients with COPD 
Patients with COPD experience increased blood lactate concentrations compared to healthy 
individuals of the same age and gender at the same absolute submaximal work load (Sue et al., 
1988; Gallagher 1990; Patessio et al., 1993). The mechanism for this increased blood lactate 
accumulation during exercise is not known. Various hypothesis including hypoxaemia resulting in 
dependence on ·anaerobic pathways· (Degre et al., 1974), physical deconditioning, cardiovascular 
dysfunction and lactate production by overactive inspiratory muscles have been suggested 
(Gallagher 1990). 
It has been argued that early onset of "lactic acidosis» may play a role in exercise intolerance in 
patients with COPD (Degre et al., 1974; Sue et al., 1988; Patessio et al., 1993;). However, patients 
with COPD tenninate exercise at much lower concentrations of blood lactate compared to healthy 
individuals (Spiro et al., 1975; Belman 1973; Gallagher 1990) and it therefore seems unlikely that 
excessive concentrations of blood lactate are limiting exercise tolerance in these patients. 
(c) Nutritional status as a limiting factor during exercise in patients with COPD 
Malnutrition has a well documented adverse effect on exercise tolerance (McArdle et at., 1991; 
Burke et al., 1994). Although the overall incidence of malnutrition in patients with COPD is 
unknown (Driver et al., 1982), it is a documented side effect of COPD (West 1992). As many as 
50% of patients with COPD hospitalized for acute respiratory failure may suffer from malnutrition 
(Ferguson et al., 1993). · 
Various factors may cause malnutrition in patients with COPD. These include: interference with 
gastrointestinal function by medications including theophylline and corticosteroids, vascular 
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congestion of the gut due to heart failure, the catabolic effects of corticosteroids, physical inactivity, 
a high metabolic rate due to increased ventilatory demand (Oiopade et al., 1992), and a deficient 
dietary intake caused by dyspnea or hypoxaemia during eating (Brown et al., 1983). It is therefore 
possible that poor nutritional status may play a role in impaired exercise tolerance in patients with 
COPD. 
(d) Physical deconditioning as a cause of exercise intolerance in patients with COPD 
As patients with chronic diseases are often physically inactive and/or bedridden, their exercise 
intolerance has often been attributed to physical deconditioning (Sinoway et al., 1988; Drexler et 
al., 1992). Patients with COPD are often extremely sedentary and the physiological changes 
associated with bed rest and inactivity are likely to contribute to their exercise intolerance (Oiopade 
et al., 1992). It is well established that bed rest and physical inactivity decrease maximal oxygen 
uptake and stroke volume, increase heart rate and blood pressure response to exercise and cause 
a reduction in the size of the left ventricle (Mcardle et al., 1991; Olopade et al., 1992). 
Additionally, deconditioning causes skeletal muscle atrophy (Dubowitz 1985). Gallagher (1990) 
suggests that decreased limb strength in patients with COPD may be due to physical inactivity. 
Various authors attribute the exercise intolerance experienced by patients with COPD, at least in 
part, to physical deconditioning (Gallagher 1990; Olopade et al., 1992; Belman 1993; Tade etaf., 
1992). However, to the best of our knowledge no well controlled studies examining the effect of 
physical inactivity on the exercise intolerance experienced by patients with COPD are reported in 
the literature. 
(e) Psychological contribution to exercise Intolerance in patients with COPD 
The psychological implications of the sensation of dyspnea and the effect this may have on 
exercise intolerance in patients with COPD has been discussed. However, in addition, depression, 
anxiety and inappropriate fear of exercise are present in patients with CGPD (Lustig et al., 1972) 
and the role that these psychological factors may ptay in limiting exercise capacity in patients with 
COPD should not be overlooked {Oiopade et al., 1992). 
In summary therefore, these findings suggest that a variety of factors may play a role in the 
exercise intolerance experienced by patients with COPD. 
5. Predictors of Exercise Capacity in Patients with COPD 
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In an attempt to determine what factors limit exercise capacity in patients with COPD, various 
researchers have performed correlation analyses to assess the role of: lung function, respiratory 
muscle strength, blood lactate accumulation, cardiovascular factors and peripheral skeletal muscle 
function in the exercise intolerance experienced by these patients. Although many of these studies 
have been mentioned through the review of literature, a concise summary of some of the studies is 
presented in Table 1.4. 
Table 1.4 Summary of research studies investigating factors predicting exercise capacity in patients with 
COPD. 
Measures of exercise capacity 
Authors Variables Peak V02 Endu Distance walked 
time during a SMWT 
Pulmonary Function 
Spiro et al., 19751n=40)_ FEV1 (I) r-0.70 (p<0.001) 
Sue et al., 1988 (n=43) FEV1 (I) NSC 
Bauerle et al., 1995ln=53) FEV1 (%of predicted) r-0.49 (p<0.05) 
Montes et al., 1996 (n= 25) FEV1 (I) and FEV1/FVC NS NS 
Spiro et al., 1975 (n=40) VE r-0.85 (p<0.001) 
Bauerle et al., 1995 (n=53) IC r-0.46 (p<0.05) 
Gosselink et al., 1996 (n=42) TLCOsb r-0.68 (p<0.05) r-0.38 (p<0.05) 
Miscellaneous factors 
Sue et al., 1988 (n =22) [Lactate] r-0.75 (p<0.05) 
Fu]i et al., 1996 (n=21) PQ slope r=-0.67 (p<0.001) 
Respiratory muscle 
strength 
Montes et al., 1996 (n= 25) Pdi Max r=O. 68 (p<O. 05) r-0.54 
(p<0.05) 
Gosselink et al., 1996 (n=42) Pi Max r-0.49 (p<0.005) 
Peripheral SM factors 
Gosselink et al., 1996 QF r-0.63 (p<0.005) 
(n=42) 
Gosselink et al., 1996 (n=42) HGF r-0.61 (p<0.005) 
Maltais et al., 1997 {n=9) cs r-0.78 (l:l<0.01) 
Maltais et al., 1997 (n=9) HADH r-0.61 (p=0.08) 
.. Abbrev1at1ons: Peak V<n. max1mal 02 consumption measured dunng an rncremental maximal exerc1se test; Endurance lime. 
time to exhaustion during an incremental exercise test; SMWT, six minute walk test; NS, not statistically significant; Ve. minute 
ventilation at peak exercise; I C. inspiratory capacity; TLCOsb. transfer factor (a measure of diffusing capacity in the alveoiQ; PQ • 
slope, an indicator of the severity of pulmonay vasculcr disorder; [Lactate), blood lactate concentration at peak exercise; Pdi 
Max, measure of transdiaphragnatic twitch pressure; Pi max, inspiratory muscle strength; SM. skeletal muscle; QF. peak 
isometric quadiceps force; HGF, peak isometric hand grip force; CS. citrate synthase; HADH. 3-hydroxyacyl CoA dehydrogenase 
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In Table 1.4 measures of exercise capacity are listed horizontally across the top and include: Peak 
V02 and endurance time achieved during an incremental exercise test to exhaustion and distance 
walked during a SMWT. Variables correlated to the measures of exercise are listed in column two 
of Table 1.4. 
It is clear that conflicting results are presented in the literature regarding the role that FEV1 plays in 
predicting exercise capacity in patients with COPD. This is further confounded by authors 
expressing FEV1 in different ways. Therefore, some authors have shown a strong correlation 
between FEVt and measures of exercise ability (Spiro et al., 1975), others have shown a weaker 
but significant correlation (Bauerle et al., 1995), and yet others have reported no significant 
correlation between these two variables (Sue et al., 1988; Montes et al, 1996). 
Various other parameters, including blood lactate concentrations at peak exercise (Sue et al., 
1988), cardiovascular function (Fujii et al., 1996), respiratory muscle strength (Montes et al., 1996; 
Gosselink et al., 1996) and various indices of peripheral skeletal muscle function (Gosselink et al., 
1996; Maltais et al., 1996) have been shown to correlate with exercise tolerance in patients with 
COPD. 
In summary, therefore, it appears that multiple factors may account for the exercise intolerance 
experienced by patients with COPD. 
6. A Summary of the Review of Literature 
A review of the literature investigating exercise limitation in patients with COPD over the last four 
decades demonstrates a focus on those factors related to the heart and lungs. However, despite 
three decades of research, none of these factors appear to be the major limiting factor during 
exercise in patients with COPD. In contraSt, preliminary research in the -last decade suggests that 
skeletal muscle may play a major role in this exercise intolerance. This finding is suggested by 
reports of functional, metabolic and morphometric abnormalities in the skeletal muscle of patients 
with COPD. In addition preliminary research supports the hypothesis that after exercise training 
the improved skeletal muscle metabolism and skeletal muscle function experienced by these 
patients is related to their improved exercise tolerance. 
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However, no study, to our knowledge, has investigated the histology and ultrastructure of the 
peripheral skeletal muscle, or investigated both isokinetic skeletal muscle strength and endurance 
in the skeletal muscle of patients with COPD. Additionally, no study has examined the relationship 
between skeletal muscle structure and skeletal muscle function in patients with COPD or the 
relationship between skeletal muscle structure and general exercise perfonnance. Therefore, 
further research investigating the role of peripheral skeletal muscle in exercise intolerance in 
patients with COPD is clearly necessary. 
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CHAPTER TWO 
GENERAL METHODS 
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1. General Considerations 
To be included in the studies described in this thesis, patients had to be free of any serious chronic 
illness other than COPD; and be able to exercise. Patients had to present with an FEV1 of less 
than 50% of predicted and were excluded from the studies if they had experienced an acute 
exacerbation of their disease or an episode of chest infection in the four weeks immediately prior to 
entry into the study. Similarly, control subjects had to be free of any chronic disease. 
The study protocols were approved by the Ethics and Research Committee of the Faculty of 
Medicine at the University of Cape Town. Prior to commencement of the study all participants 
provided written informed consent and the patients with COPD obtained the full consent of their 
attending physician. Patients were instructed to remain on their medication throughout the testing 
period and both patients and controls were instructed to avoid any strenuous physical exercise for 
36 hours preceding each laboratory test. 
On entry to the study all patients underwent a forced maximal expiratory manoeuvre before and 
after bronchodilation for measurement of FEV1 and FVC using a vitalograph rM (Wurzburg, 
Germany). Those with a greater than 15% reversibility in FEV1 after bronchodilation were excluded 
from the study due to a presumed asthmatic component to their disease. 
2. Physical Activity Questionnaire 
The Yale physical activity questionnaire for older adults (Dipietro et al., 1992) was administered to 
all patients with COPD and control subjects. Participants were asked to report the number of hours 
in a "normal" week spent completing various pre-determined activities. Categories of activities 
included work, yardwork, caretaking, exercise and recreational activities (appendices, Chapter 
nine). The examiner recorded the participants' responses on the data sheet supplied with the 
questionnaire. Accordingly, -weekly caloric expenditure for each participant was calculated 
(Dipietro et al., 1992). 
The second part of the questionnaire included questions regarding the frequency of certain 
activities in a "normal" month. Subjects were questioned about the frequency of their participation 
in various activities. In retrospect, this section of the questionnaire was not analysed, as the 
frequency of different activities in patients with COPD was not being investigated in this 
dissertation. 
3. Medical Questionnaire 
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A brief medical questionnaire was conducted on entry to the study by all participants. This served 
to highlight risk factors for chronic disease, chr~nic medical complications and/or contra-indications 
for participation in maximal exercise or any of the tests included in the studies conducted in this 
dissertation. 
4. Pulmonary Function Tests 
All pulmonary function tests were conducted in the Groote Schuur Hospital Respiratory Clinic by 
trained respiratory technologists, using the Masterlab (Erich Jaeger Vers 3.4,Jaeger, Wurzburg, 
Germany 1992) computerised system utilising a Jaeger pneumotach with rubber mouthpiece 
(Jaeger, Wurzburg, Germany 1992) (Fig 2.1 ). Tests of pulmonary function included tests of (a) 
forced spirometry, (b) static lung volumes and (c) transfer factor. 
(a) Forced Spirometry 
Patients and control subjects were asked to expire and inspire normally for three breaths followed 
by a forced maximum inspiratory and expiratory manoeuvre. The manoeuvre was performed 
according to ATS criteria (American Thoracic Society, 1987). During normal breathing TV was 
calculated (Fig 2.2). During the forced manoeuvre, FVC, FEV1 (Fig 2.3), FEFso, PIFR and PEFR 
were measured from the flow volume loop (Fig 2.4). 
Fig 2.1 Masterlab Erich Jaeger lung function analyser Vers 3.4 
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Fig 2.2 Lung volumes calculated from spirometry. Note that the FRC and RV cannot be measured with 
spirometry. VC is also known as IC (West 1995) 
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Fig. 2.3 Diagrammatic representation of measures of FEV1 and FVC (West 1995) 
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Fig 2.41nspiratory and expiratory flow volume curves in normal subjects and in patients with COPD (West 
1992). The COPD flow volumes are represented by the smaller of the two curves 
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The manoeuvre was repeated at least three times and the highest values recorded. FEV1/FVC 
was calculated from these measures. During a test of MW, subjects were asked to inspire and 
expire as deeply and as quickly as possible for a period of 12 seconds whilst receiving verbal 
encouragement. Gas volumes were measured during the 12 second period. The subjects 
repeated this manoeuvre twice and the highest value obtained was multiplied by five to calculate 
MW (ATS, 1987). 
fig 2.5 Airtight Erich Jaeger Masterlab body plethysmography box used to measure static lung volumes 
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(b) Static Lung Volumes 
Body plethysmography was used for calculation of FRC and RV in this study. This method is 
more accurate than the helium dilution technique in patients with COPD due to the likelihood of gas 
trapping in these patients. Patients were seated in a large airtight box and asked to breathe 
normally into a mouthpiece (Fig 2.5). 
At the end of normal expiration, a shutter seale~ off the mouthpiece whilst the subject was asked 
to continue breathing normally. As the subjects attempted to inhale, lung gas volume increased 
and the box pressure increased as gas volume decreased (Fig 2.6). Boyle's law states that 
pressure x volume is constant at constant temperature. Thus FRC and RV were calculated using 
the following equations: 
RV: 
Pressure in box before inspiratory effort= P1 
Pressure in box after respiratory effort = P2 
Pre-inspiratory box volume = V1 
Change in volume of the box = .1 V. 
(P1 )(V1) = P2 (V1 - .1 V) 
Therefore .1 V can be calculated 
FRC: 
P3 = mouth pressure before inspiratory effort 
P4 = mouth pressure after inspiratory effort 
V2 = FRC 
(P3)(V2) = P4 (V2 = .1 V) 
Therefore V2 can be calculated 
39 
ptv~ 
PV=K 
Fig 2.6 Diagrammatic representation of measurement of FRC with a body plethysmograph. When the subject 
makes an inspiratory effort against a closed airway, lung volume is slightly increased causing airway pressure 
to decrease and box pressure to increase 
(c) Transfer factor 
The single breath carbon monoxide diffusion method was used to determine transfer factor in the 
studies conducted in this dissertation. Participants were asked to take a single VC breath of a gas 
containing 0.3% CO, 10% He, 18% 02 and 71.7% N2. The rate of diffusion of the CO from the 
alveolar gas during a ten second breath hold was then measured. This rate of diffusion of the CO 
was expressed relative to lung volume to determine the transfer coefficient (K10). 
5. Anthropometric a/ Analysis of Body Composition 
Standing height without shoes was measured to the nearest 0.1 em. Total body mass with clothes 
on and shoes off was measured to the nearest kg. For determination of body composition a Holtain 
skinfold caliper (Crymych, UK) was used for measurements of subcutaneous fat at seven sites. A 
Holtain bone caliper (Crymych, UK) was used for measurement of bone diameters at six sites and 
a Rabone Chesterman Silverflex metal tape measure (Crymych, UK) was used for the 
measurement of 12 girths. Body composition was assessed using an anthropometric technique 
that fractionated the body composition into muscle mass (Martinet al., 1990), fat and lean body 
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mass (Durnin and Womersley 1974). 
Distance from the sub-gluteal fold to one centimetre above the knee was recorded. Using this 
distance, the measures of midthigh girth, sub gluteal girth, above the knee girth (1cm) and midthigh 
skinfold, LTV was calculated (Noakes et al., 1980). 
6. Graded Exercise Test to Exhaustion 
All subjects performed a maximal progressive cycle ergometry exercise test to exhaustion using an 
electro-mechanically braked cycle ergometer with manual adjustment of resistance in Kp.m 
(Siemens, Elena, Erlangen, Germany). Prior to testing, the height of the saddle was adjusted to the 
preferred height for the subject. During exercise, subjects cycled with a mouthpiece connected to 
a CPX/D pneumotach (Medgraphics, Boston, USA). A nasal clip prevented nasal breathing. 
Patients commenced pedalling at no resistance for the first minute. As the electromechanically 
braked bicycle was linked to a manual resistance adjustment system measured in Kp.m, the 
workload was increased by 50 Kp.m (8.3 W) every minute until the patient voluntarily terminated 
the test. For the first ten minutes of the exercise trial control subjects followed an identical protocol 
to the patients with COPD. However, to ensure that the control subjects attained true maximal 
exercise, their workload was increased by 200 Kp.m (33.3 W) every minute, as opposed to 50 
Kp.m every minute, once the first ten minutes of the initial protocol were completed. Patients and 
control subjects were asked to maintain a fixed pedalling speed (60 rpm). Failure to maintain the 
fixed rpm resulted in test termination. 
During exercise, breath by breath 02, C02 and VE analysis was performed using the Medgraphics 
Cardiopulmonary Exercise CPX/D System and an on-line micro computer (Boston, USA). 
Analysers were calibrated before and after each test using gases of known composition. 
Accordingly, V02, VC02 and -RER were c~lculated. The average value-for each minute for each 
parameter was stored for later printing. The V02 max was taken as the highest rate of oxygen 
consumption measured during any 60 second period (Noakes 1988). 
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Peak workload was taken as the highest workload maintained for a complete minute during the 
test. When a subject was unable to complete the full minute at a particular workload, the workload 
of the immediately preceding, completed workload was recorded as the peak workload. The same 
method was used to calculate the exercise time to exhaustion. 
Patients and control subjects were asked to report their level of perceived exertion from the Borg 
scale after each minute of the exercise test. Most studies have used the 20-point Borg scale. This 
method causes inaccurate scaling of variables such as blood lactate concentrations and 
ventilation, which increase according to non-linear power functions (Noble et al., 1982). The 10-
point category scale with ratio properties (Borg 1980;1982) was therefore used in this study. The 
ratio scale has verbal expressions that are simple to understand and more accurately describe 
sensations of perceived peripheral effort. 
Indications for halting the exercise test before exhaustion included adverse symptoms such as light 
headed ness, confusion and chest pain. Adverse clinical signs such as facial pallor, decline in 
heart rate or blood pressure, failure of blood pressure or heart rate to rise with increasing effort, 
systolic blood pressure exceeding 280 mmHg, or diastolic blood pressure exceeding 140 mmHg 
were additional indicators for early test termination. 
Prior to the bicycle test, the resting heart rate and blood pressure (Korotkoff Phase I and IV) were 
measured and recorded. Blood pressure at rest and every two minutes during exercise was 
measured by means of audible sphygmomanometry using a calibrated mercury column 
sphygmomanometer with an appropriately sized cuff. The cuff was placed on the arm that did not 
have an intravenous cannula placed in the forearm vein. 
Although, the measurement -of diastolic blood pressure during exercise can be difficult, the results 
are quite reproducible if Phase IV of the Korotkoff sound is taken. Heart rate and rhythm were 
determined at rest and each minute during exercise, using a Sirccust 403-2P Siemens monitor 
(Erlangen, Germany). The monitor transferred information directiy into the Medgraphics 
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Cardiopulmonary Exercise CPX/D System for later printing. Self-adhering electrodes were placed 
in the CMS position. 
Arterial oxygen saturation was measured noninvasively at rest and continuously during exercise 
using a fibreoptic ear-pulse oximeter (Ohmeda Biox 3700; Boulder; USA}. The saturation values 
were transferred directiy into the Medgraphics Cardiopulmonary Exercise System (CPX/D} and 
stored for later printing. 
7. Collection of Blood for Analysis of Blood Lactate Concentration, Partial Pressure of 
Carbon Dioxide and pH Measurements in Arterialised Blood During the Graded Exercise 
Test to Exhaustion 
(a} Blood Sample Collection 
Resting arterial blood samples were drawn from the radial artery of the COPD patients using a 
winged needle infusion set (Venisystems™, 4721 Butterfly®, 21 I NT, Sligo, Ireland}. Resting 
arterial samples were not drawn from the control group due to the invasive nature of the procedure 
and the fact that normal values are well established amongst healthy subjects (West 1995}. 
Prior to the start of the cycle test, an 18-gauge flexible cannula (Criticon, Tampa, Florida, USA} 
was inserted into a subcutaneous forearm vein of each subject. A 3-way stopcock (Discofix-3, 
Belgium} was attached for multiple blood sampling. A custom made heating blanket was placed 
around the arm immediately proximal to the catheter and was set to maintain a temperature of 
270C for the duration of the exercise test. 
Arterialised venous blood samples were drawn at rest and subsequentiy at one minute intervals 
during the exercise bout. Five millilitres of blood was drawn from the stopcock directly into a five 
millilitre syringe. Three millilltres was decanted into a sodium oxalate iined glass test tube and 
immediately placed on ice for later analysis of plasma lactate concentrations. The two millilitres 
remaining in the syringe were capped and immediately placed on ice for determination of 
arterialised PaC02, pH and Sa02. Additional blood samples were drawn at exhaustion and every 
minute for five minutes in the post exercise recovery period and an identical collection procedure 
was followed. 
(b) Blood Sample Analysis 
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The resting arterial blood was analysed immediately for Pa02, PaC02, pH and Sa02 by means of a 
pH/blood gas analyser (Radiometer ABL3, Copenhagen, Denmark). 
Measurement of Pa02 is not considered accurate from arterialised blood (AST, 1987). Accordingly, 
the two millilitres of arterialised blood in the capped syringe was analysed immediately upon 
termination of the exercise test for PaC02, pH and Sa02 by means of a pH/blood gas analyser 
(Radiometer ABL3, Copenhagen, Denmark). 
At termination of the exercise test, the three millilitre blood samples in the sodium oxalate test 
tubes were centrifuged using a Sigma 302-K centrifuge (Munich, Germany) at 3000 rpm for 12 
minutes at 4oc. Lactic acid concentrations were measured on plasma by means of an enzymatic 
kit technique (bioMerieux sa, lactate PAP 69280, Marcy I" Etoille, France). 
B. Six Minute Walking Test 
The SMWT was administered by having patients cover as much ground as possible whilst walking 
repeated lengths of a 30m corridor in the six minute period. Subjects were encouraged to pace 
themselves to avoid requiring a rest during the six minute period. Verbal encouragement was given 
throughout the test. The number of lengths walked was recorded and used for calculation of 
distance covered to the nearest metre. Heart rate was measured continuously during the six 
minute period by means of a Polar heart rate monitor (Polar Company, Kempele, Finland). 
Additionally, subjects reporte.d a rating ofJatigue from the 10 pain! Borg RPE scale (Borg 1980, 
1982, described in section five of this Chapter) in the last ten seconds of every minute. 
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9. Tests of Skeletal Muscle Function 
(a) lsokinetic Concentric Skeletal Muscle Function 
lsokinetic muscle strength was measured using an Akron lsokinetic Dynamometer (lpswitch, 
Suffolk, UK) and an Akron Data Reduction computer (Vers. 2.0) (Fig 2.7). This system is designed 
to maintain angular velocity at a constant pre-set level regardless of the torque generated by the 
subject. The subjects were seated on the Akron apparatus with the head of the femur fully 
supported and the knee flexed to goo. The fulcrum of the lever was positioned in line with the axis 
of rotation corresponding to the transverse line through the femoral condyles. The lever arm was 
secured to the subject via a shin strap placed just proximal to the malleoli. In an attempt to isolate 
movement to the knee joint, the thigh, waist and shin straps were fastened as tight as was tolerable 
for the patient. During the testing, subjects were instructed to keep their arms folded across their 
chests. 
Each patient was given a practice bout at each testing speed. This warm-up consisted of five 
familiarisation repetitions at 6QOfsec and at 1250/sec. After the familiarisation period, patients 
rested for two minutes before starting the test. Any necessary adjustments to the equipment were 
made during this time. The strength test measured maximum isokinetic torque of the quadriceps 
and the hamstring muscle groups of the dominant limb, recording data during four maximal 
contractions through a full range of motion at a limb contraction speed of 600/sec. After a five 
minute rest, an endurance test of the dominant leg was performed. The subject performed 30 
repeated full knee extensions at a rate of 1250/sec. Total power generated, work done and peak 
torque generated by the quadriceps and hamstrings at this speed were recorded. Verbal 
encouragement was given throughout the tests. 
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Fig 2.7 An Akron isokinetic dynamometer used for measurement of skeletal muscle strength and endurance 
(b) Eccentric Skeletal Muscle Strength 
lsokinetic eccentric muscle strength was measured using a Kin-Com lsokinetic Dynamometer 
(Chatanooga, USA) and Kin-Com data reduction computer (Vers. 5.13) (Fig 2.8) on six patients 
with COPD and six controls. The small sample number was the result of equipment unavailability 
until midway through the data collection phase of the study. Equipment alignment and subject 
positioning was as for the Akron skeletal muscle function tests. Each subject was instructed to 
complete a warm up including five minute of cycling and two hamstring stretches prior to being 
positioned on the machine. For familiarisation, a practice bout of two concentric and two eccentric 
contractions was given. For testing purposes, two repetitions of concentric contractions were 
performed, followed by tw~ repetitions of eccentric contractions for both the quadriceps and the 
hamstring muscle groups at a speed of 600/sec. 
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Fig 2.8 A Kin-Com isokinetic dynamometer used for measures of skeletal muscle strength and endurance 
10. Skeletal Muscle Biopsy Procedure 
A sample of skeletal muscle was removed from the vastus lateralis muscle under local anaesthesia 
according to the needle biopsy technique of Bergstrom et al., (1962), as modified by Evans et al., 
(1982). 
The skeletal muscle sample was divided into two pieces. One piece of the muscle was snap-frozen 
in isopentane and cooled in liquid nitrogen. Transverse sections (5-7 J.Lm) were stained for 
haemotoxylin and eosin, Gomoris trichrome, NADH, SOH, PAS, Cytochrome C Oxidase, Oil Red 0 
and ATPase at pH 4.3, 4.6, and 9.4 (appendices, Chapter nine). The fibre type proportions and the 
-
minimum diameter of approximately 200 Type I and Type II muscle fibres differentiated by ATPase 
staining were measured using an I BAS Kontron image analysis system (Munich, Germany). 
The second portion of the skeletal muscle was desensitised in 3% phosphate buffered 
I 
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glutaraldehyde for ten minutes. The tissue was sliced into smaller sections and fixed overnight. The 
slivers of transverse and longitudinal muscle sections were post-fixed in 1% buffered osmium 
tetroxide (pH 7.4) and processed by standard methods into Spurrs epoxy resin. Ultra-thin 
transverse and longitudinal sections were stained with uranyl acetate and lead citrate and 
examined using a Phillips 201 electron microscope (Einthoven, The Netherlands). 
11. Statistical Analysis 
Statistical differences between the control group and the patients with COPD were determined 
using independent t tests for continuos and ordinal variables by means of Statgraphics computer 
software (Vers. 6.1; Statistical Graphical Corporation Inc., USA). Correlation coefficients within the 
patient population were calculated by means of the Spearmans rank correlation coefficient in the 
case of rank ordered data and the Pearsons product moment correlation coefficient in the case of 
continuous data using the Statgraphics computer software (Vers. 6.1). Levels of significance were 
calculated at the 0.01 and 0.05 confidence levels (Glanz 1980) and data was presented as the 
mean± the SO. In the case of the correlations, correlation coefficients were denoted as rand the 
sample size as n. 
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CHAPTER THREE 
EXERCISE TOLERANCE AND SKELETAL MUSCLE FUNCTION IN PATIENTS WITH CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE 
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1. Introduction 
In Chapter One, it was documented that the past three decades have witnessed an increased 
interest in the factors limiting exercise performance in patients with COPD (Gallagher 1990; Kilian 
et al., 1992; Karlsson et al., 1992; Olopade et al., 1992; Belman 1993). To date, the exercise 
intolerance reported in patients with COPD has been attributed to central limiting factors directly 
related to pathological changes in the heart and lungs. These factors include ventilation 
mechanics (Derenne et al., 1978; O'Donnell et al., 1988; Marin et al., 1993; Belman 1993), 
impaired gaseous exchange (Woodcock et al., 1981; Jones 1988; Olopade et al., 1992; Palange et 
al., 1995; Soguel Schenkel et al., 1996), respiratory muscle weakness (Derenne et al., 1978; 
Rochester et al., 1979; Bellemare et al., 1983; Dodd et al., 1983; Tobin 1988) and central 
cardiovascular limitations secondary to pulmonary disease and pulmonary hypertension 
(Wilkinson 1988; Matthay et al., 1992; Fujii 1996). Despite contradictory research regarding the 
contribution of central factors to the exercise intolerance in patients with COPD, until recently, the 
possibility that peripheral factors in skeletal muscle might play a role in this exercise intolerance 
has not been considered. 
Recent research has however demonstrated that peripheral skeletal muscle plays a pivotal role in 
exercise intolerance in patients with renal failure and in patients with cardiac failure (Derman et al., 
1992; Diesel et al., 1993). It is possible, for a variety of reasons, that this could be the case in 
patients with COPD. Firstly, traditional cardiovascular exercise training programmes for patients 
with COPD result in improved functional capacity. However, no parallel improvements in 
traditionally measured central factors of lung function (McGavin et al., 1977; Carteret al., 1991; 
Olopade et al., 1992; O'Donnell et al., 1993), Pa02 at rest (an indicator of gas exchange 
proficiency) (Patessio et al., 1992) or central cardiovascular factors (Degre et al., 197 4; Chester et 
al., 1977) have been reported with training in patients with COPD. This suggests that factors other 
than the central factors of lung function, gas exchange or cardiovascular capacity may be 
responsible for the improved functional ability in trained patients with COPD. It is possible that 
peripheral factors adapt to the training stimulus and are responsible for the improved functional 
ability in the patients with COPD. 
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Secondly, low intensity skeletal muscle circuit weight training programmes have also induced 
improvements in skeletal muscle strength (Simpson et al., 1992) and endurance (Clark et al., 
1996) with a corresponding improvement in general functional ability and endurance capability in 
patients with COPD (Simpson et al., 1992; Clark et al., 1996). These findings suggest a 
relationship between peripheral skeletal muscle function and exercise tolerance in these patients. 
Thirdly, Gosselink and co-workers (1996) reported a relationship between quadriceps muscle 
force and distance walked during the SMWT in patients with COPD. This research further 
supports the suggestion of a relationship between peripheral skeletal muscle function and exercise 
tolerance and/or functional ability. 
Finally, Decramer et al., (1997) demonstrated a relationship between skeletal muscle strength and 
frequency of health care facility use. Those patients who demonstrated greater skeletal muscle 
weakness required a greater degree of health care. This suggests a possible relationship between 
skeletal muscle function and acute exacerbations of the disease requiring health care utilisation in 
patients with COPO. This preliminary study quite obviously has important implications for health 
care economy and suggests that further research investigating skeletal muscle strength in patients 
with COPD is warranted. The importance of investigating the relationship between peripheral 
skeletal muscle functional ability and exercise tolerance in patients with COPD has therefore 
clearly been established. 
Accordingly, the aims of the study reported in Chapter Three were threefold. Firstly, to document 
the exercise tolerance of 13 patients with COPO and compare their exercise capacity to an age 
and gender matched healthy control group. Secondly, to document skeletal muscle functional 
ability in these patients relative to the control group. Finally, to determine the relationship between 
skeletal muscle function and exercise tolerance in the 13 patients with COPO. 
2. Methods 
Ten male patients and three female patients (mean age 57± 7 years; average mass 65 ± 14 kg) 
with an FEV, of below 50% of predicted were recruited for participation in this study. The patients 
were recruited from either the Respiratory Clinic at Groote Schuur Hospital or from private 
pulmonologists in Cape Town. One patient, whilst on a three week vacation to Cape Town, was 
recruited from a pulmonok>gist in Johannesburg. 
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Patients were excluded from the study if they had any signs, symptoms or history of a second 
chronic illness or if they had suffered an acute exacerbation of their disease or an episode of chest 
infection in the four weeks immediately prior to the start of the study. Initially, patients were 
excluded if they were on steroid treatment However, it proved too difficult to recruit patients with 
moderate to severe COPD who were not ingesting oral steroid medication. Therefore five patients 
were ingesting low doses of prednisone (5-1 Omg daily) during the course of this study. Patients 
ingesting medications at the start of the trial were instructed to continue with their medication 
during the period of exercise testing. 
Thirteen sedentary age and gender matched individuals free of any chronic disease (mean age 55 
± 7 years; average mass 83 ± 10 kg) were recruited to form a control group. 
(a) Exercise testing 
Patients and controls were tested on three separate occasions with a 48 hour rest between testing 
sessions. On the first occasion, subjects performed a SMWT, an isokinetic muscle function test 
to determine concentric skeletal muscle strength and endurance and full anthropometrical analysis 
for determination of body composition. Additionally subjects completed the Yale physical activity 
questionnaire for older adults to determine activity levels and a precautionary summarised medical 
questionnaire for exclusion of high risk subjects on this testing occasion. 
On the second occasion, subjects performed tests of eccentric isokinetic skeletal muscle strength. 
This was to allow a 48 hour rest between tests of skeletal muscle concentric strength and skeletal 
muscle eccentric strength. 
During the third testing occasion, pulmonary function was measured in both groups and a resting 
arterial blood sample was drawn from the patients with COPD. Arterial blood samples were not 
drawn from control subjects as the procedure is painful and invasive and norms are well 
established {West 1995). Additionally, an incremental cycle ergometer test to exhaustion was 
conducted to determine peak workload achieved and time to completion of the exercise bout. In 
addition, the following variables were measured at regular intervals throughout the exercise bout 
and at peak exercise: V(h, VC02, RPE, RER, HR, BP, VE, arterialised blood lactate concentration, 
pH and PC02. All tests were conducted according to the methods detailed in Chapter Two. 
(b) Statistical analysis 
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All data are expressed as mean± SO. Statistical analysis was perfonned according to the general 
methods detailed in Chapter Two. 
3. Results 
(a) Subject characteristics on entry to the study 
Subject characteristics on entry to the study are detailed in Table 3.1. 
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Table 3.1 Characteristics of patients with COPD and the control group on entry to the study 
Patient Gender Age (yr) Mass (kg) Ht (em) DOD (months) WPAE 
No (kCallwk) 
1 F 50 50 153 84 1785 
2 M 54 44 163 84 4305 
3 M 58 69 168 180 2145 
4 M 55 48 155 120 7350 
5 M 58 57 164 120 3986 
6 M 54 66 181 12 2700 
7 M 55 78 164 UK NC 
8 M 56 83 171 12 4320 
9 M 56 61 162 36 6945 
10 M 72 84 180 12 4005 
11 F 55 63 173 130 4800 
12 F 54 61 177 108 5955 
13 M 65 82 172 48 8505 
Mean 57 65** 167 78 4733 
so 5 14 8 55 2098 
Controls 
Mean as 55 83 174 n/a 6669 
above 
so 7 10 7 n/a 2985 
.. AbbreVIations: M, male; F, female; m, metres; kg, k1lograms; DOD, duration of d1sease, WPAE, weekly phys1cal actNIIy energy expenditure; em; 
centimetres; Yr, years; SO, standard deviation; .. , p<0.01 COPD vs Control; UK, unknown; NC, not completed. 
The average time since diagnosis of COPD was 78 ±55 months. One patient did not known the 
date of diagnosis and it could not be established from the patient file. The mean weekly energy 
expenditure was not different between groups although the control subjects tended to be more 
active (4733 ± 2098 vs 6669 ± 2985 kCal/wk; COPD vs control; p=0.07). The results from one 
patienfs physical activity questionnaire were uninterpretable. Average mass was significantly 
different between groups (65 ±14 vs 83 ±10; COPD vs Control; p<0.01). 
(b) Subject resting lung function and blood gas variables on entry to the study 
Resting lung function results for the patients and the control group are presented in Table 3.2 
Table 3.2 Resting lung function variables of patients with COPD and the control group on entry Into the study. 
FEV1 
FEV1/ FVC 
M
W
 
PEFR 
TLCOsb 
PIFR 
IC 
Pa02 
Sa02 
PaC02 
Patient 
Gender 
(I) 
.{%) 
(1/min) 
{1/min) 
,
 {ml/mmHg/min) 
jllmin) 
.Ql 
(kPa) 
(%) 
(kPa) 
1 
F 
0.7 
25 
31 
150 
7 
150 
1.6 
9.86 
93 
4.96 
2 
M
 
1.2 
36 
67 
300 
20 
270 
2.4 
11.88 
99 
5.61 
3 
M
 
0.5 
24 
31 
220 
14 
190 
1.4 
NSO 
95 
NSO 
4 
M
 
1.7 
49 
66 
292 
20 
225 
2.3 
10.68 
94 
5.01 
5 
M
 
1.7 
47 
53 
170 
21 
160 
2.2 
10.24 
91 
5.97 
6 
M
 
1.6 
39 
71 
307 
17 
278 
2.3 
10.32 
98 
5 
7 
M
 
1.4 
54 
89 
380 
25 
270 
2.6 
9.17 
100 
5.34 
8 
M
 
1.9 
43 
160 
290 
32 
271 
3.6 
9.99 
NMR 
5.65 
9 
M
 
1.6 
43 
78 
356 
24 
308 
2.0 
NSO 
96 
NSO 
10 
M
 
1.8 
33.9 
80 
311 
23 
375 
3.3 
NSO 
98 
NSO 
11 
F 
1.6 
25 
23 
152 
14 
295 
1.2 
8.70 
93 
4.77 
12 
F 
0.6 
32 
26 
173 
7 
191 
1.6 
8.25 
93 
4.62 
13 
M
 
1.1 
29 
55 
271 
14 
391 
2.7 
8.71 
91 
5.78 
M
ean 
1.3 tt 
37** 
64 ** 
259 ** 
18** 
260** 
2.2 
** 
9.78 
95.08 
5.27 
SD 
0.5 
9 
36 
78 
7 
75 
0.7 
1.1 
3.09 
0.46 
Controls 
Mean 
3.4 
76 
141 
547 
30 
355 
3.6 
11.9-13.2 
99-100 
4.841.3 
{norm) 
{norm) 
{norm) 
SD 
0.7 
7 
29 
92 
6 
102 
0.7 
.
 
.
 
.
 
-
-
.
 
-
Abbreviations: FEV, forced expiratory volum
e in 1 second; FEV1 (%), forced expiratory volum
e in 1 second/forced vital capacity; MVV, m
aximum voluntary ventilat1on; PEFR, peak 
expiratory flow 
rate; TLCOsb, transfer factor; PIFR, peak inspiratory flow rate; IC, inspiratory capacity; NMR, no m
easurem
ent recorded; NSO, no sample obtained; Pa(h, partial pressure 
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I I ' . ' I i 
of oxygen in arterial blood; Sa(h, arterial oxygen saturation levels; PaC(h, partial pressure of carbon dioxide in arteriahsed blood; kPa, kilopascals; 
.
.
 , p <0 01 COPO vs control subjects; SO, standard dev1at10n, 
norm
; norm
s (West; 1992). 
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FEV,, FEV,/FVC, ~. PEFR, TLCOsb, PIFR and IC were all significantly lower in patients 
compared to control subjects. None of the 13 patients presented with chronic respiratory failure 
[criteria for respiratory failure = Pa~ < 8.0 kPa and/or PaC~ > 6. 7 kPa (Wiles et al., 1984)] at the 
time of testing. However, five of the 13 patients were hypoxic at rest (criteria for hypoxia Sa02 < 
94%, Gimenez et al., 1992) and two patients used supplemental oxygen when sleeping. 
(c) Medications ingested by the patients with COPD 
Medications ingested by the patients with COPD during the study are presented in Table 3.3 
Table 3.3 Ust of medications ingested by patients with COPD during the course of the study 
Pt No. Medication {Generic name} 
1. lpatropium Bromide; Prednisone; Theophylline; Salbutamol. 
2. Theophylline; Salbutamol. 
3. lpatrcpium Bromide; Prednisone; Budesonide; Theophylline 
4. Fenoterol; Prednlsone; Salbutamol 
5. lpatrcpium Bromide 
6. Beclometasone; lpatropium Bromide; Budesonide; Theophylline/Etofyfline; Sa!butamol 
7. Beclometasone; Theophylline; lpatropium Bromide 
8. Fenoterol; Prednisone; Theophylline 
9. Prednisone; lpatropium Bromide 
10. nil 
11. Beclometasone; Salmeterol; Theophylline; lpatropium Bromide 
12. lpatrq>ium Bromide; Budesonide; Formoterol; Theophylline 
13. lpatrcpium Bromide; Theophylline 
Categories of medications included !12 agonists, anticholinergics, theophyllines and corticosteroids. 
Most patients in this study were ingesting bronchodilators, anticholinergic agents and in the case of 
five patients corticosteroids. Individual doses of corticosteroids ranged from 10mg daily to 10mg 
on alternate days with a mean daily ingestion of 6mg. 
(d) Anthropometrlcal analysis 
Anthropometrical data are detailed in Table 3.4. 
Table 3.4 Anthropometrical data for patients with COPO and control subjects on entry to 
the study 
Patient Ht(cm) Body Mass (kg) BF(%) LTV (I) 
Mean 168 65 .. 21* 2.76 .. 
SD 9 14 8 0.55 
Control 
Mean 174 83 26 3.73 
SD 7 10 5 0.66 
. . Abbreviations: c:m, centimetres; kg. kilograms; BF, percentage boct; fat; LTV, lean thi!Jh volume; ~ litres; SO, standard devration; •, p<0.05 
COPD vs control subjects; •, p<0.01 COPO vs control subjects 
Body mass, percentage body fat and L 1V were significan~y lower in the patients with COPD 
compared to the control group. Height did not differ between the two groups. 
(e) The six minute walk test: Exercise perfonnance, cardiovascular and fatigue 
measurements 
All patients and control subjects completed the SMWT. 
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Fig 3.1 Distance covered by the patients with COPD compared to the control group 
during the six minute walk test(**= p<0.01). Data are presented as mean ± SO. 
The distance covered during the SMWT was significantiy lower in the patients with COPD 
compared to the control group (494± 150 vs 718± 75 m, p<0.01) (Fig 3.1). Peak RPE was higher 
(3.5 ± 2.1 vs 1.3 ± 1.5 Borg units, p<0.01) whilst peak HR tended to be lower in the patients with 
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COPD compared to the control group (127 ± 21 vs 138 ± 15 blmin; p=0.07) at termination of the 
SMWT. 
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Fig 3.2 Heart rate for the duration of the six minute walk tesl Data are presented as 
mean± SO. 
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Fig 3.3 RPE for.the duration of the six minute walk test(* p<0.05) (**"p<= 0.01). Data are 
presented as mean ± SO. 
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Heart rate was not different between patients with COPD and control subjects for the duration of 
the SMWT (Fig 3.2). In contrast, RPE was higher in the patients with COPD compared to controls 
at minutes three, four, five and six (Fig 3.3) of the SMWT. Three of the 13 patients with COPD 
reported greater leg fatigue than shortness of breath during the SMWT. All13 patients reported 
"tired legs• associated with shortness of breath at termination of the SMWT. 
(f) Heart rate, oxygen consumption, minute ventilation and blood lactate concentration at 
submaximal workloads during the incremental cycle test to exhaustion 
Twelve patients and 13 control subjects completed the maximal exercise tests to exhaustion 
according to the protocol detaifed in Chapter Two. One patient did not complete the maximal cycle 
ergometer test due to equipment malfunction on the day of testing. This patient resided in 
Johannesburg and was returning that afternoon, thus repeat testing was not possible. 
Peak vo2 (17 ±3 vs 25 ±5 mlcnlkg/min; p<0.01), VE (41 ±13 vs 87 ±221; P<0.01) and workload (72 
±37 vs 211 ±69W; p<0.01) achieved during the cycle test were significantly lower in patients 
compared to controls. Comparisons of HR, VE, V02 and arterialised blood lactate concentrations 
were made at the same absolute workloads between groups. Additionally, relative comparisons of 
VE, HR and arterialised blood lactate concentrations were made at 25, 50, 75 and 100% V02 max. 
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Ag 3.4 Heart rate during the incremental cycle test to exhaustion(** p=<0.01; • p= <0.05). 
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Fig 3.5 V02 during the incremental cycle test to exhaustion(** p--<0.01; * p= <0.05). Data are 
presented as mean ± SO. 
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Fig 3.6 Minute ventilation during the incremental cycle test to exhaustion (** p=<0.01; * p= <0.05). 
Data are presented as mean :!: SO. 
Heart rate (Fig 3.4), Vfh. (Fig 3.5), VE (Fig 3.6) and arteriatised blood lactate concentrations (Fig 
3.7) increased over time in response to increased workloads in both groups. However, a 
comparison of physiological variables at the same absolute workload demonstrated that HR (Fig 
60 
3.4), V(h(Fig 3.5), Ve (Fig 3.6) and arterialised blood lactate concentrations (Fig 3.7) were 
elevated in the patients with COPD compared to controls during the incremental cycle test to 
exhaustion. Heart rate was elevated in the patients with COPD compared to controls at the same 
absolute workload until a workload of 75 Watts; thereafter values were no longer different VO-z 
was elevated in the patients with COPD compared to controls until a submaximal workload of 58 
Watts; thereafter values were no longer different and in fact V(h declined in the patients. 
Arterialised blood lactate concentrations were only cfiffe.rent at workloads between 17 to 50 Watts. 
The most likely reason for lack of significant differences at higher workloads and the decline in VO-z 
in the patients with COPD after 75 Watts is because seven patients with COPD achieved a 
maximum workload greater than 42 Watts whilst only four achieved a maximum workload of or 
greater than 75 Watts. In contrast, all the control subjects exceeded a maximum workload of 75 
Watts. 
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Fig 3.7 Arterialised blood lactate concentrations during the incremental cycle test to 
exhaustion (** ~.01). Data are presented as mean ± SO. 
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Fig 3.8 Heart rate relative to % V02 max during the incremental cycle test to exhaustion. 
Data are presented as mean ± SO. 
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Fig 3.9 Arterialised blood lactate concentrations relative to % V02 max during the incremental 
cycle test to exhaustion (* p=<0.05). Data are presented as mean ± SO. 
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Fig 3.10 Minute ventilation relative to o/o V02 max during the incremental cycle test to 
exhaustion (* p=<0.05; ** p=<0.01). Data are presented as mean :t SO. 
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In contrast to comparisons made at absolute workloads, comparisons at relative workloads of 25, 
50,75 and 100% ofV(h max demonstrated the following. Firstly, heart rate was not different 
between the patients with COPD and control subjects during the incremental cycle test to 
exhaustion (Fig 3.8). Secondly, arterialised blood lactate concentrations were higher at 100% V(h 
max (Fig 3.9) and VE was higher at 50, 75 and 100% of V(h max (Fig 3.1 0) in control subjects 
compared to patients with COPD during the incremental cycle test to exhaustion. 
(g) Exercise perfonnance, cardiovascular and respiratory measurements at peak exercise 
during the Incremental cycle test to exhaustion 
Cardiorespiratory variables, metabolic responses and perception of effort responses at peak 
workload are listed in Table 3.5 
Table 3.5. Cardiorespiratory measurements, metabo6c responses and perfonnance 
variables at the peak exercise workload during the incremental cycle test to exhaustion in 
patients with COPD and control subjects 
Exercise Pk Pk Ve PkRER Pk Post Pk PkW2 Pk 
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time HR SBP Olmin) rJCOv Exercise Sa02 (ml021'kglmin) RPE (Borg 
(minutes) (blmin) (mmHg) v~ Plasma (%) Units) 
[lactate] 
(mmoln) 
Patient 
(mean} 9.!r 150 17~ 41.3 .. 1.1 .. 5.1** 96.r 26 6 
SD 3.9 16 44 13.5 0.2 2.7 3.0 6 2 
Control 14.4 156 202 87.5 1.4 9.7 98.6 17 5 
(mean} 
SD 2.2 11 27 22.1 0.2 2.7 1.2 4 3 
. . Abbreviations: Pk, peak; SBP, systoliC blood preswe; HR, heat rate; Ve, mtnute ventilation; RER, respiratory exchange ratio; 
Post Exercise Plasma (Lactate); highest Merialised blood lactate concentration in the live minutes immediately after exercise; 
SaOz, sat\lation of oxygen in ataialised blood; RPE, rating of perceived exertion;*, p<0.05 COPD vs Control; .. p<0.01 COPD vs 
Control; SO, standard deviation. 
vo2 peak (Fig 3.5), peak workload (Fig 3.4), peak SBP (Table 3.5), peak VE (Fig 3.6/Table 3.5), 
peak RER, peak arterialised blood lactate concentrations (Table 3.5) and exercise time to 
exhaustion (Table 3.5) were lower in the patients with COPD compared to control subjects. 
100 ~ 
oo l 
I 
I 
I 
iOControl j so ~ f 
-
70 1 1tmCOPD i c I ~ so + 
~ I I 50 1 > 
40 1 
30 1 
20 
Fig 3.11 Maximal minute ventilation rJE) achieved during the Incremental cycle test to 
exhaustion as a percentage of maximum voluntary ventilation (MW) measured at rest 
Data are presented as mean± SO. 
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Peak VE recorded during the cyde test calculated as a percentage of MVV measured at rest, was 
not different between patients with COPD and the control group (Fig 3.11 ). 
Patient arterialised blood gas results at peak workloads are presented in Table 3.6. 
Table 3.6. ArteriaUsed blood gas results In patients with COPD and control subjects at peak 
exercise during the Incremental cycle test to exhaustion. 
Patient No: pH at peak exercise Lowest Sa02 (0/o) Rest Sa02 (%) 
1 7.40 89 93 
2 7.29 89 99 
3 7.29 87 95 
4 7.38 90 94 
5 7.34 87 91 
6 - 93 98 
7 7.45 98 100 
8 7.41 98 -
g 7.32 96 96 
10 7.31 92 98 
11 7.32 86 93 
12 
- - 93 
13 7.34 81 91 
Mean 7.35# 90** 95.08 
SD 0.05 5 3.09 
Controls 
Mean 7.40 95 99-100 (norm) 
SD 0.07 3 . 
. . Abbrevtations: pH at peak exerctse, highest pH recorded dunng the maxi!Tlal cycle test to exhaustion; Lowest SaOz,desaturation 
level measured dlxing the maximal cycle erg;xneter test to exhaustion; Rest SiOl, resting oxygen saturation level prior to strt of 
the cycle test, ",p= <0.01 COPD vs control subjects;#. p=0.09 COPD vs control; -. no data obtained for that subject due to 
difficulty obtaining blood~ or the patient did not pa"ticipate in a maxirntm cycle test to exhaustion; SO, stancad deviation, 
noon; norms (West; 1992). · 
The highest recorded pH tended to be lower (more acidic) in patients with COPD compared to the 
control subjects. Sa(h measured by fibreoptic ear oximetry during the maximum cycle test to 
exhaustion was significan~y lower in the patients with COPD compared to the control subjects. Six 
. - -
of the 12 patients with COPD who participated in the incremental cycle test to exhaustion became 
hypoxaemic to below 90%. Four of the five patients who were hypoxaemic at rest dropped their 
saturation levels to below 90% during the maximal cycle test. The fifth subject who was 
hypoxaemic at rest did not participate in the maximum cycle test. Two subjects who were not 
hypoxaemic at rest presented with saturation levels below 90% during the cycle test 
I 
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To examine the effect of desaturation (Sa(h below 90%) on exercise tolerance within the group of 
12 patients with COPD, the six patients who became hypoxaemic below 90% during the cycle test 
were compared to the six patients who maintained saturation above 90% during the cycle test. No 
differences were found between peak V02 (16 ±4 vs 19 ±4 ml{h/kg/min;NS), peak time achieved (8 
±4 vs 12 ± 3 min; NS) and peak watts achieved (104 ±20 vs 80 ±25, those who maintained 
saturation vs those who became hypoxaemic; NS) between these two groups. However, RPE was 
significantly higher in the six patients who became hypoxaemic (4.67 ±1.25 vs. 2 ±1.83 Borg 
units;p=0.05) compared to the six patients with COPD who maintained saturation during the 
incremental cycle test to exhaustion. 
Six patients terminated exercise due to leg muscle fatigue and six patients terminated due to 
shortness of breath. The six patients who terminated exercise due to shortness of breath were not 
the same six patients who became hypoxaemic during exercise. Nine control subjects terminated 
exercise due to general fatigue, whilst two control subjects experienced excessive leg fatigue. Two 
of the control subjects' tests were terminated by the physician in attendance due to high systolic 
blood pressure during exercise. 
(h) Skeletal muscle function 
(i) Skeletal muscle strength 
Peak isokinetic torque of the quadriceps was significantly lower in the patients with COPD 
compared to the controls (Fig 3.12). lsokinetic peak torque of the hamstrings tended to be lower in 
the patients with COPD compared with controls (Fig 3.13). However, once corrected for LTV, 
values were no longer significantly different between groups for either quadriceps (Fig 3.12) or 
hamstrings peak torque (Fig 3.13). 
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Fig 3.12 Absolute peak torque and peak torque relative to lean thigh volume achieved by 
the quadriceps muscle during the isokinetic strength test in respective order from left to 
right (**p<0.01). Data are presented as mean± SO. 
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Fig 3.13 Absolute peak torque and peak torque relative to lean thigh volume achieved by 
the hamstring muscle during the isoklnetic strength test in respective order from left to 
right. Data are presented as mean f SO. 
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Qi) Skeletal muscle endurance 
Work done during 30 repetitive contractions by the quadriceps was significantly lower in the 
patients with COPD compared to the control group (Fig 3.14). Even when corrected for LTV, the 
work done by the quadriceps remained significantly lower in the patients with COPD compared to 
the control subjects (Fig 3.14). 
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Fig 3.14 Absolute work done and worl< done relative to lean thigh volume by the quadriceps 
muscle during the isokinetic endurance tesl (**, P<0.01 COPO vs Control; * P<O.OS COPD vs 
ControQ. Data are presented as mean ± SD and in respective order from left to righl 
Total power generated by the quadriceps during 30 repetitive contractions was lower in the 
patients with COPD compared with the controls (Fig 3.15). Once corrected for LTV, differences 
tended towards significance (34 ±15 vs 44 ±13 Nm/1; COPD vs Control; p=0.09). 
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Fig 3.15 Absolute total power and total power relative to lean thigh volume produced 
by the quadriceps muscle during the isokinetic endurance tesl (**, P<0.01 COPD vs 
Control). Data are presented as mean ± SO. 
68 
Peak torque achieved during the isokinetic endurance test was lower in the patients with COPD 
compared to the controls, prior to (114± 59 vs 187±72 Nm; p<0.01) but not after correction for L lV 
(42 ±19 vs 51± 21 Nm/1; p=NS). Peak torque achieved by the hamstrings during the isokinetic 
tests of skeletal muscle endurance was not different between groups either before (1 00±63 vs 
141 ± 60Nm; COPD vs Control; p=NS) or after correction for L lV (37 ± 22 vs 38± 15Nmll, COPD 
vs Control; p=NS). 
(iii) Eccentric skeletal muscle function 
Eccentric peak torques generated by the quadriceps and the hamstring muscles (Fig 3.16) were 
lower in the patients with COPD compared to controls. This difference persisted after correction for 
L lV in the quadriceps (0.9 ±1.2 vs 2.6±0.7Nmll; COPD vs Control; p<0.05) and in the hamstrings 
(0.8 ±1 vs. 2.1 ±0.6 Nm/1; COPD vs Control; p=0.05). 
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Fig 3.16 Eccenbic peak torque generated by the quadriceps and the hamstrings respectively 
during the eccentric isokinetic muscle test (*, p<O.OS COPD vs ControQ. Data are presented as 
mean± SO. 
0) Results of correlation analysis between measures of exercise tolerance and tests of 
peripheral skeletal muscle function In patients with COPD. 
Correlation analyses was performed between measures of exercise perfonnance (distance 
covered during the SMWf and exercise time, peak V(h and peak Watts achieved during the 
incremental cycle test to exhaustion) and tests of skeletal muscle function in the 12 patients with 
COPD who completed the incremental cycle test to exhaustion. The resul1s of the correlation 
analyses are presented in Table 3.7 
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Table 3.7 Results of a correlation analysis between measures of exercise ability and tests of 
peripheral skeletal muscle function in thirteen patients with COPD. 
Performance Variables 
Peripheral SM function Exercise Duration PkV!h PkWL DistSMWT 
measurements (mins) (m1021kg/min) _@ lml 
PKTQ (Nm) (Strength) r-0.60 r-0.65 r-0.54 
n=12 NS n=12 n=12 
p=<0.05 J>:_<0.05 _Q--Q.05 
PKTQ (Nm) r-0.62 r-0.76 r-0.56 
(Endurance) n=12 NS n=12 n=12 
p=<0.05 _Q_=<0.01 j>==_<0.05 
r-0.64 r-0.87 r-0.59 
TPQ(Nm) n=12 NS n=12 n=12 
p=<O.OS j>==_<0.01 __rc<0.05 
r-0.66 r-0.81 r-0.61 
WDQ \'N) n=12 NS n=12 n=12 
p=<0.01 _Q_<0.05 __rc<0.02 
r-0.83 r-0.89 
ECCQ (Nm) n=6 NS NS n=6 
j>:'0.08 j>==_0.01 
Abbreviations: SM, skeletal musde; Pk, peak; WL, workload; W, Watts; Dtst, chtance; SMWT, soc mmute walk test ; m, metres; PKTQ 
(strength~ peak tor~ achieved by the ~eps during the isokinetic strength lest; PKTQ (endurance~ peak tor~ achieved by the quadriceps 
during !he isokinetic endurance test; Nm, Newton metres; TPQ, total power produced by the quadriceps during the isokinetic endurance test; WOO. 
work done by the qJadriceps during the isokinelic endurance test; ECCO. peak torque produced by the quadriceps during the isokinetic eccenbic 
strength test; NS, not significant 
Strong significant correlations were found between work done by the quadriceps, total power 
produced by the quadriceps during the isokinetic endurance test and peak watts achieved during 
the incremental cycle test to exhaustion (Table 3.7). Similarly a strong correlation was found 
between the peak torque generated by the hamstrings during the isokinetic endurance test and 
peak watts achieved during the incremental cycle test to exhaustion (Table 3.7). Additionally 
strong correlations were found between the test of eccentric skeletal muscle function and distance 
covered during the SMWT (Table 3.7). Weaker, but still significant corrleations were found 
between various other exercise performance variables and the tests of skeletal muscle function 
(Table 3.7). The peak V02 achieved during the incremental cycle test to exhaustion did not 
correlate with any of the tests of skeletal muscle function. 
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4. Discussion 
The first important finding of this study was that exercise tolerance was significantly reduced in the 
patients with COPD during the incremental cycle test to exhaustion and during the SMWT. This 
finding would support current findings investigating exercise intolerance in patients with COPD 
(Gallagher et al., 1990; Olopade et al., 1992; Belman 1993; Cooper et al., 1994; Redelmeier et al., 
1997). As reported by other authors, VE, HR, V02 and arterial blood lactate concentrations were 
significantly higher at the same submaximal workloads in the patients with COPD during the 
incremental cycle test to exhaustion (Gallagher et al., 1990; Olopade et al., 1992; Belman 1993; 
Cooper et al., 1994; Redelmeier et al., 1997). However, when these variables were compared 
between groups at the same% of maximum V02, results could be interpreted differently. 
Arterialised blood lactate concentrations at 100% Vfh. max and VE at 50%, 75% and 100% V02 
max were higher in controls than in the patients, whilst HR was not different between groups. 
These findings suggest that at the same submaximal workload, patients with COPD are working at 
a higher percentage of their maximum. Therefore, physiological variables such as VE. heart rate 
and arterialised blood lactate concentration are higher. The reported findings of higher 
physiological variables at submaximal workloads in patients with COPD compared to controls has 
led to the conception that the exercise intolerance in patients with COPD is due to central factors 
such as impaired ventilation mechanics (Mahler et al ., 1988), impaired gaseous exchange (Degre 
et al., 1978), increased blood lactate accumulation (Sue et al., 1988) and cardiovascular factors 
(Fujii et al., 1996). However, when physiological variables are analyzed at the same relative 
workload, the findings of this study suggest that only VE may have played a role in the exercise 
limitation seen in these patients with COPD. VE was the only variable that remained significantly 
and consistently lower in patients with COPD when compared with controls at the same relative 
workload. This would imply a possible limitation in ventilatory mechanics. Findings from this study 
therefore suggest that the tr~cfrtional interpretation that increased blood lactate accumulation (Sue 
et al., 1988) and cardiovascular factors (Fujii et al., 1996). may not be the primary limiting factors 
during exercise in these patients. 
Thus, in order to assess the suggestion that ventilation mechanics may be a limiting factor in the 
exercise intolerance in the patients investigated in this study, VE during exercise was measured. If 
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ventilation mechanics were limiting the patients with COPD during the incremental cycle test, a 
plateau of VE towards termination of exercise would be expected. However, no plateau was 
evident A large number of the patients achieved their maximum VEin recovery. The patients were 
therefore capable of greater ventilation mechanics in recovery than during the exercise test. This 
may be a reflection of a limitation to ventilatory mechanics during exercise in the patients with 
COPD. 
Additionally, to determine the contribution of ventilatory mechanics to exercise intolerance in 
patients with COPD, MW at rest was measured. The average peak VE achieved for the patients 
during the incremental cycle test to exhaustion, as a percentage of the average MW measured at 
rest was 69%. For the controls it was 62%. If ventilation mechanics were limiting the patients, aVE 
at peak exercise close to 100% of the MW measured at rest would be expected (Gallagher et al., 
1990). This further supports the argument that ventilation mechanics are unlikely to be the primary 
cause of exercise intolerance in patients with COPD. Guyatt (1990) argued that VE/MW was not a 
good measure of the role of ventilatory mechanics during exercise in patients with COPD. He 
argued that this measure did not consider possible bronchodilation in response to exercise in 
these patients which would result in an ability to achieve a higher VE during exercise than MW at 
rest. However, pre and post exercise spirometry was conducted on the patients in this study and 
none of the patients displayed bronchodilation immediately post exercise. It therefore seems 
unlikely that bronchodilation would have aided VE during exercise in the patients in this study. 
It therefore seems that although ventilatory mechanics may play a role in limiting exercise 
tolerance in patients with COPD, it seems unlikely that they are the major contributing factor. 
Secondly, in order to assess the role of gas exchange in exercise intolerance in patients with 
COPD, the six patients who -became hypoxaemic during the incremental cycle test to exhaustion 
were compared to the six patients who did not become hypoxaemic.-No differences were found for 
time to exhaustion, peak Watts achieved or peak V02 achieved during the cycle test between 
groups. These finding suggest that gas exchange was not a major determining factor for exercise 
termination in the patients with COPD. 
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Additionally, the average lowest saturation level for the patients with COPO during exercise was 
90%. This is not a level low enough to suggest a pulmonary limitation to exercise. If the literature 
is reviewed these findings are supported by results indicating no changes reported in Pa(h 
concentrations (an indicator of the efficacy of gas exchange) before and after training, yet 
improved exercise tolerance in patients with COPO (Chester et al., 1977). 
RPE was, however, significantly higher in the patients who became hypoxaemic and saturation 
levels may therefore play a role in perception of fatigue in patients with COPD. 
Thirdly, to determine the role of blood lactate accumulation in exercise intolerance in the patients 
with COPO, arterialised blood lactate concentrations were measured during the incremental cycle 
test to exhaustion and for the first five minutes of recovery. Other authors have attributed early 
exercise termination in patients with COPD to excessive blood lactate accumulation at submaximal 
workloads (Sue et al., 1988). However, although patients responded with higher concentrations of 
blood lactate at the same absolute workload compared to controls, they terminated exercise at 
peak blood lactate concentrations significantly lower than the control subjects. In addition, peak 
blood lactate concentrations during recovery were higher in control subjects compared to patients 
and blood lactate concentrations at the same relative workload (% V(h max) were significantly 
higher in control subjects. If excessive blood lactate accumulation was limiting exercise tolerance 
in these patients, one would expect higher concentrations of blood lactate at termination of 
exercise and higher concentrations of blood lactate at the same relative workload in the patients 
with COPD. This strongly suggests that elevated blood lactate concentrations were not 
responsible for exercise intolerance and early exercise termination in the patients investigated in 
this study. 
The patients investigated in this study were not in cardiac failure as determtned by the medical 
examination on entry to the study. Therefore it is unlikely that cardiovascular limitations attributed 
to their exercise intolerance. 
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Physical inactivity is often hypothesised as the aetiological factor causing exercise intolerance in 
patients with COPD (Oiopade et al., 1992) and other chronic diseases. In an attempt to consider 
the role of inactivity in exercise intolerance, a physical activity questionnaire was completed. It is 
an important and interesting finding of this study that although activity levels tended to be different 
between the patients with COPD and the controls (p=0,07) differences were not statistically 
significant. When considering the role of inactivity in patients with COPD it is important to consider 
socio-economic status. Many of the patients came from a socio~economic group in which inactivity 
would create impossible economic consequences. Patients were dependent on their physical 
ability for both transport and employment Many of the patients therefore remained active, despite 
the physical debilitations of COPD. It would therefore appear that inactivity alone could not account 
for the exercise intolerance experienced by the patients in this study. 
Thus the traditionally central factors of impaired lung mechanics, impaired gas exchange, 
excessive blood lactate accumulation, physical inactivity and cardiac failure could not account for 
the exercise intolerance seen in the patients with COPD in this study.ln contrast, peripheral factors 
(skeletal muscle} did appear to contribute to the exercise intolerance in these patients. 
Firstly, a number of patients reported leg fatigue during both the incremental cycle test to 
exhaustion and during the SMWT. Secondly, the correlation analysis demonstrated significant 
correlations between the various measures of skeletal muscle function and performance variables 
including: exercise time to exhaustion during the cycle test, peak workload achieved during the 
cycle test and maximum distance walked during the SMWT. In contrast, peak V02 (traditionally a 
measure of heart and lung capacity during exercise) did not correlate with the measures of skeletal 
muscle function. Rnally, the tests of skeletal muscle function demonstrated functional disabilities 
in the skeletal muscle of the patients with COPD. These functional disabifrties were seen during 
tests of skeletal muscle strength and skeletal muscle endurance. The tests of skeletal muscle 
function were not limited by central factors as only a small and specific mtJscle group was active at 
the time of testing (McArdle et at., 1991}. These findings therefore suggest that skeletal muscle is 
an important contributor to exercise intolerance in patients with COPD. 
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The existence of skeletal muscle abnormalities in patients with COPD has been suggested by 
some preliminary research papers (Decramer et at., 1994; Maltais et al., 1997).1n addition, skeletal 
muscle abnormalities have been reported in patients with other chronic diseases (Harber et al., 
1986; Harber et at., 1987; Upkin et al., 1988; Kempeneers et al., 1990; Buller et at., 1991; Minotti et 
al., 1991; Derman et at., 1992; Diesel et al.,1992; Magnusson et al., 1994) 
The patients with COPD in this study presented with significantly lower strength in the quadriceps 
whilst hamsbing strength tended to lower (p=O.O?) compared to control subjects. Once corrected 
for LTV, these values were no longer different between groups. This finding suggests that maximal 
force production per unit of cross sectional area of the skeletal muscle is not different between the 
patients with COPD and the control subjects. However, due to skeletal muscle wasting seen in 
patients with COPD, absolute strength of the skeletal muscle is reduced compared to control 
subjects. This has previously been documented in patients with renal failure (Diesel et at., 1992} 
and patients with cardiac failure (Upkin et al., 1988; Kempeneers et al., 1990; Buller et al., 1991; 
Minotti et at., 1991; Derman et al1993; Magnusson et al., 1994). It is therefore possible that this 
finding is common to various chronic diseases. 
In contrast to the skeletal muscle strength in the patients with COPD examined in this study, the 
skeletal muscle endurance was decreased both before and after correction for LTV compared to 
the control group. This finding suggests that during repetitive contractions of the peripheral skeletal 
muscle these patients demonstrated a decreased resistance to fatigue. Decreased resistance to 
fatigue was not due to_ decreased muscle mass as it persisted once corrected for LTV. Repetitive 
skeletal muscle contractions of this nature would be performed during activities such as walking 
and cycling (Jones et al., 1990) .. Therefore, it is likely that this decreased resistance to fatigue 
plays a role in limiting exercise tolerance in patients with COPD. This decreased resistance to 
fatigue in the skeletal muscle has been reported in patients with renal failure (Diesel et at., 1992) 
and in patients in cardiac failure (Upkin et at., 1988; Minotti et at., 1991; Derman et at., 1992) 
indicating once again that these skeletal muscle abnormalities may be common to various chronic 
diseases. Additionally, the functional abnormalities seen in the skeletal muscle of the patients with 
COPD in this study would correspond well with the metabolic abnormalities reported by other 
authors in the skeletal muscle of these patients (Jacobbson et al., 1990; Maltais et al., 1997). 
These findings strengthen the argument that skeletal muscle may contribute to exercise 
intolerance in patients with COPD. 
Lasijy, two interesting findings emerge from this study. Firstiy, although the hamstrings tended to 
be absolutely weaker in-the patients compared to controls, the difference was not statistically 
significant. The quadriceps muscles are known to atrophy rapidly whilst the hamstrings are more 
resistant to atrophy in human subjects (Dubowitz et al., 1985). It is therefore possible that the 
muscle weakness observed in patients with COPD has not yet reached the stage where the 
hamstrings have atrophied sufficienijy to cause a measurable strength deficit. 
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Secondly, eccentric strength of the hamstrings and the quadriceps was significant lower in the 
patients with COPD, both before and after correction for LTV. These results suggest, firstiy, a 
reduced contraction ability during eccentric contractions in the skeletal muscles of the patients. 
Secondly, that maximal force production per unit of cross sectional area is not within the normal 
range during eccentric contraction in patients with COPD compared to controls. The importance of 
eccentric muscle contraction in activities of daily living is established in the normal population 
(Jones et al., 1990). Therefore, it is likely that eccentric muscle contractions are important in daily 
living activities of the patients with COPD. However, to our knowledge no other studies have 
examined eccentric muscle strength in patients with COPD. The sample size used to analyse the 
eccentric skeletal muscle functional ability in this study was small. This should be considered 
when interpreting these findings. The_ results of this preliminary study of the eccentric skeletal 
muscle in patients with COPD suggest that further research into this area is warranted. 
In conclusion, patients with COPD appear to be limited by peripheral rather than central factors 
during exercise. Strong evidence to support this conclusion was demonstrated during the 
incremental cycle test to exhaustion, the SMWT and the isokinetic tests of peripheral skeletal 
muscle strength and endurance. Additional evidence was provided by correlations between 
various measures of skeletal muscle function and exercise performance variables in the twelve 
patients with COPD. This conflicts with the more traditional view that exercise tolerance in patients 
n 
with COPD is limited by central cardiac, metabolic and respiratory factors (Fujii et al., 1996; Tobin 
et al., 1988; Belman 1992; Matthay et al., 1992; Patessio et al., 1993). 
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CHAPTER FOUR 
STRUCTURAL ABNORMALITIES OF SKELETAL MUSCLE IN PATIENTS WITH CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE; RELATIONSHIP TO SKELETAL MUSCLE FUNCTION 
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1./ntroduction 
In Chapter Three of this dissertation two important concepts were demonstrated. Firs~y. functional 
abnormalities exist in the skeletal muscle of patients with COPD. Secondly, these functional 
abnormalities play a role in exercise intolerance in patients with COPD. Additionally, in Chapter 
Three the existence of metabolic abnormalities in the skeletal muscle of patients with COPD was 
documented (T ada et al., 1992; Wuyam et al., 1992; Thompson et al., 1992; Maltais et al., 1997). 
These findings therefore suggest that functional and metabolic abnormalities exist in the skeletal 
muscle of patients with COPD and that these abnormalities may play a role in exercise intolerance. 
Accordingly, investigation of the structure or histology of such muscle in patients with COPD is 
warranted. 
Very few studies have investigated the histological or structural status of the peripheral skeletal 
muscle of patients with COPD. Some preliminary evidence is however available. Jacobbson et al., 
(1990) reported a decline in the percentage of Type I fibres in the quadriceps femoris muscle of 
eight patients with COPD in respiratory failure and 11 patients not in respiratory failure. Skeletal 
muscle histological abnormalities have been demonstrated in patients in renal failure and those in 
cardiac failure (Upkin et al., 1988; Kempeneers et al., 1990; Buller et al., 1991; Minotti et al., 1991; 
Derman et al., 1992; Magnusson et al., 1994). However, most studies have focused on metabolic 
and not structural abnormalities in the peripheral skeletal muscle of patients with COPD. 
Therefore, to the best of our knowledge, no studies have provided a detailed histological 
description of the skeletal muscle of patients with COPD or examined whether the functional 
abnormalities evident in the skeletal muscle of these patients have a relationship to structural 
abnormalities in the skeletal muscle. 
Therefore the aims of this study were firs~y to provide a detailed description of the histological, 
ultrastructural and morphological status of skeletal muscle in a group ofpatients with COPD and to 
compare the morphology, histology and ultrastructure to age matched controls. Secondly, to 
quantify skeletal muscle structural changes and finally, to determine if a relationship exists 
between skeletal muscle structural status and (i) skeletal muscle functional ability and (ii) general 
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exercise intolerance of patients with COPD. 
2. Methodology 
(a) Skeletal muscle biopsy procedures 
Twelve of the 13 .patients with COPD described in Chapter Three consented to a skeletal muscle 
biopsy. Skeletal muscle biopsies of the vastus lateralis muscle were performed according to the 
methods described in Chapter Two. One biopsy produced inadequate skeletal muscle sample and 
a second biopsy produced enough sample for light microscopy only. Therefore 11 biopsy samples 
were successfully obtained for analysis by light microscopy and ten for analysis by electron 
microscopy from patients with COPD. Eleven control subjects consented to a skeletal muscle 
biopsy. 
(b) Morphometric analysis of Hght microscopy samples 
The investigator completed a morphometric analysis of the light microscopy skeletal muscle biopsy 
samples according to the methods detailed in Chapter Two. Analysis of skeletal muscle fibre type, 
size, distribution and predominance was perfonned in a randomized order. The investigator had 
no prior knowledge of which samples were from patients with COPD and which samples were from 
control subjects at the time of analysis. 
(c) Histological scoring of skeletal muscle biopsy samples 
The specimens were examined initially to ascertain the existence of a pathology and the features 
of the pathology observed. A skeletal muscle histological scoring system was then used to 
quantify the pathology observed in the skeletal muscle of the patients with COPD and the control 
subjects. The skeletal muscle biopsy samples for light microscopic analysis from both patients and 
controls subjects were numbered, randomized and examined by a histopathologist and the 
investigator both of whom had.no knowledge of whether biopsies w~re f[OIJ1 a control subject or a 
patient. The scoring system used by Derman et al., (1992) was modified to be made appropriate 
for the changes that were being observed in the skeletal muscle biopsies being examined. Each 
specimen was closely examined for the presence of the following characteristics: fibre atrophy, 
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necrosis, fibre splitting, presence of moth-eaten fibres, fibrosis, nuclear abnormalities including 
presence of nuclear chains, knots, vesicular and internal nuclei and the presence of ragged red 
fibres. Each identified abnormality was graded according to the following system; 1 = mild, 2 = 
moderate, 3 = severe. The skeletal muscle pathology scores were then summed for each 
specimen. 
(d) Electron microscopy analysis of skeletal muscle biopsy samples 
Skeletal muscle biopsy samples were then analyzed under electron microscopy by the 
histopathologist. The histopathologist examined and reported on the biopsy samples in a 
randomized order. 
3. Results 
(a) Skeletal muscle fibre morphometry 
Skeletal muscle morphometric analysis is displayed in Table 4.1. Morphometric analysis of the 
skeletal muscle biopsy samples revealed a mean Type II fibre size significantly smaller in patients 
with COPO compared to the control group (45± 5; range 41 - 55~m; vs 58± 8; range 44- 66JJIT1; 
p =0.01) The mean size of the Type I fibres was not different between the two groups. Two 
patients had more than 80% Type II fibres which in the vastus lateralis muscle indicates a 
predominance of Type II fibres (Oubowitz 1985). No control subjects demonstrated a 
predominance of either fibre type. The average Type II fibre percentage for the patients with 
COPD tended to be higher than established norms for both genders. Two patients had an average 
Type I fibre size of greater than 70JJIT1, which indicates possible hypertrophy (Dubowitz 1985). 
None of the controls had an average Type I fibre size of greater than 67J.tm. 
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Table 4.1 Morphometric analysis of Type I and II fibres in the skeletal muscle of patients with 
COPD compared to the control group and to established norms. 
Fibre size (J.Lm) 
Patient Gender Type I Type II Type I(%) Type II(%) Predominance 
1 F 67 43 12 88 Type II 
2 M 45 43 43 57 -
3 M 56 44 29 71 -
4 M 73 41 22 78 -
5 M 40 43 28 70 -
6 M 60 44 35 65 -
8 M 76 52 30 70 -
9 M 55 48 34 66 -
10 M 46 42 49 51 -
11 F 56 43 12 88 Type II 
13 M 56 55 30 70 
-
Mean 57 45** 30 70 
so 11 5 12 12 
NORMS Males= 61 Males = 62-69 Males= 36 Males= 64 
(Oubowitz Females= 53 Females = 42-52 Females= 39 Females= 61 
1985) 
Control 
1 F 60 44 26 74 -
2 M 66 64 38 62 -
3 M - - - - -
4 M 58 59 44 56 -
5 M 58 64 31 69 -
6 M 63 66 35 65 -
8 M 59 61 35 65 -
9 F 54 49 46 54 -
10 M 52 54 38 62 -
11 M 59 64 31 69 -
12 M 55 60 58 42 -
Mean 58 59 38 62 
so 4 8 9 9 
. . AbbreVIations: Data are presented as mean ±SO. **, p<0.01 ;COPO vs control; •, p<0.05, COPO vs control; NORMS, normal 
fibre size for age and gender (Dubowitz 1985). 
(b) Ught microscopy 
The light microscopic descriptions and pathology scores for the skeletal muscle biopsy samples 
from individual patient and control subjects are presented in Tables 4.2a and 4.2b respectively. 
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Table 4.2a Light m
icroscopic descriptions from
 individual skeletal m
uscle biopsy samples of patients with COPD 
Patient 
Description 
1 
Variation in fibre size is present with groups of sm
all angulated fibres tending to run in units
.
 Nuclear bags and chains are present. Internal nuclei are increased 
in number. A necrotic fibre Is present as w
ell as several regenerating fibres. The fntrafasicular collagen is increased
.
 Type II fibre predominance and m
ost of the 
atg>phied fibres are Type II. Rare sm
all fibres are Type I. Moth-eaten fibres are present on NAOH staining
.
 
2 
Occasional extrem
ely atrophied fibres are present. Nuclear knots and subsarcolemmal proliferation is present. Some fibre splitting is seen
.
 NADH and SOH 
staining show m
oth-eaten fibres particularly am
ongst the Type If fibres
.
 Lipofuscin is present. 
3 
There Is m
arked atrophy of fibres with nuclear proliferation and the formation of nuclear bags. Occasional fibres are hypertrophied and there is a
 large variation In 
fibre size. An increased number of internal nuclei are present as is subsarcofemmal nuclear proliferation. SOH and NAOH staining show m
oth-eaten fibres 
pred:>minantly affecting Type I fibres
.
 35% of Type If fibres are atrophied and 5% of Type I fibres are hypertrophied
.
 
\ 
4 
A large variation in fibre size is seen, with sm
all fibres tending to occur in groups but also individually. Fibre splitting is present. lntrafasicular collii!gen appears to 
be increased
.
 Type If fibre predominance as w
ell as Type II fibre atrophy are seen
.
 Type I fibres seem
 to be hypertrophied. Internal nuclei are present in 
Increased numbers. Mild fibrosis is ()resent. On NAOH staining m
oth-eaten fibres are seen predominantly in
 Type I fibres 
5 
a
 mild variation in fibre size som
e fibre splitting and occasional nuclear knots and chains are present. On NAOH staining som
e fibres are m
oth-eaten
.
 
6 
Numerous flat angulated atrophic fibres are present as are occasional nuclear knots and subsarcolemmal proliferation
.
 Frequent fibre splitting is seen. A few 
internal nuclei are seen often in the atrophic fibres
.
 Some Type I fibres have a
 disturbed pattern on NAOH staining. 
8 
Mild variation in fibre size Is noted. On NAOH staining som
e subsarcolemmal accum
ulations are present. A slight increase in lipid deposits is seen
.
 
9 
Frequent atrophic fibres, nuclear knots and fibre splitting are seen. NAOH staining shows m
oth-eaten Type II fibres and Type I fibre subsarcolemmal 
accum
ulations. 
10 
Occasional tiny fibres are present and num
erous nuclear knots can be seen. Subsarcolemmal proliferation is present. An increase in internal nuclei is seen
.
 
NAOH and SOH staining shows subsarcolemmal accum
ulation
.
 
11 
Frequent very atrophic fibres and nuclear knots, som
e of which are pyknotic are seen. Subsarcolemmal nuclear proliferation, increased number of satellite cells, 
increased lipofuscin pigment, occasional split fibres, an increase in internal nuclei, occasional necrotic fibres with phagocytes, adipose infiltration, abundant 
glycogen are seen
.
 Occasional m
oth-eaten fibres are seen on NAOH staining, particularly am
ongst the Type I fibres. Type II fibre dominance is seen (Ratio 1;11 
13:97 =
 12% Type I fibres). 
13 
Severe atrophy with tiny fibres is present. Occasional hypertrophied fibres are seen. An increase in nuclei that are pyknotic and nuclear knots are present. 
Subsarcolemmal proliferation and m
oderate fibre splitting are seen. A mild increase in internal nuclei is noted
.
 On NAOH staining som
e subsarcolemmal 
accum
ulation is present and Type I fibres appear sm
aller than Type II fibres. Some fibres are m
oth-eaten on NAOH staining. 
Table4.2b 
Control 
2 
3 
4 
5 
6 
8 
9 
10 
11 
12 
Control subject light microscopic descriptions for skeletal muscle biopsy 
samples 
Description 
8~ 
Occasional nuclear knots and some moth-eaten Type II fibres are present. Essentially normal skeletal 
muscle. 
A moderate number of nuclear knots with tiny fibres are present. Essentially normal skeletal muscle 
Normal skeletal muscle. 
Occasional nuclear knots and clumps are seen. Essentially normal skeletal muscle 
Occasional atrophied fibres, nuclear knots and moth-eaten fibres are seen. Some necrosis is present. 
Occasional nuclear knots and moth-eaten fibres are present. 
Severe atrophy with small fibres, nuclear knots, pyknotic nuclei and some nuclei chains are present. 
Internal nuclei, fibre splitting, occasional ragged red fibres and some large mitochondria are seen. 
Mild atrophy with occasional nuclear knots is present. Some subsarcolemmal nuclear proliferation and 
mild subsarcolemmal proliferation are present. 
Moderate nuclear chains, knots and occasional Type II moth-eaten fibres are present. Essentially 
normal skeletal muscle 
Occasional nuclear knots are present. Essentially normal skeletal muscle 
Moderate atrophy with tiny fibres, mild increase in internal nuclei, moderate number of nuclear knots, 
severe capillary basement membrane thickening, several severely moth-eaten and degenerative fibres 
are present. 
Light and electron microscopy slides were photographed for graphical depiction of the peripheral 
skeletal muscle abnormalities. A normal control fibre size variation and structure is presented in 
Fig 4.1 In contrast, all the patients with COPD displayed a variation in fibre size as presented in 
Fig 4.3. Nine patients had extreme Type II fibre atrophy involving very small fibres or angulated 
atrophied fibres (Figs 4.2 and 4.4). One control subject showed severe atrophy, another control 
subject showed moderate fibre atrophy and two control subjects showed occasional atrophied 
fibres. 
Six patients with COPD showed frequent evidence of fibre splitting (Figs 4.8 and 4.9), whilst only 
one control subject showed fibre splitting. Seven patients showed an increased number of internal 
nuclei, some of which were pyknotic (Fig 4.5), whilst two control subjects showed evidence of 
increased internal nuclei. Severe or moderate nuclear changes including nuclear bags, nuclear 
knots and pyknotic nuclei were evident in all ten patients with COPD (~igs 4.5, 4.6 and 4.7). 
Moderate, less frequent nuclear changes were found in all control subjects. 
Moth-eaten fibres were found in eight patients (Fig 4.11 ). Moth-eaten fibres were not selectively 
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distributed to one fibre type. Three control subjects showed moth-eaten fibres. 
Two patients displayed some evidence of fibrosis or regeneration, whilst this was not found in any 
of the control subjects. One control subject showed ragged red fibres, whilst no patients showed 
evidence of ragged red fibres. One control subject and one patient with COPD showed necrotic 
fibres. Two patients showed evidence of increased intrafasicular collagen. Evidence of 
subsarcolemmal accumulations of mitochondria, glycogen and lipid will be discussed under 
electron microscopy. 
(c) Light microscopy pathology score 
The individual skeletal muscle biopsy pathology scores are presented in Table 4.3. The mean 
pathology score was significantly higher in the patients with COPD compared with the control 
group. The range of scores in the patients with COPD was five to 13 (arbitrary units) whilst the 
range for the control group was zero to ten. Two control subjects obtained relatively high skeletal 
muscle pathology scores, one obtained a score of nine and the other a score of ten. It is 
interesting to note that subsequent to this skeletal muscle scoring one of these control subjects is 
undergoing a series of neurological investigations due to the development of a tremor. A similar 
finding has previously been reported in this laboratory. A control subject scored a skeletal muscle 
pathology score which was high relative to the other control subjects in a study examining patients 
with chronic heart failure relative to controls (Derman et al., 1992). Eight months later the control 
subject was diagnosed with cancer. 
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Table 4.3 Individual light m
icroscopy skeletal m
uscle biopsy pathology scores for patients with COPD com
pared to control subjects 
Patient 
Atrophy 
Necrosis/ 
Fibre 
Internal nuclei 
Nuclear 
Ragged red 
Fibrosis 
M
oth-
Pathology score 
,
 
regeneration 
Splitting 
Abnorm
alities 
eaten 
(AU) 
.
 
1 
3 
1 
0 
3 
3 
0 
0 
3 
13 
2 
2 
0 
1 
0 
3 
0 
0 
1 
7 
3 
3 
0 
2 
3 
3 
0 
0 
2 
13 
4 
3 
0 
2 
3 
3 
0 
1 
2 
14 
I 
5 
1 
0 
2 
0 
1 
0 
0 
2 
6 
6 
3 
0 
3 
0 
2 
0 
0 
0 
8 
8 
NS 
9 
2 
0 
0 
0 
3 
0 
0 
1 
I 
6 
10 
2 
0 
0 
0 
2 
0 
0 
1 
5 
11 
3 
1 
1 
2 
3 
0 
0 
1 
11 
13 
3 
0 
2 
0 
3 
0 
0 
1 
9 
Mean 
9** 
so 
3 
Control 
1 
0 
0 
0 
0 
1 
0 
0 
2 
3 
2 
1 
0 
0 
0 
2 
0 
0 
0 
3 
3 
0 
0 
0 
0 
0 
0 
0 
0 
0 
4 
0 
0 
0 
0 
1 
0 
0 
0 
1 
5 
2 
1 
0 
0 
1 
0 
0 
1 
5 
6 
0 
0 
0 
0 
1 
0 
0 
2 
3 
8 
3 
0 
1 
2 
3 
1 
0 
0 
' 
10 
9 
2 
0 
0 
0 
1 
0 
0 
0 
3 
10 
0 
0 
0 
0 
2 
0 
0 
2 
4 
11 
0 
0 
0 
0 
1 
0 
0 
0 
1 
12 
2 
0 
1 
1 
2 
0 
0 
3 
9 
Mean 
4 
so 
6 
-
-
-
-
-
-
-
-
-
Abbreviations
: AU, crbitrary units; NS, not scored, the light microscopy slides w
ere accidentally lost by the technicians after reporting, prior to scoring
.
 Data are presented as m
ean ±SO; 
*
*
,p<0
.01 COPD vs Control. 
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Table 4.4 Electron microscopic descriptions for individual skeletal muscle biopsy samples 
in patients with COPD and control subjects. 
Patient Description 
1 Glycogen accumulation, focal lipofuscin deposition, degenerate nuclear bags, disrupted myofilaments 
and z-banding streaming are present. Central nuclei are increased in number and the plasmalemma! 
basement membrane is redundant. 
2 Nuclear knots, fibre atrophy, a moderate number of abnormally shaped and enlarged mitochondria are 
present. Occasional mitochondria contain paracrystalline rectangular inclusions. 
3 Atrophic fibres are present and the sarcolemmal membrane shows a saw-tooth edge. Satellite cells 
are present as is a small area of fibre disarray. Subsarcolemmal glycogen is present. 
4 InadeQuate muscle sample for electron microscopy. 
5 Muscle contains lipofuscin. 
6 Atrophic fibres with patches of thick and thin filaments are shown. Thickened sarcolemmal basement 
membrane, saw-toothed sarcolemmal membrane, nuclear knots in atrophic fibres, increased satellite 
cells and some myelin degeneration in mitochondria are shown. 
8 Increased lipid accumulation, a few subsarcolemmal accumulations of mitochondria, glycogen and 
lipid are displayed. 
9 Subsarcolemmal accumulations of mitochondria and lipids. Atrophic fibres present, lipofuscin present 
10 Enlarged and elongated mitochondria are present, often associated with a lipid vacuole. Occasional 
subsarcolemmal accumulations can be seen. Areas of fibre streaming are present. The sarcolemmal 
basal lamina is thickened. 
11 Myofibrillardegeneration and disarray are shown with some large mitochondria present. 
13 The basement membrane is thickened and reduplicated. Nuclear proliferation, nuclear knots, 
increased glycogen and some increased fibril dissolution are shown. 
Control 
1 The mitochondria have rounded cristae and some are elongated. Some lipid, nuclear and 
mitochondrial accumulation below the sarcolemma is present. Lipofuscin is present. 
2 Occasional "normal" subsarcolemmal accumulations are present. 
3 The sarcolemmal membrane has a ·saw-tooth" appearance and there is increased glycogen 
distribution in the area under the sarcolemmal membrane. 
4 Mild subsarcolemmal accumulation of mitochondria, glycogen and lipid are present. The sarcolemmal 
membrane has a "saw-tooth" appearance. 
5 Some lipofuscin and subsarcolemmal accumulations are present. 
6 Occasional enlarged mitochondria are present. 
8 Subsarcolemmal accumulations of large mitochondria and some area of fibre dissolution are present. 
9 Occasional subsarcolemmal accumulations of glycogen and mitochondria are present. 
10 Subsarcolemmal accumulations of lipid, mitochondria and glycogen are present whilst the 
mitochondrial are elongated with rounded cristae deposits in them. Lipofuscin is present. 
11 Subsarcolemmal accumulations of mitochondria and lipid are present. 
12 Moderate amount of fibre dissolution, subsarcolemmal accumulations of mitochondria and glycogen 
are present. Enlarged, elongated mitochondria and some lipofuscin are present. 
Fig 4.1. A light photomicrograph showing normal fibre size variation in the skeletal muscle of a control 
subject (H&E x16). Note the structure and regularity of the fibres. 
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Fig 4.2. A light photomicrograph showing atrophied fibres in the skeletal muscle of a patient with COPD (H&E 
x40). 
89 
Fig 4.3 A light micrograph showing abnormal fibre size variation in the skeletal muscle of a patient with 
COPD (H&E x16). Note the differences between fibre sizes and the irregularity of fibre sizes. 
Fig 4.4 A light micrograph showing atrophied, angulated fibres in the skeletal muscle of a patient with COPD 
(H&E x16). 
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Fig 4.5 A light micrograph showing prominent nuclear chains, nuclear knots and centralized nuclei in the 
skeletal muscle of a patient with COPD (H&E x40). 
Fig 4.6. A light micrograph showing nuclear bags, chains and knots in the skeletal muscle of a patient with 
COPD (H&E x16). 
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Fig 4.7 A light micrograph showing nuclear chains in longitudinal section in the skeletal muscle of a patient 
with COPD (H&E x16). 
Fig 4.8. A light micrograph showing possible fibre splitting in the skeletal muscle of a patient with COPD 
(H&E x40). 
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Fig 4.9 A light micrograph showing possible fibre splitting in the skeletal muscle of a patient with COPD 
(Gomori's Trichrome stain x16). 
Fig 4.10. An NADH stained light micrograph showing Type II fibre predominance in the skeletal muscle of a 
patient with COPD (Type II fibres stain a lighter colour on NADH staining) (NADH x16). 
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Fig 4.11 A light micrograph showing moth-eaten Type II fibres in the skeletal muscle of a patient with COPO 
(NAOH x16). 
(d) Electron microscopy 
The electron microscopic descriptions for individual skeletal muscle biopsies are presented in 
Table 4.4. The ultrastructural changes included fibril dissolution in five patients and two controls 
(Fig 4.12), subsarcolemmal accumulations and proliferation of either mitochondria, glycogen or 
lipid were present in almost all biopsies (Figs 4.13 and 4.14). However, the severity was greater in 
the patients compared to the control group. Saw-tooth sarcolemmal membranes were found in 
both groups (Fig 4.19), but more frequently in the patients with COPD than in the control group. 
Satellite cells were found in two of the patients with COPD. Two control subjects showed circular 
mitochondria cristae (Fig 4.23) whilst one patient with COPD had rectangular paracrystalline 
mitochondrial inclusions (Fig 4.17). Lipofuscin deposits were found in a number of patients and a 
number of controls (Fig 4.18). 
The changes found on light microscopy such as internal nuclei (Fig 4.16), small atrophic fibres (Fig 
4.15) and nuclear bags and chains (Fig 4.20, Fig 4.21, Fig 4.22) were once again more evident in 
the patients with COPD than in the control group when viewed under electron microscopy. 
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Fig 4.12 An electron micrograph showing fibril dissolution in the skeletal muscle of a patient with COPD 
(x3000). Note the disruption of the fibre structures by deposits of various substances. 
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Fig 4.13 An electron micrograph showing subsarcolemmallipid (l) and nuclear (N) accumulation in the 
skeletal muscle of a patient with COPD (x4500). 
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Fig 4.14. An electron micrograph showing subsarcolemmal accumulation of mitochondria (M) and lipid (l) in 
the skeletal muscle of patient with COPD (x3000). 
·~· 
.. ~ '· f •• 
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Fig 4.15. An electron micrograph showing small atrophic fibres in the skeletal muscle of a patient with COPD 
(x2000). 
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Fig 4.16 An electron micrograph Showing centralized nuclei in the skeletar musele· of a patient with COPD 
(x3000). 
Fig 4.17 An electron micrograph showing rectangular paracrystalllne mitochondrial deposits In the 
mitochondria of a patient with COPD (x4500). 
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Fig 4.18 An electron micrograph showing lipofuscin in the skeletal muscle of a control subject (x15000). 
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Fig 4.19 An electron micrograph showing a saw-tooth subsarcolemmal membrane in the skeletal muscle of a 
patient with COPD (x3000). 
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Fig 4.20 An electron micrograph showing nuclear bags in the atrophic fibre in the skeletal muscle of a patient 
with COPD (x7000). Note that the nuclear bag is almost the full size of the atrophic fibre. 
r 
Fig 4.21 An electron micrograph showing nuclear bags and chains in the atrophic fibres in the skeletal 
muscle of a patient with COPD (x2500). 
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Fig 4.22 An electron micrograph showing a nuclear bag in an atrophic fibre in the skeletal muscle of a patient 
with COPD (x15000). 
w; 
Fig 4.23 An electron micrograph showing circular mitochondrial cristae in the skeletal muscle of a control 
subject (x15000). · • · 
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Relationships between skeletal muscle pathology scores, skeletal muscle function and 
general exercise perfonnance in patients with COPD 
To determine if any relationship existed between the observed skeletal muscle structural 
abnormalities and skeletal muscle function and/or general exercise capacity in the patients with 
COPD, a correlation analysis was performed between the biopsy pathology scores of the 11 
patients with COPD and various measures of skeletal muscle function and general exercise 
performance. 
Table 4.5. Correlation coefficients between skeletal muscle biopsy pathology score and 
FEV1, peak exercise variables and measures of skeletal muscle functional ability. 
Correlation with SM biopsy pathology score 
Patients Controls 
lung Function Variable rValue pValue p Value 
FEVt (I) -0.52 NS NS 
Peak Exercise Variables 
vo2 peak (ml02/kg/min) -0.67 0.04 NS 
Peak Ve (1/min) -0.75 0.02 NS 
Wlpeak (W) -0.67 0.04 NS 
Maximum exercise time (min} -0.82 0.01 NS 
Measures of SM function 
PKTQ (Nm) (Strength) -0.69 0.03 NS 
PKTQ(NrrVI}(Strength~~ -0.54 0.08 NS 
PKTQ (Nm) (Endurance) -0.79 0.01 NS 
PKTQ (Nm) (Endurance~ TV) -0.63 0.05 NS 
TPQ(Nm) -0.56 0.09 NS 
TPQ {Nm/1) -0.39 NS NS 
WDQ 0N) -0.67 0.04 NS 
WDQ (Wn) -0.01 0.08 
Functional measure of exercise 
tolerance 
SMWT distance (m) -0.63 0.05 
.. AbbreVIations: SM, skeletal muscle; FEV1, forced expiratay volume 1n 1 second; VOz peak, peak oxygen consumption achreved 
during the incremental cycle test to exhaustion detailed in Chapter Three; Peak Ve. peak minute ventilation achieved during the 
incremental cycle test to exhaustion; ~ peak 'Mlrk load achieved <iling the incremental cycle test to exhaustion; 
Maximum exercise time, maximal exercise time achieved during the incremental cycle test to exhaustion; PKTQ (Strength), 
peak b"que p-oduced by the quadiceps muscle cilring the isokinetic stength tests; LTV, leaO-thiQh volume; I, litre; PKTQ 
(Endurance), peak torque produced by the quacticeps muscles during the isokinetic endurance tes~ W, watts; Nm,.Newton 
me!re; TPQ, total power produced by the quaaiceps muscle during the isokinetic endurance test; WD, v.o1< done by the 
quadiceps muscle during the isokinetic endurance test; SMWT, six minute walk test; m, metres; min, minutes; r Value, 
cmelation coefficient 
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A significant negative correlation was found between the biopsy pathology scores and the peak 
exercise variables; VE and exercise time achieved during the incremental cycle test to exhaustion 
discussed in Chapter Three. Similarly, a significant negative correlation was found between the 
biopsy pathology score and peak torque achieved by the quadriceps prior to correction for LTV 
during the isokinetic endurance test involving 30 repetitive contractions (Fig 4.24). 
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Fig 4.24 Relationship between the biopsy pathology score and (a) peak torque achieved during the isokinetic 
endurance test (n=10) and (b) peak workload achieved during the incremental cycle test to exhaustion (n=9). 
Abbreviations: AU, arbitrary units. 
Weaker but significant correlations were found between the biopsy pathology scores and the 
following variables; peak VQ.z achieved during the incremental cycle test to exhaustion, peak 
workload achieved during the incremental cycle test to exhaustion (Fig 4.24), peak torque 
achieved during the isokinetic strength test of the quadriceps involving two contractions, total 
power generated by the quadriceps during the isokinetic endurance test involving 30 repeated 
contractions, work done during the isokinetic endurance test of the quadriceps involving 30 
repeated contractions, peak torque achieved by the quadriceps before correction for LTV during 
the isokinetic endurance test and distance covered during the SMWT. 
A correlation analysis was performed between the variables of performance and skeletal muscle 
function and the biopsy pathology scores of the control subjects. No significant correlations were 
found (Table 4.5). 
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Comparison between skeletal muscle structure, function and exercise performance in five 
patients ingesting prednisone compared to eight patients not ingesting prednisone: 
In an attempt to determine the effect of ingesting corticosteroid on skeletal muscle structure, 
function and exercise performance in patients with COPD a comparison was made between the 
five patients ingesting prednisone and the eight patients not ingesting prednisone. Results of the 
comparison are presented in Table 4.6. 
Table 4.6. Results of a comparison of skeletal muscle structure, function and general 
exercise performance between five patients with COPD ingesting prednisone compared to 
eight patients not ingesting prednisone. 
Variable Patients ingesting Patients not ingesting Significance 
prednisone prednisone level 
Measures of SM structure 
Biopsy path score (AU) 11 ±4 7±3 p=0.06 
Measures of SM function 
PKTQ (Nm) (Strength) 132 ±66 200 ±101 NS 
WDQ (W) (Endurance) 1845 ±942 2370 ±1058 NS 
Measure of general 
exercise performance 
V02 peak (ml021kg/min) 17±5 16±3 NS 
WL peak (W) 73±73 89±33 NS 
SMWT(m) 486 ±209 522 ±117 NS 
.. Abbrevratrons: SM, skeletal muscle;Bropsy path score, bropsy pathology score; AU, crbrtrCIY unrts; VOJ. peak, peak oxygen 
consumption achieved during the incremental cycle test to exhaustion detailed in Chapter Three; Wlpeak, peak v.OO< load 
achieved during the incremental cycle test to exhaustion; PKTQ (Strength), peak torque produced by the quaciiceps muscle 
during the isokinetic strength tests; W, watts; Nm, Newton metre; WDQ, v.OO< done by the quaciiceps muscle during the isokinetic 
endurance tes~ SMWT, six minute walk tes~ m, metres; 
No significant difference was found in skeletal muscle function or general exercise performance in 
the patients ingesting prednisone compared to the patients not ingesting prednisone (Table 4.6). 
The biopsy pathology score, which is indicative of skeletal muscle structure, tended to be higher 
(greater pathology) in the patients ingesting prednisone compared to patients not ingesting 
prednisone (Table 4.6). · 
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4. Discussion 
The most important contribution of this study was to document and describe the structural 
abnormalities seen in the skeletal muscle of patients with COPD. Evidence from analysis of light 
microscopy, electron microscopy and morphometry of the skeletal muscle biopsy samples of the 
patients resulted in a detailed description of the abnormalities. The abnormalities seen in the 
skeletal muscle of the patients with COPD included; severe nuclear abnormalities, Type II fibre 
predominance, Type II fibre atrophy, fibre splitting, internal nuclei, moth-eaten fibres, 
subsarcolemmal proliferation and aggregation and, in one patient mitochondrial paracrystalline 
deposits. The most frequent pathological features observed in the skeletal muscle of the patients 
with COPD were abnormalities of the nuclei including nuclear chains, nuclear bags, nuclear knots 
and pyknotic nuclei. Indeed, nuclear abnormalities were the most outstanding feature within the 
skeletal muscle of these patients. 
Many of the changes documented in the peripheral skeletal muscle of the patients with COPD are 
non-specific findings and are seen in a variety of disorders. Atrophy of Type II fibres is a non-
specific change seen in a variety of muscular disorders and has been described in patients with 
rheumatoid arthritis, osteomalacia, and thyroid disease as well as in a variety of non-muscular 
disorders (Edwards et al., 1980). Additionally, moth-eaten fibres are a non-specific change seen in 
muscular dystrophy, inflammatory disorders of skeletal muscle and spinal muscular atrophy 
(Edwards et at., 1980). Similarly, paracrystalline deposits are regarded as a relatively non-specific 
finding, although they are considered an ultrastructural marker of mitochondrial myopathies 
(Diamauro et al., 198:4). As these paracrystalline deposits were found in the skeletal muscle of 
only one patient in this study, it is possible that this patients had an underlying mitochondrial 
myopathy. However, the patient did not show any other signs of mitochondrial myopathy such as 
the presence of ragged red fibres. Furthermore, Uoreta et al., (1996a) described the first case 
report of paracrystalline deposits in the diaphragm muscle of a patient with COPD. As Lloreta et 
al., (1996a) did not find these paracrystalline deposits in the latissimus doFsi muscle or the 
intercostal muscle of the same patient, they suggested selective involvement of the diaphragm 
muscle and hypothesized that this was due to overuse of the diaphragm in these patients. 
However, the findings in our study suggests that this abnormality is not selective to the respiratory 
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skeletal muscles and includes the larger muscles of locomotion. 
It is therefore apparent that various non-specific structural abnormalities exist in the skeletal 
muscles of patients with COPD. It is difficult to determine what might be responsible for this 
muscle damage. Possible causes include; age, disuse of the peripheral limbs, ischaemia and 
ingestion of corticosteroid medications (Horber et al., 1986; Decramer et al., 1994). 
Age, however was not responsible for the structural abnormalities seen in the peripheral skeletal 
muscle of the patients investigated in this study. An age and gender matched control group did not 
show the same degree of muscle damage in their peripheral skeletal muscle. Although some of 
the structural abnormalities were present in the age matched controls, the extent of the pathology 
was significantly less. It almost appeared as though the peripheral skeletal muscle of the patients 
with COPD had aged prematurely. 
Similarly, it is unlikely that disuse was responsible for the structural abnormalities reported, for the 
following reasons. Firstly, as discussed in Chapter Three of this dissertation, the patients with 
COPD were not significantly less active than the control subjects as measured by the Yale 
Physical Activity Questionnaire for Older Adults. Secondly, some of the structural changes 
described in the peripheral skeletal muscle of the patients with COPD in this study have previously 
been documented in the respiratory muscle of these patients (Campbell et al., 1980). The 
respiratory muscle in patients with COPD are overused, rather than underused and therefore 
similar changes in the large locomotor muscles are unlikely to be a result of disuse of the 
peripheral skeletal muscle. Thirdly, some of the structural abnormalities reported in the locomotor 
muscles of the patients with COPD are not usually associated with disuse. Fibre splitting and 
internal nuclei are associated with muscular activity rather than disuse and are signs of 
regeneration in skeletal muscle (Edwards et al., 1980). 
Corticosteroid medication has been reported to cause myopathy of skeletal muscle in patients with 
chronic disease (Horber et al., 1986). The main feature of steroid myopathy is atrophy of both fibre 
types (Pleasure et al., 1970). The dose of corticosteroids necessary to induce myopathy is 
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variable; prednisone 15-1 OOmg daily ranging from one month to five years has been shown to 
cause a skeletal muscle myopathy (Affifi et al., 1968; Askari et al., 1976). It is unlikely that 
ingestion of corticosteroid medications was solely responsible for the skeletal muscle pathology 
seen in the patients in this study for the following reasons: Firs~y. the main feature of corticosteroid 
myopathy, Type I and Type II fibre atrophy, was not observed in the patients examined in this 
study. In contrast, atrophy seemed to be isolated to the Type II fibres. Horber et al., (1986) 
reported increased Type II fibre atrophy in renal transplant patients ingesting prednisone. 
Unfortunately Horber et al., (1986) compared the skeletal muscle biopsies of renal transplant 
patients ingesting prednisone to skeletal muscle biopsies of normal healthy control subjects. It is 
therefore difficult to assume that the skeletal muscle structural changes seen in Herber's study 
(1986) is due solely to prednisone ingestion. Despite the fact that the average time since 
transplant was 16 months, the effects of the previous renal failure itself cannot be overlooked in 
relation to the observed skeletal muscle structural changes in the renal transplant patients. 
Secondly, the patients with COPD ingesting prednisone in this study tended to have greater 
skeletal muscle pathology than those not ingesting prednisone. However, only five of the 13 
patients were ingesting corticosteroid medication, whilst all13 patients showed skeletal muscle 
pathology. Therefore prednisone alone could not be responsible for the structural skeletal muscle 
abnormalities observed in the patients with COPD in this study. Thirdly, the greater structural 
skeletal muscle abnormalities observed in the patients with COPD ingesting prednisone did not 
seem to effect the function of the skeletal muscle in these patients. The group of patients with 
COPD ingesting prednisone did not have significan~y greater impairment in skeletal muscle 
function or exercise tolerance compared to those patients not ingesting prednisone. The results of 
this dissertation contradict those of Horber et al., (1987) who reports significan~y lower isokinetic 
peak quadriceps force in renal transplant patients ingesting prednisone compared to controls. 
However, Horber et al., (1987) compared peak quadriceps force in renal transplant patients 
ingesting prednisone to controls, as opposed to renal transpla~t patients not ingesting prednisone. 
Therefore, the observed weak-ness in skeletal muscle strength in the reoal transplant patients may 
have been due to the effects of the renal disease itself prior to transplantation and not to the 
prednisone as such. In summary therefore, despite the fact that prednisone ingestion may have 
contributed, in part, to the structural abnormalities in the skeletal muscle of the patients with COPD 
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in this dissertation, prednisone ingestion did not seem to effect skeletal muscle functional 
abnormalities or exercise intolerance in these patients. In addition, although prednisone ingestion 
may have played a role in the structural skeletal muscle damage seen in patients with COPD in 
this study, it is unlikely to be the primary cause. 
Lastly, the possibility that the patients with COPD in this study have a decreased capillary density, 
which was unfortunately not measured, cannot be overlooked. Decreased capillary density or 
normal capillary density coupled with fibre atrophy could retard the delivery of oxygen and 
nutrients to the muscle cells. This would lead to a relatively ischaemic environment for the muscles 
cells. However, an ischaemic environment for the peripheral skeletal muscle of the patients with 
COPD in this study is unlikely to have caused the development of a myopathy in these peripheral 
skeletal muscles. As previously reported, during ischaemic training, the metabolic profile of skeletal 
muscle shifts towards facilitating aerobic metabolism with a higher percentage of Type I fibres and 
a lower percentage of Type II fibres (Esbjornsson et al., 1993). The patients in this study showed 
an increased percentage of Type II fibres and not an increased percentage of Type I fibres as 
would be expected in response to an ischaemic environment. 
Therefore, the mechanism causing the skeletal muscle pathology documented in the peripheral 
skeletal muscle of the patients with COPD is not known. Considering the importance of the 
skeletal muscle pathology and the fact that the pathology may play an important role in the 
exercise intolerance experienced by these patients, further research investigating the mechanism 
of this peripheral skel~tal muscle pathology in is warranted. 
A further important finding of this study was that the skeletal muscle pathology previously reported 
in the respiratory muscle of -patients with COPD (Campbell et al., 1980) is unlikely to be isolated to 
the respiratory muscles. Previous research has shown pathological structural changes in the 
respiratory skeletal muscle of these patients (Mizuno et al., 1991; Campbell et al., 1980; Karllson et 
al., 1992). The changes reported in the respiratory skeletal muscle included: fibre splitting, 
centralized nuclei, variation in fibre size and atrophy of Type II fibres (Campbell et al., 1980). 
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These changes have previously been reported to be exclusive to the respiratory skeletal muscle of 
patients with COPD as a result of selective overwork of the respiratory muscles (Campbell et al., 
1980). However, the changes in the respiratory skeletal muscle are identical to the changes 
reported in the quadriceps femoris muscle of the patients with COPD in this study. This finding 
therefore suggests that this skeletal muscle pathology occurs not only in the respiratory muscle of 
these patients but within the larger muscles of locomotion. Further evidence to support the 
hypothesis that the skeletal muscle abnormalities may not be exclusive to the respiratory muscles 
of these patients is provided by current literature reports detailing metabolic abnormalities in the 
oxidative pathways of both the respiratory skeletal muscle (Campbell et al., 1980) and the vastus 
lateralis muscles (Maltais et al., 1997) of patients with COPD. 
An interesting finding from this study is that the pathological changes reported in the skeletal 
muscle biopsies of patients in this study, including fibre size variation, fibre splitting, internal nuclei 
and moth-eaten fibres have previously been reported in patients in patients with chronic heart 
failure and chronic renal failure in this laboratory (Derman et al., 1993; Diesel et al., 1993). 
However, the skeletal muscle abnormalities reported in patients with COPD can primarily be 
distinguished from those reported in cardiac failure patients by two observations. Firs~y. there was 
no evidence of thickened basement capillary membranes in the patients with COPD which was the 
outstanding feature amongst the patients with chronic heart failure and secondly, the severe 
nuclear abnormalities reported in the patients with COPD were not the most prominent feature in 
the skeletal muscle of the patients with chronic heart failure. 
The second aim of this study was to examine whether the decreased functional ability of the 
skeletal muscle in patients with COPD as reported in Chapter Three was related to the extent of 
the structural abnormalities seen in the skeletal muscle in these patients. It would appear that this 
is indeed the case. A significant relationship exists between the isokinetic strength and endurance 
measures of skeletal muscle function and the extent of the skeletaliTlusGie pathology . Patients 
with the highest pathology scores generated the lowest peak torque, particularly during the test of 
isokinetic endurance ability involving 30 repeated contractions. 
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Furthermore, the functional and structural abnormalities seen in the skeletal muscle of the patients 
with COPD appeared to play a role in their exercise limitation. A relationship between the extent of 
the skeletal muscle damage and the measures of peak exercise performance during both the 
incremental cycle test to exhaustion and the SMWT demonstrated the importance of the role that 
this skeletal muscle damage may play in the exercise intolerance reported in these patients. 
The last and unexpected finding in this study was that despite the fact that the skeletal muscle 
pathology in the patients with COPD clearly correlates to skeletal muscle functional ability and 
general exercise tolerance, no relationship was found between FEV1 and the extent of skeletal 
muscle damage. This raises the question of whether FEV1 is an accurate predictor of either 
disease severity or functional capacity in patients with COPD. 
Therefore, in summary, structural skeletal muscle abnormalities characterized by severe nuclear 
abnormalities are present in the peripheral locomotor muscles of patients with COPD. These 
abnormalities are unlikely to be a result of age, corticosteroid ingestion, disuse of the peripheral 
skeletal muscle or an ischaemic environment for the skeletal muscle of these patients. The 
structural abnormalities relate to the functional abnormalities described in Chapter Three and seem 
to play a role in the exercise intolerance experienced by patients with COPD. Thus, further 
investigation into the mechanism of this skeletal muscle damage is warranted. 
CHAPTER FIVE 
PREDICTORS OF EXERCISE CAPACITY IN PATIENTS WITH CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE 
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1. Introduction 
In the last decade, numerous researchers have investigated predictors of exercise capacity in 
patients with COPD (Bauerle 1985; Gallagher 1990; Rampulla et al., 1992; Maltais et al., 1997). 
Whilst some researchers have shown that FEVt , used historically as a measure of severity of 
COPD, is indeed a useful predictor of exercise capacity in these patients (Bauerle 1985; Gallagher 
1990; Karlsson et al., 1991 ), others have shown poor or no correlations between FEVt and 
exercise capacity in patients with COPD (Rampulla et al., 1992; Younes 1995; Maltais et al., 1997). 
Variables other than FEVt have been shown to predict exercise capacity in patients with COPD. 
These include TLCOsb, which is a measure of pulmonary diffusing capacity, (Karlsson et al., 
1991 ; Anderssen et al., 1992; Wijkstra et al., 1994; Gosselink et al., 1996), VE (Younes et al., 
1995), IC (Younes et al1995), cardiovascular function (Fujii et al.,1996), blood lactate 
accumulation (Patessio et al., 1992) and measures of respiratory skeletal muscle strength 
(Gosselink et al., 1996). 
In Chapters Three and Four of this dissertation, evidence that abnormalities in skeletal muscle 
structure and function contribute to exercise limitation in patients with COPD was provided. It is 
therefore likely that the skeletal muscle structure and function may play a role in predicting 
exercise capacity in these patients. Some preliminary research supports this hypothesis. 
Gosselink et al. , (1996) measured peak V02 during an incremental cycle test and the distance 
walked during a SMWT in 41 patients with COPD (FEVt 43±19 %). In addition, lung function, 
peripheral skeletal muscle strength and respiratory skeletal muscle strength were measured and 
correlated with distance walked during the SMWT and peak V02 achieved during the incremental 
cycle test to exhaustion. Peak quadriceps force accounted for 25% of the variability of the peak 
V02 achieved during the in~remental cycle test to exhaustion and 40% of the variability of the 
distance walked during the SMWT. Maximal hand grip strength accounted for 28% of the variability 
in the peak V02 achieved and J7% of the ~ariability in the distance walked-during the SMWT, whilst 
FEVt did not correlate to exercise tolerance. Therefore, in these 41 patients it would appear that 
peripheral skeletal muscle function was an important predictor of exercise capacity. 
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However, research investigating the role of peripheral skeletal muscle function as a predictor of 
exercise capacity in patients with COPD is sparse. In addition, to the best of our knowledge, no 
research is available examining the role of peripheral skeletal muscle histology in predicting 
exercise capacity in patients with COPD. Accordingly, the aim of this study was to examine the 
role of lung function, peripheral skeletal muscle structure and function, physical activity levels and 
duration of disease in predicting the exercise capacity of 13 patients with COPD. 
2. Methods 
A correlation analysis was performed, according to the methods detailed in Chapter Two to 
determine the relationship between various measures of exercise capacity including 1) peak V02 
achieved during the incremental cycle test to exhaustion, 2) peak workload achieved during the 
incremental cycle test to exhaustion, 3) distance walked during the SMwr and various possible 
predictors of this exercise capacity including 1) lung function variables, 2) physical activity level, 3) 
duration of disease and 4) measures of peripheral skeletal muscle structure and function in 13 
patients with COPD. The characteristics of the 13 patients are described in Chapter Three. 
3. Results 
The results of the correlation analysis are presented in Table 5.1 
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Table 5.1 Results of the correlation analysis between measures of resting lung function, 
measures of peripheral skeletal muscle function, miscellaneous variables and parameters of 
physical perfonnance in patients with COPD. 
Performance 
Variables 
Lung function variables Peak V02 Peak WL SMWT distance walked 
(m102ik~min) (Watts) (metres) 
FEVt!FVC r-0.72 NS r =0.81 
(%) p<0.01 p<0.01 
(Rest) n=12 n=13 
FEVt r-0.52 NS r-0.59 
(Q p=0.08 p<0.05 
(Rest) n=12 n=13 
TLCOsb r =0.81 r =0.52 r =0.62 
(mVmmHflmin) p<0.01 p=0.07 p<0.05 
(Rest) n=12 n=12 n=13 
IC NS r =0.70 r =0.58 
(Q p<0.05 p=0.07 
(Rest) n=10 n=10 
Pa<h NS NS NS 
(kPa) 
{Rest) 
PaC02 NS r =0.74 NS 
(kPa) p<0.05 
(Rest) n=9 
LwSa<h NS NS NS 
(%) 
(During exercise) 
Miscellaneous variables 
Physical activity levels NS NS NS 
Duration of NS r =-0.60 r =-0.65 
disease p<0.05 p<0.05 
n=11 n=12 
Peripheral SM structure 
Biopsy Pathology Score r =-0.63 r =-0.67 r =-0.63 
(AU) p=0.05 p<0.05 p=0.05 
n=10 n=10 n=10 
Peripheral SM function 
Peak Torque Quads NS r =0.65 r =0.54 
(Strength) p=<0.05 p=0.05 
(Nm) n=12 n=13 
Work Done Quads NS r =0.87 r =0.59 
(Endurance p=<0.01 p=<0.05 
(W) n=12 n=13 
Total Power Quads NS r =0.81 r =0.61 
(Endurance) . 
-
p=0.01 . 
-
p=<0.05 
-- -(J) n=12 n=13 
Peak Torque Quads Eccentric NS NS r =0.89 
(Strength) p=0.01 
(Nm) n=6 
Abbreviations: FEV1, forced exp1ratory volume 1n 1 second; FVC, forced v1tal capac1ty; VOz peak, peak oxygen consumption; WL, work load; IC, 
inspiratory capacity measured at rest, TLCOsb; transfer factor measured at rest; PaOz, partial pressure of oxygen in the arterial blood at rest; 
PaCOz, partial pressure of carbon dioxide in the arterial blood at rest, LWSaOz, lowest level of oxygen saturation during the maximal cycle test to 
exhaustion as measured by ear oximetry; Duration of disease, length of time in months since diagnosis of COPD; AU, arbitrary unrts; Biopsy 
Score, score given to the extent of pathology from the biopsies of patients with COPD; SMWT, six minute walk lest; NS, not significant 
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(a) Predictors of peak V02 
FEV1,FVC accounted for 52% of the variability of peak V02 achieved, whilst FEV1 accounted for 
27% of the variability of peak V~ achieved by the patients with COPD during the incremental cycle 
test to exhaustion. Transfer factor accounted for 66% and the skeletal muscle biopsy pathology 
score accounted for 40% of the variability of the peak V02 achieved amongst the patients during 
the incremental cycle test to exhaustion (Fig 5.2b). No relationship was found between the peak 
V~ achieved during the incremental cycle test to exhaustion and; IC, physical activity reported, 
Pa02 at rest, PaC02 at rest, desaturation during exercise, duration of disease and the tests of 
skeletal muscle function. 
(b) Predictors of peak workload achieved 
Predictors of peak workload achieved during the incremental cycle test to exhaustion included; 
TLCOsb, IC, PaC02 at rest, duration of disease, skeletal muscle biopsy pathology score and 
measures of isokinetic strength and isokinetic endurance in the knee extensors. No relationship 
was found between peak workload achieved during the incremental cycle test to exhaustion and 
FEV1, FEV1/FVC, Pa~ at rest, desaturation during exercise, physical activity reported and 
eccentric peripheral skeletal muscle function. 
(c) Predictors of distance walked during the six minute walk test 
The strongest predictors of the distance walked during the SMWT were FEV1/FVC (Fig 5.1 b) which 
accounted for 66% of the variability and peak torque during the eccentric quadriceps strength test 
which accounted for _79% of this variability. Weaker predictors of the distance walked during the 
SMWT included FEV1 (Fig 5.1a), TLCOsb, IC, duration of disease (Fig 53b), skeletal muscle 
biopsy pathology score (Fig 5.2a), quadriceps isokinetic strength and quadriceps isokinetic 
endurance (Fig 5.3a). No relationship was found between the distance walked during the SMWT 
and Pa02 at rest, PaC02 at rest, desaturation during exercise and physical activity reported. 
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Fig 5.1 Relationship between distance walked during the six minute walk test and (a) FEV1 and (b) FEV11FVC 
in patients with COPD 
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Fig 5.2 Relationship between biopsy pathology score and (a) distance walked during the six minute walk test 
and (b) peak V02 achieved during the incremental cycle test to exhaustion in patients with COPD (AU; 
arbitrary units) 
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Fig 5.3 Relationship between distance walked during the six minute walk test and (a) total power produced by 
the quadriceps during the isokinetic test of skeletal muscle endurance and (b) duration of disease in patients 
with COPD 
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4. Discussion 
The most important finding of this study was that skeletal muscle structure and function contributed 
to exercise intolerance in patients with COPD. Structural skeletal muscle damage was inversely 
related to peak V(h, peak workload and distance walked during the SMWT. Additionally, skeletal 
muscle function positively related to peak workload and peak Vfh achieved during the incremental 
cycle test to exhaustion in these patients. Gosselink et al., (1996) also showed that both peak 
quadriceps force and peak handgrip strength were related to exercise limitation in patients with 
COPD. These findings suggest that skeletal muscle is an important contributor to exercise ability in 
these patients. 
The second important finding was that the lung function measures of TLCOsb, FE'NFVC and 
FEV1 contributed significanijy to exercise intolerance in patients with COPD. The contribution of 
TLCOsb to exercise limitation in theses patients has been previously reported by other authors 
(Karlsson et al., 1991; Anderssen et al., 1992; Wijkstra et al., 1994; Gosselink et al., 1996). 
Some authors (Rampulla et al., 1992; Maltais et al., 1997; Gosselink et al., 1996) have 
demonstrated no relationship between FEV1 and exercise capacity in patients with COPD. In 
contrast, the findings of this study are similar to those of Gallagher (1990) and Bauerle (1985) who 
demonstrated a positive relationship between exercise capacity and FEV1. In deriving the 
relationship between exercise capacity and FEV1 in these patients, authors have used different 
methods of describing the FEV1 including FEV1 (I) (Gosselink et al., 1997; Karlsson et al., 1991 ); 
FEV1 as a% of predicted or FEV1 as a % of FVC (Bauerle et al., 1985). This could account for 
some of the differences reported in the literature. The results of this study suggest that FEV1/FVC 
is a better predictor of exercise tolerance in patients with COPD than FEV1. 
An interesting finding was that duration of COPD contributed to exercise intolerance whilst reported 
level of physical activity energy expenditure did not appear to contribute to this exercise 
intolerance. Support for the foriner finding is shown by an inverse relationship between the 
duration of COPD and the distance walked during the SMWT and the peak workload achieved 
during the incremental cycle test to exhaustion. The fact that the subjects' physical activity level 
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was not related to any of the measures of exercise ability can be interpreted in two ways. FirsHy, it 
is possible that the factors affecting self reported physical activity are different to the factors limiting 
exercise ability in patients with COPD. Alternatively, the questionnaire used to assess physical 
activity in this study may not have been a sensitive enough predictor of actual physical activity 
level in these patients. 
A further interesting finding was the significant positive relationship between the knee flexor 
eccentric function and the distance patients were able to walk during the SMWT. This data needs 
to be interpreted with caution due to the very small sample size. Further research with a larger 
sample size is needed to confirm this finding. 
In conclusion therefore, it is clear that lung function and skeletal muscle function contribute to 
exercise intolerance in patients with COPD. However, lung function does not alter after exercise 
training in these patients (Clark et al., 1996; Younes et al, 1996; Simpson et al., 1992). 
Accordingly, a factor other than improved lung function must be responsible for the improved 
functional ability of trained patients with COPD. Chapter Six examines the possibility that improved 
skeletal muscle structure and function may be responsible for the improved functional ability of 
trained COPD patients. 
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CHAPTER SIX 
A CASE REPORT OF THE SKELETAL MUSCLE STRUCTURAL AND FUNCTIONAL CHANGES 
AND EXERCISE CAPACITY IN A PATIENT WITH CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE, BEFORE AND AFTER EXERCISE TRAINING 
. ...- -
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1. Introduction 
Exercise rehabilitation programmes for patients with COPD are a common component of their 
treatment (Degre et al., 197 4; Ferguson et al., 1993; Siafakis et al., 1995). Patients with COPD 
benefit from regular exercise by demonstrating improvements in functional ability (Morley et al., 
1976; Ferguson et al., 1993). However, despite improved functional ability, these patients do not 
demonstrate improvements in lung function measures of either gas exchange or ventilation 
mechanics after exercise training (Clark et al., 1996; Younes et al, 1996; Simpson et al., 1992). 
This finding implies that a factor other than improved lung status must be responsible for the 
improved functional ability in the patients with COPD after exercise training. 
If, as shown in this dissertation, skeletal muscle damage contributes to exercise intolerance in 
patients with COPD then it could be hypothesized that exercise rehabilitation training reduces this 
skeletal muscle damage and results in improved exercise tolerance in patients with COPD. 
Therefore investigation into the responses of these peripheral skeletal muscles to training in 
patients with COPD is clearly warranted. 
The aim of this case study was therefore to examine changes in skeletal muscle structure and 
function in a patient with COPD before and after exercise rehabilitation. 
2. Methodology 
One of the patients (AJ) with COPD described in Chapters Three, Four and Five of this dissertation 
agreed to participate_ in an exercise rehabilitation training programme for 12 months. Patient AJ 
had a pack history of 37.5 years and had terminated smoking one year prior to the onset of the 
study. On entry to the rehabilitation programme and again after 12 months of training AJ 
underwent; a maximal cycle test to exhaustion, a SMWT, pulmonary function measurements, a 
skeletal muscle biopsy from the vastus lateralis muscle, isokinetic tests of skeletal muscle strength 
and endurance and anthropometrical analysis according to the methods detailed in Chapter Two. 
AJ completed the Yale Physical Activity Questionnaire for Older Adults on entry to the study and 
after 12 months of exercise rehabilitation training. For the purpose of interim data collection, after 
three months of training the patient underwent; a skeletal muscle biopsy from the vastus lateral is 
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muscle, a SMWT and a maximal cycle test to exhaustion. Due to technical failure of the isokinetic 
apparatus, the isokinetic tests of skeletal muscle functional ability were not recorded after three 
months of exercise training. The results were compared to an average value for the 13 sedentary 
control subjects examined in Chapters Three and Four. 
Patient AJ participated in exercise rehabilitation at the Respiratory Rehabilitation Programme 
conducted at the Sports Science Institute of SA, Cape Town, South Africa. The patient attended 
rehabilitation three times a week, each time for an hour. The patienfs training programme is 
described in Table 6.1. 
Table 6.1 Exercise training programme undertaken by patient AJ three times a week for 12 
months. 
Exercise Programme at start of Programme after 12 Description 
rehabilitation months of rehabilitation 
Walking 150m 2200m 11ap = 74m 
Cycling none 5-10 min. 0-15W(self selected) 
Circuit Weight Training 10 reps 20-30 reps Upper and lower limb 
Exercises 1 set 3 sets load constantly upgraded 
6 machines 6 machines 
Jog none 150m 
Breathing Exercises Pursed lip breathing performed during exercise and durinq recoverv phases 
The exercise rehabilitation programme was gradually increased by the patient over the 12 month 
period as his exercise tolerance improved. 
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3. Results 
(a) Resting characteristics of and medication ingested by the patient AJ 
Table 6.2 Resting characteristics of, and medication ingested by, the patient with COPD on 
entry to the study and after three months and 12 months of training. 
Training Mass (kg) WPAE Medications 
(months) (kCal) 
lpratropium Bromide (when necessary), Budesonide (2 puffs a.m. 
0 71 2145 & 2 puffs p.m.), Theophylline (2 x 5mg daily) & (2 x 5mg daily) 
Prednisone (2 x 5mg daily) 
lpratropium Bromide (when necessary), Budesonide (2 puffs a.m. 
3 68 Not tested & 2 puffs p.m.), Theophylline (2 x 5mg daily) & Prednisone (2 x 
5mg daily) 
lpratropium Bromide (when necessary), Budesonide (2 puffs a.m. 
12 68 4467 & 2 puffs p.m.), & Prednisone (2 x 5mg daily) 
.. . . .. AbbreVIations: kg, kllogan; WPAE., weekly physical activity expenditure; kCal, kllocalones; mg, mllhgans; am, mom1ng; pm, 
evening. 
Patient AJ was a 58 yr old male with a mass of 71 kg on entry to the study. He had been 
diagnosed with COPD 15 years previously and had a smoking pack history of 37.5 years. Patient 
AJ had been very physically active as a young man and had not smoked for 10 years on entry to 
the study. 
His weight decreased to 68kg after three months of training and remained the same after 12 
months of training. After 12 months of exercise training, the patient AJ's weekly physical activity 
energy expenditure had more than doubled and he was no longer ingesting theophylline (Table 
6.1). 
(b) Lung function results 
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Fig 6.1 (a) FEVt and (b) Maximum Voluntary Ventilation (MVV) in patient AJ on entry to the study and after 
three and 12 months of training; compared to controls. 
None of the lung function variables, including FEV1 or MW (Fig 6.1 ),altered substantially after 
training. 
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Table 6.3 Pulmonary function test results of the patient with COPD on entry to the study and 
after 3 and 12 months of training 
Training PEFR TLCOsb PIFR IC Sa02 
.(months) 0/min) (ml/mmHg/min) (1/min) (I) (%) 
0 220 14 190 1.4 95 
3 267 16 271 1.4 96 
12 210 15 110 1.3 97 
CONTROL 547 30 354 3.6 99 
.. Abbreviations: PEFR, peak exp1ratory ftow rate; TLCOsb, transfer factor; PEFR; peak expiratory ftow rate; PIFR, peak 1nsp1ratory 
ftow rate; IC, inspiratory ~ity; SaOz, oxygen saturation in arterial blood as measured by eel' oximetry at rest 
(c) Anthropometrical results 
Percentage body fat and LTV ~id not change after three or 12 months of exercise training in the 
patientAJ. 
(d) Peak exercise variables 
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Fig 6.2 (a) Peak V02 and (b) peak work load achieved by patient AJ during the incremental cycle test to 
exhaustion on entry to the study and after three and 12 months of training; compared to controls. 
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I (a) Workload (W) (b) 
I 
Fig 6.3 (a) V02 at three cycling work loads and (b) distance covered during the six minute walk test by patient 
AJ on entry to the study and after three and 12 months of training 
Table 6.4 Peak variables achieved during the maximal cycle test to exhaustion in patient AJ on entry 
to the study and after three and 12 months of training 
Training SBP VE RERmax Plasma pactate] Pk Sa02 (%) Lw Sa02 Sa02 at 
(months) - (mmHg) · max r-JCOVVOZJ (mmoln) (%) Pk Watts 
(I) 
0 190 30 0.84 6.4 98 87 87 
3 180 23 0.92 NS 97 88 90 
12 170 25 1.06 4.6 98 87 88 
• 0 AbbreVIations: SBP, systoliC blood pressure; HR, heat rate; Ve max, peak mmute ventilation; RER max, peak resp~ratory 
exchange ratio; vco2, volume of cat>on dioxide expired; Pk SaOz, highest recording of .arteri;~l saturation during the maximal cycle 
test and recovery; LW SaOz, lowest recording of arterial oxygen saturation during the maximal cycle test and recovery; SaOz at Pk 
watts, level of oxygen saturation of arterial blood at peak watts as measured by eCI' oximetry 
The maximal cycle test to exhaustion demonstrated an unchanged peak work load after three 
months of exercise training and an increase of 8 Watts after 12 months of training. Time to fatigue 
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during exercise did not change in the first three months and increased by one minute after 12 
months of training. Heart rate at peak exercise increased from 114b/min to 144b/min during the 
first three months of training and decreased to 125blmin after 12 months of training. Systolic blood 
pressure at peak exercise decreased by 1 0 mmHg at three months and by a further 1 0 mmHg after 
12 months of exercise training. 
V02. (Fig 6.3), Ve, RER and HR were higher after three months and after 12 months of exercise 
training at a selected submaximal work load in the patient with COPD. Peak V02 was slighijy higher 
after three months and after 12 months of exercise training (Fig 6.2). Peak RER increased by 0.08 
after three months of training and by a further 0.14 after 12 months of training. Neither peak Sa02, 
the lowest Sa~ or the Sa02 at peak work load changed after exercise training. 
(e) Results of the six minute walk test 
After three months of training, the distance covered by patient AJ during the SMWT had increased 
by more than 50% (Fig 6.3), for the same RPE (4; Borg Units) and a similar peak HR (129 vs 124 
b/min; 0 vs 3 months). After 12 months of training the distance had increased by only a further 4 
metres (Fig 6.3), for a slighijy higher peak HR (134 b/min) and a lower RPE (3; Borg Units). 
(f ) Results of the tests of skeletal muscle function 
(i) Muscle strength 
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Fig 6.4 Peak torque produced by the (a) quadriceps and (b) hamstrings musculature during the isokinetic 
strength test by the patient AJ on entry to the study and after 12 months of training, compared to controls 
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Peak torque generated by the quadriceps and the hamstring muscles during the isokinetic strength 
test improved after 12 months of exercise training (Fig 6.4). 
(ii) Muscle endurance 
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Fig 6.5 Peak Torque produced by the (a) quadriceps and (b) hamstrings musculature, (c) work done and (d) 
total power generated by the quadriceps during the isokinetic endurance test by the patient AJ on entry to the 
study and after 12 months of training, compared to controls 
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All the skeletal muscle function variables of muscle endurance measured during the isokinetic test 
improved after 12 months of exercise training (Fig 6.5). In particular, marked improvements were 
noted in work done and total power generated by the quadriceps during the endurance test. 
(g) Skeletal muscle structural changes 
(i) Light microscopy 
Table 6.5 Light microscopy findings of the skeletal muscle biopsy of patient AJ on entry to 
the study and after three and twelve months of training. 
Training Description Pathology 
(months) Score 
(arbitrary units) 
0 Marked atrophy of fibres, with nuclear proliferation and the formation of nuclear 
bags are seen. Marked fibre splitting is present. Occasional fibres are 
hypertrophied and there is a large variation in fibre size. There is an increase in 13 
both internal nuclei and subsarcolemmal nuclear proliferation. SOH and NADH 
staining show a moth-eaten appearance affecting predominately Type I fibres 
3 Numerous atrophic fibres, some only slightly larger than the nucleus are present. 
A mild increase in internal nuclei, occasional areas of nuclear proliferation, 4 
occasional fibre splitting and some nuclear clumps are seen. 
12 The sections show numerous atrophic fibres, some nuclear bags and clumps and 
occasional internal nuclei. 5 
The biopsy pathology score decreased from 13 AU to four AU after three months of exercise 
rehabilitation, this decrease was maintained after 12 months of exercise training. The improved 
biopsy pathology score in the patient AJ was achieved by reductions in fibre atrophy, internal 
nuclei, fibre splitting, nuclear abnormalities and moth eaten fibres. Fibre structure, size and 
regularity improved in patient AJ after three months of exercise training (Fig 6.6 and Fig 6.7). 
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Fig 6.6 A light micrograph of the skeletal muscle biopsy sample of patient AJ prior to exercise training. Note 
the atrophy and the variation in fibre size and structure. (H&E x16) 
Fig 6.7 A light micrograph of the skeletal muscle biopsy sample biopsy of patient AJ after three months of 
exercise training (H&E X16). Note the improvement in fibre size variation, atrophy and structure. 
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(ii) Electron microscopy 
Table 6.6 Electron Microscopy descriptions of the skeletal muscle biopsy samples from the 
patient AJ on entry to the study and after three and 12 months of training. 
Training (months) Description 
0 Atrophic fibres are present, the sarcolemmal membrane shows a saw-tooth edge, 
satellite cells are present and there is a small area of fibre disarray. Subsarcolemmal 
glycogen is present. 
3 Apart from mild streaming of the Z-bands, there is no abnormality on electron 
microscopy. 
12 Mild fibre disarray is present. 
-
The electron microscopy report had improved such that only a mild abnormality of fibre disarray 
was present after three and 12 months of exercise training. 
(iii) Morphometric analysis 
Table 6.7 Results of the morphometric. analysis of the skeletal muscle biopsy samples from 
·patient AJ on entry to the study and after three and twelve months of exercise training 
Training Type I size Type II size Type I Type II Predominance 
(months) ijlm) ijlm) (%) (%) 
0 56 (5% are 44 (35% are 29 71 Normal distribution 
hn""' u ~hied) atrophied) 
3 55 54 29 71 Normal distribution 
12 57 55 30 70 Normal distribution 
CONTROL 58 58 38 62 
.. Abbreviations: J.1m, m1crometres 
The average size of the type II fibres increased from 44 to 54flm, whilst the type I fibre size 
remained the after three months of exercise training (Table 6.7). The fibre sizes did not change 
from three months to 12 months of training. There was no change in the % Type I or% Type II 
fibres after either three or 12 months of exercise training. 
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(d) Discussion 
The most important finding of this case study was the improved functional capacity demonstrated 
by patient AJ after exercise training. Patient AJ doubled both the distance he was able to walk 
during the SMWT and his weekly physical activity energy expenditure after exercise training. 
The second important finding of this case study was that this improved functional capacity in 
patient AJ was not due to changes in either lung function or peak V02. These two variables did not 
improve substantially after exercise training. Similarly, the improved functional capacity was not a 
result of improved gas exchange as demonstrated by the absence of change in either peak or 
lowest saturation levels during the maximal cycle test after exercise training. 
In contrast, both structural and functional changes in skeletal muscle were seen after exercise 
training in patient AJ. After 12 months of exercise training improvements were shown in the 
functional strength and endurance of the skeletal muscle of patient AJ. The improved skeletal 
muscle endurance ability in response to exercise training would correspond with the findings of 
Maltais et al., (1996) who demonstrated improved skeletal muscle oxidative capacity in patients 
with COPD after three months of exercise training. Unfortunately, in this case study, functional 
skeletal muscle ability was not measured after three months of exercise training. 
After three months of exercise training the structural status of the peripheral skeletal muscle had 
improved. This improvement was maintained, but not further improved after 12 months of exercise 
training. After training, the skeletal muscle abnormalities typically seen in a patient with COPD (as 
discussed in Chapter Four) such as fibre atrophy and nuclear abnormalities were still present. 
However, the severity of these abnormalities had decreased. Therefore it would appear that 
participation in an exercise training programme resulted in some degree of reversal of the 
abnormalities seen in the skeletal muscle of patient AJ. These finding therefore suggest that the 
improved functional capacity seen in patient AJ after exercise training was related to the structure 
and function of his skeletal muscle. 
Other interesting and important concepts demonstrated by this case study include: (i) no 
demonstration of a cardiovascular training effect in the maximum cycle test in patient AJ; (ii) no 
improvement in peak VCh after training; (iii) FEV1 as a predictor of functional ability in a trained 
COPD patient and (iv) no change in anthropometric data after training. These will be briefly 
discussed in this numerical order. 
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Firstly, the V02, VE, HR and RER at a set submaximal work load during the cycle test increased 
after three months of training and after 12 months of training in patient AJ. This increase in 
physiological variables at a set submaximal work load contrasts to a normal training effect. A lack 
of the normal cardiovascular training effect in patients with COPD has been reported by other 
authors (Degre et al., 197 4; Chester et al., 1977). Degre et al., (197 4) and Chester et al., (1977) 
attributed this lack of a cardiovascular training effect in patients with COPD to an inability of these 
patients to train at an intensity high enough to induce a training stimulus. However, patient AJ 
trained at a HR above 70-80% of his maximum, three times a week for a period of 20-40 minutes. 
This should be sufficient to induce a cardiovascular training effect (McArdle et al., 1991 ). A 
possible explanation for the higher VE, HR, RER and V02 at submaximal work loads in this patient 
with COPD after training is that considering the improved structural status of the skeletal muscle, 
this patient may have been able to recruit more muscle fibres with a subsequent increase in the 
physiological response at that particular work load. 
Secondly, a training response in a normal healthy control would result in an increase in peak V02. 
However, the peak V02 did not improve substantially in patient AJ after training. A possible 
explanation for the lack of improvement in peak V02, peak work load and exercise time to 
exhaustion after three months of training and minimal improvement after 12 months of training is 
the tool used for assessment. Peak V02 may not be an accurate predictor of exercise ability in 
patients with COPD. A dissociation between a measure ofV02 max and the functional ability of 
patients~ COPD has been reported by other authors (Guyatt et al.,-1985; Clark et al. , 1996; 
Milne et.al., .19.97 unpublished data from this laboratory). Milne et al., (1997) showed that peak V02 
achieved during a m~imal test was significantly lower in patients with COPD when a mouthpiece 
rather than a mask was tised. The authors therefore suggested that the mouthpiece may impede 
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pursed lip breathing and thereby impair exercise capacity. All the maximal V02 tests conducted in 
this dissertation used a mouthpiece. Therefore, this patient may have terminated exercise earlier 
in this laboratory setting than he would have done so in a functional setting such as the SMWT 
rendering the peak vo2 test an inaccurate predictor of his functional ability. 
Thirdly, it is well established that FEV1 does not improve after exercise training in patients with 
COPD (Clark et al., 1996; Younes et al, 1996; Simpson et al., 1992). However, FEV1 is historically 
used as a measure of functional ability and disease severity in patients with COPD. This case 
study suggests that in patient AJ, after exercise training, FEV1 would no longer be a good 
predictor of the functional ability. 
Lastly, it is not surprising that LTV did not change in patient AJ as he was not participating in 
skeletal muscle strength training as such, but rather in skeletal muscle endurance training. 
Improvements in muscle mass were therefore unlikely (Fiecker et al., 1997). Patient AJ 
demonstrated no change in percentage body fat after either three or 12 months of training despite 
a doubling of weekly energy expenditure. It is quite likely that he increased his food intake to 
match the increased energy expenditure. This could account for the lack of change in percentage 
body fat. 
In summary therefore it appears that patient AJ derived benefit from exercise rehabilitation and that 
the improvements seen in his functional capacity after training were most likely due to 
improvements in the _functional and structural status of his skeletal muscle. This case study 
therefore suggests that just as abnormalities in skeletal muscle may impair functional ability in 
patients with COPD, improvements in these abnormalities by exercise training increases the 
functional ability of these patients. 
This case study has several limitations. Firstly, a single patient with COPD may not be an accurate 
predictor of the average response of COPD patients due to the variable nature of the disease. 
Therefore, group studies are necessary to confirm the findings suggested by this case study. 
Secondly, a lack of measures of the functional ability of the skeletal muscle after three months of 
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training made it difficult to determine whether skeletal muscle functional changes played a role in 
the improved functional capacity of patient AJ after three months of training. 
Future research should focus on (i) functional, structural and metabolic changes in the peripheral 
skeletal muscle of a group of patient with COPD before and after exercise training and (ii) the 
response of patients with COPD to different types of training programmes, i.e. circuit weight 
training programmes as opposed to traditional cardiovascular training programmes. 
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CHAPTER SEVEN 
SUMMARY AND CONCLUSIONS 
1. Summary 
The main aim of this dissertation was to investigate the role of skeletal muscle in the exercise 
intolerance experienced by patients with COPD. This was investigated in four parts. 
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Firsijy, exercise capacity and skeletal muscle function and the relationship between these two 
variables were evaluated in a group of patients with COPD. Secondly, the histology, ultrastructure 
and morphometry of skeletal muscle in these patients was descriptively analyzed and an objective 
histological scoring system was used to quantify the skeletal muscle pathology observed. The 
relationship between this skeletal muscle pathology; exercise capability and skeletal muscle 
function was then analyzed. Thirdly, the ability of skeletal muscle function, lung function, physical 
activity levels and duration of disease to predict exercise capacity in patients with COPD was 
evaluated. Lasfiy, a case study examined changes in skeletal muscle structure and function before 
and after training in a patient with COPD. 
The first study, reported in Chapter Three, demonstrated severely limited exercise tolerance in 
patients with COPD and provided evidence to suggest that this exercise intolerance was most 
likely due to peripheral limitations of skeletal muscle as opposed to central limitations of the heart 
and lungs. Furthermore, a relationship between skeletal muscle function and exercise capacity in 
these patients supported this hypothesis. 
The study reported in Chapter Four showed significant histological and ultrastructural abnormalities 
in the skeletal muscle of the patients with COPD. The changes were evident on light microscopy 
and included non-specific changes such as type II atrophy, fibre splitting, moth eaten fibres and a 
hallmark of nuclear abnormalities including nuclear knots, nuclear chains, nuclear clumps and 
internalized nuclei . Electron microscopy supported these findings by demonstrating a variety of 
nonspecific abnormalities including mitochondrial changes, fibril dissolution and accumulation of 
subsarcolemmal material in both groups, but more prominenijy in the patients with COPD. The 
histological abnormalities were quantitatively scored and proved to-be significanijy higher in 
patients compared to age matched control subjects. This skeletal muscle pathology score 
correlated significanfiy with peak V02 achieved, peak workload achieved, skeletal muscle function 
and distance walked during the SMWT. This finding suggests that skeletal muscle structure may 
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play a role in exercise limitation in patients with COPD. 
Chapter five analyzed predictors of exercise capacity in patients with COPD. Both measures of 
lung function and skeletal muscle function proved to be useful predictors of exercise performance 
in untrained patients with COPD whilst FEV1/FVC% proved to be a better predictor of exercise 
capacity than FEV1. However, it is well established that exercise capacity in patients with COPD 
improves after training, yet lung function does not change {Clark et al., 1996; Younes et al, 1996; 
Simpson et al., 1992). 
Therefore, in Chapter Six of this dissertation changes in skeletal muscle structure and function 
before and after exercise training were analyzed in a case report of a patient with COPD. The 
results of this case report showed improvements in skeletal muscle structure and function after 
training. This preliminary finding therefore suggests that improved skeletal muscle structure and 
function in patients with COPD after training may account, at least in part, for their improved 
exercise tolerance. 
2. Conclusions 
This dissertation confirms that severe structural and functional abnormalities exist in the skeletal 
muscle of patients with COPD and that these may limit exercise capacity in these patients. In 
addition, the results of this thesis suggest that measures of skeletal muscle structure and function 
may be useful predictors of exercise capacity in patients with COPD. Some preliminary evidence 
suggests that the improved exercise capacity in patients with COPD after exercise training may be 
due to improvements in skeletal muscle structure and function. 
Future research should therefore aim to {i) determine the effects of exercise training on skeletal 
muscle in a group of patients with COPD, {ii) determine how this relates to functional ability and 
{iii) examine the use of skelefal muscle exercise in patients with Ct>PDwho are unable to 
participate in aerobic endurance training due to the severity of their illness. 
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CHAPTER NINE 
APPENDICES 
- .. - -
INTERVIEWER: 
THE YALE PHYSICAL ACTIVITY SURVEY 
FOR OLDER ADULTS 
PLEASE MARK TIME: 
HR MIN SEC 
INTERVIEWER: (Please hand the subject the list of activities while reading this statement}. Here is a 
list of common types of physical activities. Please tell me which of them you did during a typical week in 
the last month. Our interest is learning about the types of physical activities that are a part of your 
regular work and leisure routines. 
For each activity you do, please tell me how much time (hours} you spent doing this activity during a 
typical week. (Hand subject card #1.} 
Shopping (e.g., grocery, clothes} 
Stair climbing while carrying a load 
Laundry (time loading, unloading, hanging, folding only} 
Light housework: tidying, dusting, sweeping; collecting trash in 
home; polishing; indoor gardening; ironing 
Heavy housework: vacuuming, mopping; scrubbing floors and 
walls; moving furniture, boxes, or garbage cans 
Food preparation (1 0+ mins in duration}: chopping stirring; 
moving about to get food items, pans 
Food service (1 0+ mins in duration}: setting table; carrying food; 
serving food 
Dish washing (1 0+ mins in duration}: clearing table; 
washing/drying dishes, putting dishes away 
Light home repair: small appliance repair; light home 
maintenance/ repair 
Heavy home repair: painting, carpentry, washing/polishing car 
Other:--------------
·raylor et al., 1978 or McArdle et al., 1981. 
• determined by the specified activity 
Yardwork 
Gardening: planting, wedding, digging, hoeing 
Lawn mowing (walking only} 
Clearing walks/driveway: sweeping, shoveling, raking 
Other: 
---------- ---- --
Caretaking 
Older or disabled person (lifting, pushing, wheelchair} 
Childcare (lifting, carrying, pushing stroller} 
Time 
(Hrs/Wk} 
Time 
Intensity 
Code· 
(kcal/min} 
3.5 
8.5 
3.0 
3.0 
4.5 
2.5 
2.5 
2.5 
3.0 
5.5 
+ 
Intensity 
Code· 
4.5 
4.5 
5.0 
5.5 
4.0 
+ 
Exercise 
Brisk walking (10+ mins in duration) 
Pool exercises, stretching, yoga 
Vigorous calisthenics, aerobics 
Cycling, exercycle 
Swimming (laps only) 
Other: 
----------------------------
Recreational Activities 
Leisurely walking (1 0+ mins in duration) 
Needlework: knitting, sewing, needlepoint, etc. 
Dancing (mod/fast): line, ballroom, tap, square, etc. 
Bowling, bocci 
Golf (walking to each hole only) 
Racquet sports: tennis, racquet ball 
Billiards 
Other: 
----------------------------
- ... - . 
6.0 
3.0 
6.0 
6.0 
6.0 
3.5 
1.5 
5.5 
3.0 
5.0 
7.0 
2.5 
+ 
+ 
INTERVIEWER: (please read to subject). I would now like to ask you about certain types of activities 
that you have done during the past month. I will ask you about how much vigorous activity, leisurely 
walking, sitting, standing, and some other things that you usually do. 
1. About how many times during the month did you participate in vigorous activities that lasted at least 
10 minutes and caused large increases in breathing, heart rate, or leg fatigue or caused you to 
perspire? (Hand subject card #2). 
SCORE: 0 = Not at all (go to Q3) 
1 = 1-3 times per month 
2 = 1-2 times per week 
3 = 3-4 times per week 
4 = 5+ times per week 
7 =Refused 
8 = Don't know FREQUENCY SCORE: = __ _ 
2. About how long do you do this vigorous activity(ies) each time? (Hand subject card #3) 
SCORE: 0 = Not applicable 
1 = 1-3 times per month 
2 = 1-2 times per week 
3 = 3-4 times per week 
4 = 5+ times per week 
7 =Refused 
8 = Don't know 
VIGOROUS ACTIVITY INDEX SCORE: 
FREQSCORE x DURSCORE 
(Responses of 7 or 8 are scored as missing.) 
DURATION SCORE: = ___ _ 
WEIGHT= 5 
x WEIGHT = 
--------
3. Think about the walks you have taken during the past month. About how many times per month did 
you walk for at least 10 minutes or more without stopping which was not strenuous enough to cause 
large increases in breathing, heart rate, or leg fatique or cause you to perspire? (Hand subject card 
#2.) 
SCORE: 0 = Not at all (go to Q5) -
1 = 1-3 times per month 
2 = 1-2 times per week 
3 = 3-4 times per week 
4 = 5+ times per week 
7 =Refused 
8 = Don't know FREQUENCY SCORE: = __ _ 
4. When you did this walking, for how many minutes did you do it? (Hand subject card #3.) 
SCORE: 0 = Not applicable 
1 = 1 0-30 minutes 
2 = 31-60 minutes 
3 = 60+minutes 
7 =Refused 
8 = Don't know 
LEISURELY WALKING INDEX SCORE: 
DURATION SCORE:= ___ _ 
WEIGHT= 4 
FREQSCORE __ x DURSCORE __ x WEIGHT __ =-------
(Responses of 7 or 8 are scored as missing.) 
5. About how many hours a day do you spend moving around on your feet while doing things? Please 
report only the time that you are actually moving. (Hand subject card #4). 
SCORE: 0 =Not at all 
1 = less than 1 hr per day 
2 = 1 to less than 3 hrs per day 
3 = 3 to less than 5 hrs per day 
4 = 5 to less than 7 hrs per day 
5 = 7+ hrs per day 
7 =Refused 
8= OK 
MO~NG INDEX SCORE: 
MO~NG SCORE x WEIGHT 
(Responses of 7 or 8 are scored as missing.) 
MO~NGSCORE= ____ _ 
WEIGHT= 3 
= 
6. Think about how much time you spend standing or moving around on your feet on an average day 
during the past month. About how many hours per day do you stand? (Hand subject card #4.) 
SCORE: 0 =Not at all 
1 = less than 1 hr per day 
2 = 1 to less than 3 hrs per day 
3 = 3 to less than 5 hrs per day 
4 = 5 to less than 7 hrs per day 
5 = 7+ hrs per day 
7 =Refused 
8= OK STANDING SCORE= ___ _ 
WEIGHT= 2 
STANDING INDEX SCORE: 
STANDING SCORE x WEIGHT = 
------(Responses of 7 or 8 are scored a missing.) 
7. About how many hours did you spend sitting on an average day during the past month. (Hand 
subject card #5.) 
SCORE: 0 =Not at all 
1 = less than 3 hrs 
2 = 3 hrs to less than 6 hrs 
3 = 6 hrs to less than 8 hrs 
4 = 8+hours 
7 =Refused 
8 = Don't know 
(Responses of 7 or 8 are scored as missing.) 
SITIING SCORE= ____ _ 
WEIGHT= 1 
SITIING INDEX SCORE: 
SITIING SCORE x WEIGHT = 
(Responses of 7 or 8 are scored a missing.) 
8. About how many flights of stairs do you climb YQ each day? (Let 1 0 steps = 1 flight) ___ _ 
9. Please compare the amount of physical activity that you do during other seasons of the year with the 
amount of activity you just reported for a typical week in the past month. For example, in the summer, 
do you do moe or less activity than what you reported doing in the past month? 
(INTERVIEWER: PLEASE CIRCLE THE APPROPRIATE SCORE FOR EACH SEASON.) 
Lot Little Little Lot 
More More Same Less Less Don't know 
Spring 1.30 1.15 1.00 0.70 
Summer 1.30 -1.15 1.00 0.70 
Fall 1.30 1.15 1.00 0.70 
Winter 1.30 1.-15 -1.00 _..0.70 
SEASONAL ADJUSTMENT SCORE = SUM OVER ALL SEASON /4 
INTERVIEWER PLEASE MARK TIME: __ __ __ __ _ __ _ 
HR SEC MIN 
CARD# 1 
Shopping (e.g., grocery, clothes) 
Stair climbing while carrying a load 
Laundry (time loading, unloading, hanging, folding only) 
Ught housework: tidying, dusting, sweeping; collecting 
trash in home; polishing; indoor gardening; ironing 
Heavy housework: vacuuming, mopping; scrubbing floors 
and walls; moving furniture, boxes, or garbage cans 
Food preparation (1 0+ mins in duration): chopping 
stirring; moving about to get food items, pans 
Food service (1 0+ mins in duration): setting table; 
carrying food; serving food 
Dish washing (1 0+ mins in duration): clearing table; 
washing/drying dishes, putting dishes away 
Light home repair: small appliance repair; light home 
maintenance/ repair 
Heavy home repair: painting, carpentry, 
washing/polishing car 
Other:--------------
Gardening: planting, wedding, digging, hoeing 
Lawn mowing (walking only) 
Clearing walks/driveway: sweeping, shoveling, raking 
Other: 
--------------Older or disabled person (lifting, pushing, wheelchair) 
Childcare (lifting, carrying, pushing stroller) 
Brisk walking (1 0+ mins in duration) 
Pool exercises, stretching, yoga 
Vigorous calisthenics, aerobics 
Cycling, exercycle 
Swimming (laps only) 
Other: --------------
Leisurely walking (1 0+ mins in duration) 
Needlework: knitting, sewing, needlepoint, etc. 
Dancing (mod/fast): line, ballroom, tap, square, etc. 
Bowling, bocci 
Golf (walking to each hole only) 
Racquet sports: tennis, racquet ball 
Billiards 
Other: ..:....· ---------------
CARD#2 
0 =Not at all 
1 = 1 - 3 x per month 
2 = 1 - 2 x per week 
3 = 3 - 4 x per week 
4 = 4 - 5+ times per week 
7 =Refused 
8 = Don't know 
CARD#3 
0 =Not at all 
1 = 1 - 3 x per month 
2 = 1 - 2 x per week 
3 = 3 - 4 x per week 
4 = 5+ times per week 
7 =Refused 
8 = Don't know 
CARD#4 
0 =Not at all 
1 = less than 1 hour per day 
2 = 1 to less than 3 hrs per day 
3 = 3 to less than 5 hrs per day 
4 = 5 to less than 7 hrs per day 
5 = 7 + hours per day 
7 =Refused 
8 = Don't know 
METHODOLOGY FOR SKELETAL MUSCLE BIOPSY STAINING TECHNIQUES. 
RED CROSS WAR MEMORIAL CHILDREN'S HOSPITAL 
HISTOLOGY DEPARTMENT 
Haematoxylin and Eosin (H&E) stain 
1. Place sections in Harris' haematoxylin for 3 minutes. 
2. Blue in Scott's tap water substitute or TRIS buffer (pH 10.5) if tap water is acid . 
Otherwise run in tap water for 2 minutes. 
3. Differentiate in 0.2% acid alcohol (HCL-alcohol) until pink- if needed. 
4. Re-blue as appropriate (step 2). 
5. Place in 1% eosin for 15-20 seconds 
6. Wash quickly in distilled water. 
7. Dehydrate rapidly. 
8. Clear, and mount in synthetic resin. 
Harris' haematoxylin 
Eosin 
Harris' haematoxylin powder 21 .5 g 
Absolute alcohol 10 ml 
Distilled water 200 ml 
Add 4% glacial acetic acid just before use. This increases the precision of the nuclear 
staining. 
Eosin 
Distilled Water 
Dilute to 1% for use. 
5g 
100 ml 
Alkaline solution (Scott's tap water) 
Potassium bicarbonate 2 g 
Magnesium sulphate 20 g 
Distilled water 1 L 
Adenosine triphosphatase (ATPase) stain 
Method at pH 9.4 
1. Incubate freshly cut sections at 37°C for 30 minutes in the following solution: 
5 mg ATP dissolved in a few drops of distilled water. Add 10 ml of 0.1 M 
glycine/NaCL buffer with 0.75 M CaCb. Adjust to pH 9.4. Add 0.0309 g/1 0 ml 
(20 mM) dithiothreitol solution. 
2. Rinse well in distilled water. 
3. Immerse in 2% CaCI2 for three rinses, 1 minute each. 
4. Rinse well in distilled water. 
5. Immerse in dilute (1 :10) ammonium sulphide solution for 30 seconds. 
6. Rinse well in running tap water. 
7. Stain in Harris' haematoxylin for 1 minute and blue in tap water (optional). 
8. Dehydrate, clear and mount 
Method at pH 4.6 and 4.3 
1. Pre-incubate at 4oC in 0.1 M sodium acetate buffer with 10 mM EDTA added, 
for 10 minutes at pH 4.6 or 4.3 
2. Wash in distilled water 
3. Precede as for pH 9.4 method 
Solutions 
0.1 M glycine buffer 
0.75 g glycine+ 0.585 g NaCI made up to 100 ml with distilled water. 
0.1 M glycine/NaG! buffer with 0.75 M CaCI2 
50 ml 0.1 M glycine buffer. 
10 ml 0.75 M CaCI2 
Add approximately 22 ml 0.1 mM NaOH until pH 9.4 
NADH-tetrazolium reductase (NADH-TR) stain 
1. Place fresh sections flat in a petri dish on a damp filter paper. 
2. Place 1-2 drops incubating solution onto the section that it is completely covered. 
3. Incubate for 30 minutes at 37°C. 
4. Wash in distilled water. 
5. Fix in 15-20% formalin solution for 10 minutes. 
6. Rinse in distilled water. 
7. Mount in glycerin jelly. 
To remove fat, ascend in acetone (30, 60, 90%) and descend again into distilled water after 
incubation. 
Results 
lntramitochondrial deposits of black cobalt formazan indicates site of NAD 
Nitroblue tetrazolium stock solution 
20 mg/20 ml distilled water 
Store at -20oC 
NADH stock solution 
Nitroblue tetrazolium 1 mg/ml 
0.2 M TRIS buffer pH 7.4 
Cobalt chloride 0.5 M* 
6.25 ml 
6.25 ml 
1.25 ml 
Distilled water 8. 75 ml 
Store at -20°C (pH 7.4) 
*- 0.5 M CoCI2 = 11.9 g/1 00 ml distilled water. 
NADH solution 
1 ml of stock solution 
1 mg NADH 
Oil red 0 (ORO) stain for lipid 
1. Rinse sections in water. 
2. Rinse in 60% isopropyl alcohol. 
3. Transfer to oil red stain for 10-30 minutes. 
4. Differentiate in 60% isopropyl aclohol. 
5. Wash in distilled water. 
6. Counterstain in Harris' haemotoxylin for 1 minute 
7. Rinse in tap water to blue 
8. Mount in glycerin jelly. 
Results 
Nuclei - blue 
Fat globules- red 
Stock stain 
Saturated solution of oil red 0 in isopropyl alcohol (0.5%). 
For use 
Dilute 6 ml stock with 4 ml distilled water. Stand for 10 minutes and filter. 
Glycerin jelly should only be warm to prevent artefact damage. 
· Modified Gomori trichrome stain 
1. Fresh cryostat sections air dried for 2-20 minutes. 
2. Stain in Harris' haematoxylin for 5 minutes. 
3. Rinse in distilled water. 
4. Stain in Gomori's trichrome mixture 60 minutes (until green) 
5. Differentiate rapidly in 0.2% acetic acid for a few seconds 
6. Dehydrate in alcohol series. 
7. Clear, and mount in artificial resin 
Gomori mixture 
0.6 g Chromotype 2R 
0.3 g Fast green 
0.6g Phosphotungstic acid 
1 .0 ml Glacial acetic acid 
1 00 ml Distilled water 
Trichrome mixture should be made up fresh when staining becomes pale. 
Periodic Acid-Schiff technique (PAS) for glycogen 
1. Fix sections in acetic ethanol for 5-10 minutes. 
2. Wash in distilled water. 
3. Place in 0.5% periodic acid for 2-5 minutes to oxidize. 
4. Wash in distilled water. 
5. Place in Schiff's reagent for 10-15 minutes. 
6. Wash in running tap water for 5-10 minutes. 
7. Dehydrate in ascending alcohol series. 
8. Clear and mount in artificial resin. 
Periodic Acid Solution 
0.5g periodic acid crystals dissolved in 100 ml distilled water. 
Schiff's reagent 
Basic fuchsin 1g 
Distilled water 200ml 
Sodium metabisulphite 2g 
Concentrated HCI 2ml 
Decolourizing charcoal 2g 
Boil the water and carefully add basic fuchsin. When dissolved, cool to 50°C and add sodium 
metabisulphite. Dissolve and allow to cool to room temperature. Add the HCI. Leave in a dark 
cupboard overnight. Add charcoal and shake for two minutes. Filter and store in a dark bottle in 
the refrigerator. 
PAS control 
Incubate control sections in 0.5% a-amylase solution at 37°C for 1 hour. Proceed with PAS stain 
as routinely carried out. 
DAB method for cytochrome oxidase 
Incubation medium 
3,3' - diaminobenzidine tetrahydrochloride (DAB) 
50mM phosphate buffer (pH 7.4) 
(dissolve DAB and phosphate buffer together) 
Catalase solution (20~g/ml) 
Cytochrom c (type II) 
Sucrose 
5mg 
9ml 
1 ml 
10mg 
750mg 
1. Incubate fresh frozen sections for 60 minutes at room temperature (22°C). 
2. Wash quickly in distilled water. 
3. Dehydrat~ in ascending alcohol series, clear, and mount in synthetic resin. 
Results 
Sites of cytochrome oxidase activity- fine brown stain. 
Succinate dehydrogenase 
1. Incubate at 37°C for 30 minutes in the following solution: 
Sodium succinate 1 00 mg 
Nitroblue tetrazolium 1 0 mg 
Phenazine methosulphate 
0.1 M TRIS buffer 
The pH is adjusted to 7.0. 
0.25 mg 
10ml 
2. Extract in acetone, 30, 60, 90, 60 and 30 % in sequence. 
3. Rinse in distilled water 
4. Mount in glycerine jelly 
